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For Philip 
Abstract 
Background 
Over five million people in the UK are receiving treatment for asthma. Corticosteroids 
(steroids) are the mainstay of asthma therapy but some patients do not respond fully to 
steroid treatment, they are characterised as being steroid resistant (SR) and are at high 
risk of morbidity and mortality.  Earlier data from our laboratory has shown evidence 
that in vitro treatment with the active form of vitamin D, - 1!,25-dihydroxyvitamin D3 
or calcitriol - enhanced responsiveness to steroids for induction of the anti inflammatory 
cytokine IL-10. This thesis discusses the results of a proof of concept clinic trial - ‘The 
Calcitriol Study’ - which hypothesized that concomitant in vivo treatment with oral 
calcitriol improves the clinical responsiveness to systemic steroid (prednisolone) 
therapy. The study further allowed investigation of the in vitro cytokine profile of 
patients with SR and steroid sensitive (SS) asthma. Th17 cells and their hallmark 
cytokine IL-17A are proposed to play a role in the pathology of severe asthma, including 
SR asthma, and this work tested the susceptibility of IL-17A and other pro inflammatory 
cytokines important in asthma to inhibition by steroids and calcitriol in vivo and in 
culture. 
Methods 
Adult patients with moderate/severe asthma (FEV1 <80% predicted) with demonstrable 
reversibility of airways obstruction underwent a two-week, pharmacodynamically 
standardised course of oral prednisolone (screening phase) to delineate steroid resistance 
a <10% improvement in FEV1. Patients were then randomly assigned to receive 
calcitriol (n=12) or indistinguishable placebo (n=11) for four weeks, with a repeat 
course of prednisolone during the final two weeks (treatment phase). Changes in lung 
function (!FEV1) in response to prednisolone were compared between the placebo and 
calcitriol groups in the treatment phase, and within groups between the screening and 
treatment phases. Asthma Control Questionnaires and fractional exhaled nitric oxide 
(FeNo) were scored and analysed as secondary endpoints. All participants had serum 
25(OH)D levels measured at baseline. CD8-depleted PBMCs were isolated from SS and 
SR asthmatics and healthy controls and cultured with or without dexamethasone and / or 
calcitriol. Cytometric bead array, ELISA, qPCR and intracellular cytokine staining were 
used to assess cytokine production.  
Results 
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Treatment with calcitriol improved the clinical response to steroids in patients classified 
as clinically steroid resistant (SR) in a within group comparison of changes in FEV1. 
However, there was no significant difference seen between the two groups from 
screening to the end of the trial.  
A striking dichotomy was observed between SR and SS asthma patients in terms of their 
cytokine profiles; SS patients, who showed the biggest improvement in lung function 
after a course of prednisolone had the highest levels of IL-10 in culture in response to 
dexamethasone, whereas SR patients, whose lung function failed to improve, had 
significantly greater levels of IL-17A. Treatment with steroids appeared to aggravate 
production of this pro-inflammatory cytokine but in vitro and in vivo calcitriol not only 
resulted in a significant reduction of IL-17A levels but also restored the impaired, 
steroid-induced anti-inflammatory IL-10 response in SR patients. Serum 25(OH)D 
levels at baseline correlated positively with IL-13 in culture, a Th2 cytokine known to be 
associated with steroid responsive asthma. 
Conclusion 
Calcitriol may have the potential to improve the clinical responsiveness of asthma 
patients to systemic steroid therapy in SR asthma. These data identify immunological 
pathways that likely underpin the beneficial clinical effects of calcitriol in SR asthma, 
by directing the SR cytokine profile towards a more SS type, suggesting strategies to 
characterise vitamin D responder immune phenotypes. 
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Chapter 1 
Introduction 
1. 1 Asthma Prevalence  
Asthma is a chronic disease and is associated with significant morbidity and mortality.  
Episodic breathlessness and wheeze has been recognised at least since the time of 
Hippocrates (circa 460 – circa 370 BC).  Exhaustion after exertion, dyspnoea due to 
heart failure or near the end of life were all described as asthma, but it was the work of 
Hippocrates and his acolytes, detailed in the Corpus Hippocratrium, that may have given 
us the first description of asthma: it was more common in the middle aged and in the 
autumn, identified as a disease of spasm and associated with certain occupations such as 
anglers, tailors and metalworkers 1. The word asthma stems from the Greek word !! "#$%& 
aazein), which translates as “to breathe with open mouth or to pant” and first appeared 
in Homer’s Iliad 2. 
The prevalence of asthma is estimated at 300 million people in the world; in the 
developed world, it affects up to 10% of adults and 30% of children3.  5.4 million people 
in the UK are currently receiving treatment for asthma and the NHS spends around £1 
billion a year treating and caring for people with asthma (asthma.org.uk) 3.  
Most asthma originates in childhood following sensitization of the airways to common 
aero allergens such as pollen, house dust mite, animal dander and fungi and it is 
typically associated with other atopic diseases such as eczema or rhinitis 4. In atopic 
children dermatitis can precede asthma in the ‘atopic march’ suggesting a role of 
epicutaneous allergen transfer in asthma development 5. The rise in childhood asthma 
and the predominant prevalence in developed countries has been attributed among others 
to changes in diet and life style; children who grow up in an environment rich of 
microbial exposure such as farming live stock are less likely to have asthma and 
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allergies 6. Studies suggested that the protective effect of a farming environment on 
asthma development could be largely due to exposure to a wider range of microbes or 
unpasteurized milk consumption 7, 8 and exposure to pet animals has been found to 
confer protection against asthma 9. The data is supported by animal studies showing a 
strong link between germ free status and a high susceptibility of allergy 10.   
These studies have given weight to what is known as the hygiene hypothesis: the rapid 
global increase in asthma prevalence as a direct result of changes in the intrauterine and 
infant environment, including changes in maternal diet, smaller family size, reduced 
infant infections and increased use of antibiotics and immunization 11. 
There is consensus though, that the hygiene hypothesis is not the sole explanation for the 
increase in atopy and asthma. Although the majority of asthma patients are atopic, only 
a minority of people with allergies will develop asthma12. Historically, asthma has been 
regarded as a disease driven by Th2 cytokines such as IL-4, IL-5 and IL-13. These 
cytokines drive eosinophilic inflammation and bronchial hyperreactivity 13. However, 
several non-allergenic exposures such as bacterial endotoxins, air pollution or viral 
infections during early life may contribute to the development of non-atopic asthma 14 
and studies using sputum induction or bronchoalveolar lavage (BAL) techniques to 
measure airways inflammation in asthmatics have shown that some patients have severe 
disease in the absence of eosinophilia, suggestive of non-atopic inflammatory pathways 
driving pathogenesis 15. Immune regulation in severe asthma has recently found 
increased levels of IL-6, IL-8, IL-17A and IFN" in bronchial biopsies of severe 
asthmatics shifting the attention from a predominantly Th2 to a Th1/Th17 driven disease 
16. Research has also focused on aspects during fetal growth; the complex interplay 
between environmental factors including intra uterine smoke exposure, maternal diet, 
mechanical factors and the large number of genes interacting during human 
development 17.  
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Asthma is a heterogeneous disease 
There is therefore increasing evidence that asthma is in fact a heterogenous disease 
encompassing multiple phenotypes or subgroups. A phenotype (from the Greek word 
phainein, “to show” and typos, “type”) is defined as the observable properties of an 
organism that are produced by the interactions of the genotype and the environment 18. It 
is therefore not surprising that in order to gain control of their asthma symptoms, 
different patients require different therapeutic approaches and that by defining 
characteristics of their disease better, with the help of clinical and immunological 
biomarkers, treatment outcomes can be improved.  
Our understanding of asthma pathophysiology has increased considerably over the last 
decades thanks to the ability to identify biological pathways by measuring mediator cells 
and cytokines in the lungs and peripheral blood. Including biological markers of 
inflammation into phenotyping has been referred to as endotyping. Eosinophils, in 
peripheral blood and sputum, cytokines, serum markers like periostin and fractional 
exhaled nitric oxide have all become useful and important biomarkers of asthma 
endotyping. I will discuss asthma endotypes in more detail again in paragraph 1.3 
(Novel Strategies for Asthma Management), which outlines why successful therapies are 
largely based on tailoring therapy to disease phenotype. 
 
 
1. 2 Asthma Management 
Asthma UK estimates that 75% of hospital admissions for asthma are avoidable and as 
many as 90% of the deaths from asthma are preventable. The recent National Review of 
Asthma Deaths (NRAD) revealed that in two thirds of cases examined the quality of 
care was inadequate and clinicians simply failed to adhere to the BTS/SIGN 19 asthma 
treatment guideline 20.  To date, asthma management remains a challenge for healthcare 
professionals.  
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Among the earliest described remedies was to smoke the herb Datura stramonium 21. It 
has anticholinergic properties and is the forerunner of our current most commonly used 
inhaled antimuscarinic drugs ipatropium and tiotropium.  Other therapies, such as 
inhalation of the fumes of hydrocyanic acid and inflation of the lungs with bellows, have 
stood the test of time less favourably and have been abandoned 22. In the early 20th 
century more efficient treatments were found, oral ephedrine or, if the patient were in 
extremis, subcutaneous adrenaline. The diuretic theophylline was discovered to be 
helpful in asthma in the early 1920s and from the 1930s aerosolized solutions of 
adrenaline were in use right up until the development of the metered dose inhaler in the 
1950s.  
Asthma was seen as a disease of airway hyperreactivity due to the release of 
bronchoconstrictor mediators from mast cells and treatment predominantly focused on 
bronchodilators.  Parallel to the continued improvements in performing spirometry - in 
the 1940s and 1950s measurements of forced expiration became the pre-eminent means 
of diagnosing and monitoring the disease - was also the recognition that it was an 
inflammatory condition. This has led to the use of firstly oral glucocorticsteroids 
(hereafter steroids) in the 1950s, and then from the 1960s inhaled steroids, which remain 
the most successful treatment for asthma to date. The first British guidelines on asthma 
management in adults were published in the British Medical Journal in 1990 after a joint 
initiative between the British Thoracic Society (BTS), the Royal College of Physicians 
of London, the King’s Fund Centre, and the National Asthma Campaign 23, 24. Figure 1.1 
shows asthma management steps according to the current guidelines, which are 
implemented until control is achieved 19.  
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STEP 1             STEP 2                 STEP 3                       STEP 4              STEP 5 
OCS 
LABA LABA 
LABA ICS  
High dose 
ICS 
High dose 
 
ICS 
 
Low dose 
 
ICS 
 
Low dose 
add on: 
Leukotriene- 
antagonists 
Theophylline 
oral #2 agonists 
Anticholinergics 
add on: 
Anti-IgE 
Immuno-    
suppressants 
 
Short acting #-agonist (SABA) as required 
Figure 1.1: Stepwise asthma management (British Thoracic Society (BTS) 
guidelines November 2014 19). ICS = inhaled corticosteroids. Low dose = 200-800mcg/day 
Beclometasone diproprionate (BDP) or equivalent. High dose ICS = 2000mcg/day BDP or 
equivalent. LABA = long acting beta agonist.  OCS = oral corticosteroids. 
 
Step 1 recommends the use of short acting #-agonists (SABA) as required. The BAGS 
and BARGE (Beta Adrenergic Response to Genotype) trials, conducted in adults, 
showed that as-needed use of SABA was just as good as scheduled use 25, 26. The latter 
study highlights the importance of pharmacokinetics, showing that participants with the 
Arg/Arg genotype affecting the 16th amino acid of the #2 adrenergic receptor 
experienced deterioration in lung function and symptoms when using salbutamol 
regularly, whereas patients with the Gly/Gly genotype experienced an improvement. 
Environmental and gene-gene interactions such as smoking, race or polymorphisms in 
other genes have also been described to affect this 27-29. Good asthma control is 
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associated with little need for SABA. If more than 10-12 puffs per week are needed, 
asthma is poorly controlled and Step 2 (addition of regular inhaled corticosteroid, ICS) 
should be implemented. ICS remain the most effective anti-inflammatory agents 
currently available for asthma. The anti-inflammatory mechanisms of steroids include 
direct effects on gene expression by binding of the steroid receptors to steroid-
responsive elements and promotion of anti-inflammatory proteins (transactivation) and 
inhibition of transcription and synthesis of proinflammatory cytokines (transrepression). 
This entails inhibition of prostaglandin through activation of annexin I, induction of 
MAPK phostphatase 1 and repression of transcription of cyclooxygenase 2. Steroids 
further have indirect effects on gene expression through interactions with transcription 
factors (i.e. NF-$B and activator protein 1) and glucocorticoid receptor mediated effects 
on second messenger cascades (i.e. the PI3K-Akt-eNOS pathway) 30. I will discuss the 
mechanisms of steroid action and in particular  steroid resistance in detail further below. 
When used appropriately, ICS have few side effects at low-medium doses. Local side 
effects result from the deposition of the drug in the oropharynx and include hoarseness, 
candidiasis, dysphonia or cough. Efforts are being made in developing small particle 
(nanoparticle) size ICS formulations that will improve topical delivery to the lung 31.  
The fact that all currently available ICS are absorbed from the lung into the bloodstream, 
albeit minimally, means they do have the potential for clinically systemic side effects. 
These include suppression of the hypothalamus-pituitary-adrenal (HPA) axis, Cushing’s 
syndrome, obesity, impaired glucose tolerance, cataract, osteoporosis, dermal thinning 
and growth suppression in children, to name a few 32. Anti-inflammatory effects are 
largely mediated by the inhibition of NF-$B and activator protein 1, whereas systemic 
side effects are mainly caused by transactivation and by steroid receptor binding to DNA 
30, 32, 33. There have therefore been several attempts to design newer steroids with 
dissociated activity aiming to separate anti-inflammatory effects from side effects 33-35. 
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Some patients will benefit more from add-on therapy (step 3) than from increasing ICS 
doses should their symptoms persist. First choice is the addition of a long acting #2 
agonist (LABA).  Patients who show no response to LABAs should stop and either 
increase the inhaled steroid dose to 800 micrograms/day BDP (budenosine diproprionate 
equivalent) or consider sequential trials of add-on therapy with leukotriene receptor 
antagonists, theophylline or slow release #2 agonist tablets. Long acting anti-
muscarinergic bronchodilators (LAMA) have become widely used in COPD but recent 
data emerged, showing that the use of two long acting bronchodilators with different 
modes of action had a significant benefit in patients with moderate to severe asthma. 
Randomised controlled trials have found that adding tiotropium to pre-existing therapy 
with ICS or ICS-LABA combination resulted in improved lung function and reduced 
exacerbation rates in comparison with placebo 36. Furthemore, tiotropium maintained 
lung function when ICSs were tapered and LABAs were discontinued 37, 38. Trials 
comparing tiotropium with the LABA salmeterol found the beneficial effect to be 
similar 37, 39. It is noteworthy though that none of the trials provided significant evidence 
for an improvement in symptoms or quality of life. 
There have been concerns with regards to a possible increase in cardiac toxicity with 
tiotropium via the Respimat% inhaler device 40, 41. Tiotropium is currently marketed as 
Handihaler dry powder 18µg once daily or as Respimat% inhaled solution 2.5µg (2 
puffs comprise one medicinal dose) once daily. A large well conducted trial involving 
over 17,000 patients with COPD found no difference in safety profile between the two 
devices and has provided a great deal of reassurance. It remains to be said though that 
any type of anticholinergic drug ought to be used with circumspection in patients at high 
risk of arrhythmias, unstable cardiac disease, and in renal failure.  
Patients whose asthma remains uncontrolled despite treatment with high doses of ICS 
(800 micrograms BDP daily) and an additional drug ought to be treated according to 
step 4: consider increasing ICS to 2000 micrograms BDP/day, add leukotriene receptor 
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antagonists, add theophyllines or add slow release #2 agonists. Oral steroids in the 
lowest dose providing control are added if patients fail to improve at step 4 19. If, at this 
stage symptoms persist, the patient is likely to suffer from severe or difficult to control 
asthma. A number of novel biological agents have been in development in the last year 
to improve severe asthma management.  
The patients enrolled into ‘The Calcitriol Study’, which forms the main part of my 
thesis, suffered from severe therapy refractory asthma, which is why I would like to 
discuss severe asthma, and in particular its phenotypes, in more detail here. 
 24 
1. 3 Novel Strategies for Asthma Management: Targeting the Right 
Patient 
In order to optimise treatment outcomes for patients with ongoing symptoms it is 
important to further our understanding of severe asthma.  
Several approaches have been taken to characterize asthma subgroups. The Severe 
Asthma Research Program (SARP) identified five asthma sub-phenotypes by unbiased 
cluster analysis, three of which are severe asthma 42: the early-onset allergic type and the 
late-onset eosinophilic phenotype are both orchestrated by Th2 cells. They are clinically 
distinct, yet overlap immunologically. A Th2-cell signature is believed to play a 
predominant role in exercise induced asthma (EIA) with mast cells and their mediators 
understood to be driving inflammation in EIA 43. A lack of Th2 biomarkers is seen in 
obesity related asthma and neutrophilic asthma. In another study using cluster analysis, 
sputum eosinophilia was incorporated. Consequent upon this a phenotype of early onset 
severe atopic asthma, late onset asthma with persistent eosinophilia and a cluster of 
obese females with late onset asthma without eosinophilia was identified 4 (see table 
1.1).   
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T-cell 
signature Phenotype Biomarkers Therapy 
  Early onset allergic specific IgE, + SPT Corticosteroids, Anti-IgE 
Th2-high 
Late-onset 
eosinophilic sputum eosinophilia, IL-5 
Poor response to steroids, 
Anti-IL-5 
  Exercise induced Mast cells 
Leukotriene receptor 
antagonists, SABA 
     Poor response to steroids 
Th2-low Obesity related 
Mast cells, Adiponectin, Th1 
cytokines 
Weight loss, PPAR 
agonists 
  Neutrophilic Th17, sputum neutrophilia 
Vitamin D, p38 MAPK 
inhibitors, Macrolides. 
Poor response to steroids 
Table 1.1 Asthma phenotypes according to their biomarker profiles and 
therapeutic response divided into Th2-high and Th2-low asthma, adapted from 
Wenzel18  
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Molecular phenotyping has led to the development of biomarkers that specifically target 
Th2 responses in the lung: Woodruff and colleagues identified periostin (POSTN), 
chloride channel regulator 1 (CLCA1), and serpin peptidase inhibitor, clade B, member 2 
(SERPINB2) as epithelial genes that were specifically induced in asthma and directly 
regulated by IL-13 in vitro44. They further identified patients with distinctly higher 
levels of IL-5 and IL-13, termed Th2-high asthma. This was in contrast to patients with 
cytokine expression similar to healthy controls including Th1 cytokines IL-12 and IFN", 
which were significantly lower in the Th2-high group. The Th2-high and Th2-low 
groups also differed clinically with the Th2-high group showing significant higher atopy 
and higher eosinophil levels in peripheral blood and bronchoalveolar lavage (BAL). Of 
particular interest was their observation of steroid responsiveness:  lung function of Th2-
low asthmatics failed to improve following treatment with ICS, in fact patients’ FEV1 
deteriorated in the first month suggesting a detrimental effect of steroids in Th2 low 
asthma44. 
 
1. 3. 1  Th2-high Asthma 
Omalizumab remains so far the most successfully applied monoclonal antibody to treat 
allergic Th2-high asthma. Omalizumab is a humanized IgG1k monoclonal antibody that 
specifically binds to free human immunoglobulin E but not to IgE that is already bound 
by the high affinity IgE receptor (Fc&RI) on the surface of mast cells, basophils and 
antigen-presenting dentritic cells. Steric hindrance by the receptor means the receptor is 
not accessible to omalizumab binding, thus averting anaphylaxis. In a number of studies 
conducted so far, patients treated with omalizumab reported significant improvements in 
asthma-related symptoms allowing for a reduction in steroid and rescue inhaler use 45-47. 
It appears that patients with blood eosinophilia, high levels of exhaled nitric oxide and 
serum periostin benefit most from anti IgE treatment 48. However, evidence is now 
emerging that omalizumab has a role in non-atopic asthma. A recent trial demonstrated 
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significantly increased asthma control in 29 non-atopic patients and a trend to reduced 
exacerbation rates and improved lung function 49, 50.  A small randomized controlled trial 
comparing treatment with omalizumab and placebo in non-atopic asthmatics over a 
period of 16 weeks found a trend towards a decrease in exacerbations and a significant 
improvement in lung function in omalizumab-treated patients, as compared with the 
placebo group. In addition, the authors showed that the expression of the high-affinity 
IgE receptor on blood plasmacytoid dendritic cells decreased significantly in the active 
group but not in the placebo group 50. Larger trials and in particular, trials shedding light 
on how best to identify non-atopic patients who are likely going to respond to anti-IgE 
treatment are needed. 
The success of anti-IgE therapy is limited by the fact that IgE production is not affected. 
Treatment has to be given regularly and on a long term basis. Brightbill et al. have 
successfully created a monoclonal antibody against the M1' segment of membrane IgE 
on human IgE-switched B cells resulting in depletion of IgE-switched B cells via 
apoptosis or/and antibody dependent cell-mediated cytotoxicity 51. Total IgE levels were 
reduced without other immunoglobulin isotypes being affected. A phase IIb, randomized 
controlled trial is currently testing its efficacy in uncontrolled allergic asthma and study 
results are expected in 2015 (http://clinicaltrial.gov/ct2/show/NCT01582503). 
 
Promising newer treatments targeting the Th2 pathway with steroid sparing potential 
include the anti-interleukin-5 antibody mepolizumab. The first randomized controlled 
trials with anti-IL-5 were conducted in patients with mild-to-moderate asthma 52, 53. 
These studies failed to show a beneficial effect on lung function. However, after 
targeting patients with severe asthma and refractory airway eosinophilia and choosing a 
more appropriate primary outcome (i.e. asthma exacerbations), anti-IL-5 treatment has 
been shown to significantly reduce exacerbations and oral steroid doses required to 
control symptoms and has been well tolerated during the study period of over a year 54. 
Benralizumab, an IL-5 receptor alpha subunit (IL-5R')-antibody, not only reduced 
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peripheral blood eosinophils but significantly reduced eosinophil counts in airway 
mucosa/submucosa 55. However, neither of the two treatments has had any effect on 
lung function or patient rated asthma control.  
 
Clinical trials have also investigated targeted therapies against the Th2 cytokines IL-4 
and IL-13. Pitrakinra is an IL-4 mutein, which binds to the IL-4R! subunit and prevents 
the inflammation induced by IL-4 and IL-13. It has been shown to reduce allergen 
induced airway responses when given in inhaled or subcutaneous form in a study of 
mild asthmatics and to reduce exacerbation rates in those with eosinophilia 56, 57. In 
moderate – severe asthma, the fully human monoclonal IL-4R-' dupilumab improved 
lung function, symptoms and exacerbation rate 58.  
Periostin has proven to be a prognostic biomarker for treatment with the anti-IL-13 
antibody Lebrikizumab. A recent study demonstrated that treatment with Lebrikizumab 
increased FEV1 in patients with a high serum periostin level59. To date, the most 
successful anti Th2 cytokine therapies have focused on accurate identification of a 
patient’s phenotype to allow for personalized treatment regimes.  
 
1. 3. 2  Non-Th2-high Asthma: a Different Challenge 
Treatments targeting other possible inflammatory mediators have shown less clear 
evidence of clinical benefit and the reason for this might stem from the difficulty of a 
clear definition: Th2-low asthma remains identified by the absence of Th2 biomarkers.  
Although the presence of a neutrophilic phenotype of asthma has been suggested, its use 
as a biomarker is imperfect. In contrast to the significant association between blood 
eosinophilia and airway eosinophilia in patients with asthma (who are not treated with 
systemic corticosteroids), there is no correlation at all between blood neutrophilia and 
airway neutrophilia 60. Furthermore, there is no consensus as to the level of airway 
neutrophilia that would define pathology; neutrophils, unlike eosinophils are a normal 
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component of the cells retrieved in induced sputum. There is robust data however that 
the later onset, obese non-eosinophilic phenotype is often particularly steroid insensitive 
and difficult to control. TNF-' (Etanercept, infliximab, Golimumab): anti TNF-' 
treatment was tested in severe (Etanercept, 61, 62) and moderate (Infliximab, 63) 
asthmatics and resulted in improved asthma control, FEV1 and bronchial hyperreactivity, 
however the effect ceased as soon as the drug was discontinued. The fully human anti-
TNF-antibody Golimumab did not have any clinical benefit but resulted in an increase 
of respiratory infections and malignancies leading to an early discontinuation of the trial 
64.  Trials on anti-IL-4  57, 65, anti-IL-13 66, 67, anti-IL-9 62, agents targeting TSLP 68, 
Chemokine inhibitors (CCR3, CCR4 69, phosphodiesterase and kinase inhibitors 70 and 
the use of vaccination 71 with the aim to shift from Th2 to Th1 are all under 
development.  
In a randomized controlled trial the human anti-IL-17 receptor monoclonal antibody 
brodalumab was not superior to placebo in terms of asthma control 72. Interestingly, the 
authors observed a nominal significance in a subgroup of patients with high 
bronchodilator reversibility and further studies of brodalumab in this asthma 
subpopulation are warranted.   
Macrolide antibiotics have anti-inflammatory and immune-modulatory effects. They 
also increase gastrointestinal motility and to that extend might prove beneficial in 
patients with significant GERD. They have been proven effective in chronic respiratory 
diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease 
(COPD). They have also been shown to reduce severe exacerbations in patients with 
non-eosinophilic asthma and to have significantly improved Asthma Quality of Life 
Questionnaire scores 73. However, chronic antimicrobial use is associated with the risks 
of population resistance, and treatment should be restricted to severe asthma patients at 
greatest unmet need despite optimal asthma management.  
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Methotrexate has proven a valid agent in patients who, despite long term treatment with 
oral steroids, fail to gain satisfactory control of their asthma 74. Due to considerable side 
effects, close monitoring is needed and treatment should only be initiated in specialist 
centers. 
  
1. 3. 3  Bronchial Thermoplasty 
Smooth muscle hyperplasia is a distinctive feature of asthma. Applying radiofrequency 
energy to sub-segmental airways has been shown to reduce muscle mass at the site of 
thermoplasty. Trials demonstrated a reduction in the number of severe asthma 
exacerbations and improvement in asthma–specific quality of life, 75 and a recent study 
found no adverse events after a five-year follow up period 76. Although guidelines 
recommend bronchial thermoplasty for adults with severe asthma that is not controlled 
on ICS and long acting beta2 agonists (LABA), it is currently unclear which phenotypes 
respond best to the treatment.  Studies are needed to identify the phenotype of patients 
that will derive significant clinical benefit most from this invasive procedure. 
In summary, a well-defined, unbiased approach defining clinical characteristics that 
specify distinct phenotypes of asthma is critical for a better understanding of disease 
pathogenesis and thus successful management. New drug therapies are expensive and 
this substantiates the need to recognize responder patients and to select these patients for 
clinical trials.  
 
1. 4 Steroid Resistance 
Despite the availability of effective therapies a substantial number of patients with 
asthma appear to suffer from continuous symptoms. Poor compliance to treatments may 
be a reason for this. However, it is noteworthy that studies assessing asthma control 
observed persistent symptoms in over 20% of patients despite treatment adherence in 
clinical trials, where compliance is assumed as exceptional and often monitored closely 
77. It is therefore widely acknowledged that a small proportion of patients have an 
indisputable poor response, in particular to steroids. Furthermore, even when taken 
regularly, ICS do not appear to significantly modify the course of the disease and are not 
curative, asthma symptoms recur when treatment is discontinued. 
Although the concept that some asthma patients show no benefit to steroids has been 
described for nearly 50 years 78, there is no absolute consensus on how to define clinical 
steroid resistance.  
Pioneering work in this field demonstrated that cells from patients known to be 
clinically sensitive to steroid therapy did not differ significantly from those of clinically 
resistant patients in terms of their immuno-phenotype or the number of colonies 
generated by culture in the presence of phytohaemagglutinin79. However, in vitro 
steroids inhibited colony growth from cells of steroid sensitive (SS) patients, whereas 
there was less inhibition seen from cells from steroid resistant (SR) patients. In their 
work, Corrigan et al confirmed these findings and showed that proliferation of 
peripheral blood T cells from SS but not from SR asthma patients was significantly 
inhibited by dexamethasone and that there was a correlation between the degree of 
sensitivity to dexamethasone in vitro and the in vivo response to prednisolone with 
respect to improvement in lung function 80.  
Research into the exact mechanisms leading to steroid resistance remains topical. 
Genetic disease specific factors and the environment have been reported to add to 
steroid resistance: gene expression studies have linked gene modification, for example 
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in p50 (a component of NF-$B), FKBP51, a GR chaperone protein or corticotrophin 
releasing hormone receptor-1, with the degree of responsiveness of asthmatics to 
steroids 81.  
Steroid resistance is also associated with an increased expression of the transcriptionally 
inactive glucocorticoid receptor beta (GR-) ß 70, 82, 83. Further, accounting for 
corticosteroid insensitivity are defects in glucocorticoid receptor binding, activation of 
transcription factors such as AP1, which is activated by pro-inflammatory cytokines 
such as tumor-necrosis-' (TNF') or through failure to induce regulatory cytokines like 
IL-10 84. There is also an association between steroid resistance and IL-17, which is 
detailed further below.  
Cigarette smoke has been implicated in steroid resistance: oxidative stress has been 
shown to impair nuclear translocation of GR and to increase pro-inflammatory 
transcription factors such as NF-$B and AP-1, and to reduce histone deacetylase 
(HDAC2), a protein suppressing pro-inflammatory genes 85, 86. PBMCs from smoking 
asthmatics also have an elevated GR-# to GR-' ratio 87.  Allergen exposure decreases 
the binding affinity of GR and viruses and bacteria have been shown to impair GR 
nuclear translocation 88, 89.  
Obesity related asthma is poorly responsive to steroids. Factors such as insulin 
resistance, altered adaptive and innate immunity, changes in mechanical loading of the 
chest wall and abdomen and increased airway hyper responsiveness secondary to low 
lung volume breathing have all been linked to obesity related asthma 90. Furthermore it 
has been shown that obese asthmatics have impaired induction of MKP-1 expression in 
response to dexamethasone in both PBMCs and BAL cells 91. Glucorticoids inhibit pro-
inflammatory gene expression, in part through negative regulation of mitogen-activated 
protein kinase (MAPK) signaling pathways by molecules such as MAPK phosphatase 
(MKP)-1. 
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Steroid resistance has also been associated with airway remodeling: TIMP-1 is a tissue 
inhibitor of the matrix metalloproteinases (MMPs), which degrade collagen. MMP-9 and 
TIMP-1 have both been shown to be increased in asthmatic patients but interestingly 
steroid resistant patients expressed a higher ratio of MMP-9/TIMP-1 because of an 
inability of steroids to enhance TIMP-1 production 92 93. 
In The Calcitriol Study we have chosen to define SR asthma based on the previous work 
by Professor Chris Corrigan, who also acted as one of the Chief Investigators in the 
study 80. Steroid sensitivity was defined by an improvement of FEV1 of > than 10% 
following a two week course of oral prednisolone at 40mg/1.73m2 body surface area 
(BSA). 
1. 5 IL-17A 
Although the production of IL-17A by activated CD4+ T cells, the pro-inflammatory 
cytokine accredited for the recruitment, activation and migration of neutrophil 
granulocytes, had been known for a while, the recognition of Th17 cells as an 
independent and important subtype driving autoimmunity has been fairly recent 94, 95. 
Experiments in mice with experimental autoimmune encephalomyelitis (EAE, the 
murine model of multiple sclerosis), an inflammatory disease historically associated 
with a Th1 immune response, revealed that administration of antibodies to the classical 
Th1 cytokine IFN-" unexpectedly resulted in worsening of the disease 96.  Further 
investigations into these apparent discrepancies established that the p40 subunit shared 
with IL-12 could pair with another subunit p19, which would then form the cytokine IL-
23 97. This heterodimeric cytokine is critical for IL-17A production by CD4+ cells and it 
is worth mentioning here. Cua and colleagues were able to show that EAE did not 
develop in Il23a-/- mice, making IL-23 a key cytokine in Th17 driven autoimmunity 94. 
Subsequent experiments by the same group showed how IL-23 is crucial for 
differentiation and maintenance of Th17 cells and is responsible for the phosphorylation 
of STAT3, a factor involved in transcriptional regulation of Th17 cell development 98.  
These findings showed how Th1 cells alone are not fully accountable for autoimmune 
disease. To highlight the distinction of Th17 cells from Th1 cells, it was further 
demonstrated that their differentiation was not dependent on IL-12/Tbet or IL-
4/GATA3/c-Maf respectively, the main cytokines and transcription factors involved in 
Th1 and Th2 differentiation. In fact, forced expression of T-bet or overexpression of c-
Maf resulted in reduced IL-17A production 99. CD4+ T cells isolated from mice lacking 
Tbet and Gata3 retained the ability to differentiate into Th17 cells in vitro when 
activated in the presence of IL-23 100, 101.  
Studies comparing gene expression profiles of activated T cells stimulated with the 
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cytokines IL-23 and/or IL-12 showed that while Th1 cells greatly expressed T-bet, Th17 
cells expressed rorcgamma, the gene encoding for ROR"t. Expression of ROR"t in naïve 
T cells is both necessary and sufficient to induce IL-17A. Ivanov demonstrated that 
CD4+ T cells from ROR"t-deficient animals were unresponsive to IL-23, had reduced 
numbers of Th17 cells and were resistant to EAE induction 99. These findings 
established the association between IL-17 expressing cells and the transcription factor 
ROR"t.  
The balance between different Th cell subsets is controlled by various pro-inflammatory 
cytokines: three independent groups demonstrated that in mice TGF-# was required for 
initiation and IL-6 was a critical co-factor for Th17 cell differentiation from naïve T 
cells 102-104. This was surprising as TGF-# has so far been accredited anti-inflammatory 
activity and required for peripheral induction of FoxP3+ Tregs known for their anti-
inflammatory activity. Further studies highlighted the importance of the co-factor IL-6, 
which was shown to have inhibitory action on Treg development and to upregulate IL-
21, a key player in Th17 cell induction, amplification and development 105, 106. In 
humans, key cytokines involved in the development and differentiation are less clearly 
defined: Some studies suggest an inhibitory role for TGF-# in Th17 cell differentiation, 
whereas others found that TGF-# was necessary and sufficient to induce Th17 cells from 
naïve CD4+ T cells. 107-112. Both IL-23 and IL-1# have been shown to drive Th17 cell 
differentiation, the effect of IL-1# being enhanced by IL-23 and/or IL-6. The importance 
of IL-1# in the induction of IL-17 production is unique to human T cells. Furthermore, it 
has been shown that the presence in culture medium of natural agonists for aryl 
hydrocarbon receptors (Ahr) is critical for optimal Th17 cell differentiation 113. Aryl 
hydrocarbon receptors respond to a broad range of chemicals resulting in receptor 
nuclear translocation and binding to gene promoters containing dioxin-responsive 
elements. Tissues that come in contact with the external environment express high levels 
of the Aryl hydrocarbon receptor (Ahr) and it has been shown that Ahr activation boosts 
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TH17 differentiation and increased the severity of autoimmune disease in mice 114, 115.  
The hallmark cytokine produced by Th17 cells is IL-17 (also referred to as IL-17A), a 
member of the IL-17-family consisting of the six members IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E (also called IL-25) and IL-17F. Most knowledge has so far been gained on 
IL-17A, IL-17F and IL-25. IL-17A and IL-17F share >50% homology and bind to the 
same receptor, a transmembrane receptor ubiquitously expressed on various organs and 
cells. Expression of IL-17A was first described by memory CD4+ T cells but it has since 
been found to be secreted by CD8+ T cells, NK cells, "( T-cells, CD3+ cells, lymphoid-
tissue inducer (LTi)-like cells and neutrophils under certain conditions 116-119.  Each of 
these cells has an important role in tissue surveillance, notably at sites of infection in the 
gut, skin and lung. Cellular response to IL-17R-mediatied signaling induces production 
of granulocyte colony stimulating factor (G-CSF), IL-6, IL-8 and neutrophil recruitment, 
required for bacterial and fungal clearance, and highlights the protective role of IL-17A 
against extracellular bacterial infection at mucosal interfaces 120. In the lungs "( T-cells 
were identified as an invaluable source of IL-17A in promoting efficient antibacterial 
immunity, as shown for example in patients with tuberculosis 121.  IL-17A has also been 
shown to augment the expression of antimicrobial peptides, induce production of IL-12 
in dendritic cells and drive Th1 immunity and therefore support intracellular bacterial 
control 122, 123.  Dominant-negative mutations in human STAT3 lead to the development 
of hyper-IgE syndrome, which compromises the generation of IL-17A producing cells 
and patients suffer from mucocutaneous candidiasis and pulmonary infections with 
Staphylococcus aureus 124.  In cystic fibrosis, a disease characterized by bronchoalveolar 
neutrophilia, studies have shown an increased amount of IL-17A+ CD4+ T cells, "( T-
cells and NK T cells 125.  
IL-17A can have both beneficial (host defense) and harmful effects: although the 
mechanisms that underlie pathogenicity against self are still not entirely known, it has 
become clear that the immune response elicited by Th17 cells, i.e. activation of the 
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innate immune system and neutrophil influx can lead to damage of the surrounding 
tissue.  IL-17A is associated with several autoimmune diseases such as rheumatoid 
arthritis, multiple sclerosis, psoriasis or lung inflammatory disease like asthma 100, 126-128. 
Higher levels of IL-17A are found in sputum and BAL of patients with asthma 
compared to control subjects and the severity of airway hypersensitivity correlates with 
airway neutrophilia and levels of IL-17A expression 129-131. Barczyk reported almost a 
decade ago that higher levels of IL-17A correlated with increased AHR in response to 
methacholine in patients with asthma 132.  
Animal models have demonstrated in the past a role for IL-17A in Th2 cytokine-
mediated asthma by promoting an allergen driven immune response in the sensitization 
phase or by inhibiting a local allergic response in the challenge phase, suggesting that the 
timing of IL-17A administration or neutralization may play a critical role on outcome 
and function 133,134.  
It has also been reported that IL-17A can induce antigen-presenting cells (APCs) to 
produce inflammatory cytokines and in this way lead to generation of antigen-specific 
Th17 cells and exacerbate autoimmunity 120.  
Interestingly, studies in mice and humans suggest an association between steroid 
resistance and Th17 mediated disease: adoptive transfer of Th17 cells resulted in 
increased levels of CXC chemokines and G-CSF in the BAL fluid of SCID mice. 
Treatment with dexamethasone resulted in increased neutrophil numbers but no 
improvement of airway hyperresponsiveness 135. Molet reported increased levels of IL-
17A in chronic sinusitis that is resistant to steroids 129.  
Steroid resistance is associated with an increased expression of the transcriptionally 
inactive glucocorticoid receptor beta (GR-)ß 70, 82, 83. (GR)-ß increases in response to 
exogenous IL-17A and IL-17F, an effect that is more prominent in asthmatics than in 
healthy controls. It has also been shown that dexamethasone significantly decreased the 
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expression of IL-6 in epithelial cells from healthy controls but failed to do so in 
asthmatics 136. 
To date, there have been few trials assessing the clinical utility of targeting IL-17A in 
asthma. Busse recently published a report of a clinical trial of an IL-17RA antibody in 
patients with moderate – severe asthma and found improved asthma control in a small 
subgroup of patients with high beta-agonist reversibility 72. In keeping with this, an 
earlier study found higher IL-17A levels in patients with reversible severe airflow 
obstruction as compared to chronic persistent obstruction, suggesting that there might be 
a role for anti-IL-17A treatment in this particular asthma phenotype 137. Interestingly the 
same monoclonal anti-IL-17A antibody has previously been shown to be effective in 
psoriasis but has had no benefit in rheumatoid arthritis138. Targeting IL-17A is an 
attractive option. However, when designing future trials researchers must take into 
account not only its pathogenic effect in autoimmune disease but also its importance in 
host defense.  I will discuss the role vitamin D might play in this context in paragraph 
1.8.2 below. 
Comparable to IL-17, another leukocyte-derived cytokine – IL-22 - has been suggested 
to be important in sustaining inflammation in autoimmune disease and to predominantly 
have regenerative function. IL-22 is a member of the IL-10 cytokine family. Biological 
activity of IL-22 depends on tissue location and cytokine environment 139. 
The IL-22 receptor complex is composed of the heterodimer IL-22R1 and IL-10R2 140. 
Although IL-10R2 is found on various types of immune cells, IL-22R1 is expressed by 
non-hematopoietic cells, predominantly by epithelial cells of the respiratory and 
digestive tract, and skin keratinocytes. IL-22 ligation to its receptor activates STAT3 
signaling pathway leading to the expression of genes involved in inflammation, 
chemotaxis, host defense and mucosal protection 141. Among the different T cell 
populations, Th17 (mouse and human) and Th1 and Th22 (human) are the main 
producers of IL-22. 111.  IL-22 is also regulated by the transcription factor aryl 
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hydrocarbon receptor (Ahr) 142. 
In the lung, IL-22 plays a crucial role in innate immune defense. Mouse models have 
shown an increase in antimicrobial peptides and recruitment of neutrophils by IL-22 143. 
Mice deficient in IL-22 have reduced airway hyperreactivity, eosinophil recruitment and 
mucus secretion. Neutralization of IL-22 antibody during immunization in an OVA-
induced model of allergic asthma inhibited airways inflammation. Deletion of IL-22 
attenuated collagen-induced arthritis 144.  In contrast, IL-22 has also been shown to have 
a protective role. Neutralisation during antigen challenge caused enhanced allergic lung 
disease and analogously, recombinant IL-22 given during challenge protected mice from 
lung inflammation 145-147. This tissue protective activity has also been shown in murine 
models of hepatic inflammation, inflammatory bowel disease and experimental 
autoimmune myocarditis 143, 148, 149.  
Similarly to IL-17, the bioactivity of IL-22 in animal models appears to depend on the 
timing during which those cytokines are activated as well as the cellular source and 
whether they elicit a protective or pro-inflammatory response depending on the phase of 
disease.  
 
In summary, data from human and animal models demonstrate that IL-17A and IL-22 
are both crucial players in inflammatory lung disease. Their pathogenicity makes them a 
complex but attractive target for therapeutic intervention and I will be discussing the 
expression of IL-17A and IL-22 in healthy individuals and in steroid sensitive and 
steroid resistant asthma patients and investigate the cytokines’ response to vitamin D 
and dexamethasone treatment.  
1. 6 IL-10 
Unlike IL-17A and IL-22, IL-10 is an immunosuppressive cytokine with broad anti-
inflammatory properties and is thought to play a key role in maintaining immune 
homeostasis in the lung 150. It is produced by a wide range of cell types, including B 
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cells, macrophages, dendritic cells, mast cells, and eosinophils. Many T cell subsets 
synthesize IL-10, such as CD8+ T cells, CD25+FoxP3+ T reg cells, and effector CD4+ T 
cells namely Th1 cells, Th2 cells and Th17 cells.  
IL-10 affects many functions relevant to asthma; it inhibits mast cell and eosinophil 
function and favourably modulates IgE to IgG4 ratios. IL-10 acts on macrophages and 
dendritic cells to inhibit pro-inflammatory cytokine production and the capacity to 
activate T cells, including Th2 cells 154.  
In comparison to healthy controls, patients with asthma have been found to have reduced 
IL-10 mRNA and protein in bronchoalveolar lavage fluid 151. Furthermore, studies of 
polymorphisms in the IL-10 gene promoter suggest that individuals who make low IL-10 
suffer from more severe asthma152-154. Similar observations have been made in terms of 
atopy: Akdis noted, that allergic patients had a significant reduction in the frequency of 
allergen-responsive IL-10-positive T cells in the peripheral blood as compared to non-
atopic individuals 155. 
However, IL-10 may also enhance immune function and has been shown to activate mast 
cells, CD8 T cells and natural killer (NK) cells 156, 157. It promotes humoral immune 
responses and induces immunoglobulin production.  
The diverse functions of IL-10 have clinical implications as studies using recombinant 
IL-10 have shown: whilst early trials showed reduction of pro-inflammatory cytokines in 
the peripheral blood mononuclear cells of patients with psoriasis and Crohn’s disease, 
both chronic auto-immune disorders like asthma, larger studies failed to see a therapeutic 
success due to side effects such as fever, which suggests immune stimulatory effects of 
the treatment 150. Several established therapies for asthma have been shown to promote 
IL-10 in patients 156. Both, inhaled and systemic steroid therapy increases mRNA for 
FoxP3 and IL-10 synthesis. Our laboratory has previously shown that the steroid 
dexamethasone dose-dependently induced IL-10 synthesis by CD4+ T cells in culture 
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and that these cells were able to inhibit autologous effector T cells in an IL-10-dependent 
manner 158. Enhanced IL-10 activity might therefore promise greater anti-inflammatory 
activity, which is of particular benefit to patients who remain symptomatic on current 
available treatments.  
Allergen immunotherapy is associated with the induction of IL-10-secreting T cells and 
APCs 159. Subcutaneous (SCIT) or sublingual (SLIT) immunotherapy (IT) is potentially 
very successful in terms of symptom relief of, for example, allergic rhinitis, and hence 
leads to better asthma control. However, it requires administration over a lengthy period 
and works in highly atopic individuals only and carries the risk of severe allergic 
reactions. IT needs to deliver better efficacy before widespread application in asthmatic 
patients can be considered.  
A study in mice has shown that co-administration of the active form of vitamin D, 
calcitriol significantly augments the beneficial effects of IT on Ag-induced allergic 
asthma manifestations in a mouse model. Calcitriol has further been shown to induce 
tolerogenic dendritic cell phenotype with increased IL-10, which acts directly on CD4+ 
T cells to induce IL-10+ Tregs cells 160. An interesting associating exists between IL-10 
and serum 25(OH) levels. In children with both moderate and severe, therapy resistant 
asthma systemic vitamin D status directly correlated with airway IL-10 161. Vitamin D 
supplementation in patients with multiple sclerosis enhanced IL-10 synthesis 162 and in 
our own study of steroid resistant asthma, Xystrakis showed that the active form of 
vitamin D, calcitriol, restored the defective IL-10-production of CD4+ T cells 163. This 
has led to the hypothesis that vitamin D may contribute to pulmonary homeostasis via 
induction of the anti-inflammatory IL-10. Coupled with the antimicrobial activity 
vitamin D is know to have (see next section), this might promise a safer approach of IL-
10 enhancing therapies than that which we have seen so far. 
1. 7 Vitamin D 
The pathology of asthma and in particular severe and steroid-refractory asthma remains 
complex and new therapeutic approaches could have profound consequences for the 
patient and healthcare professionals.   
Our laboratory has had an interest in vitamin D and its effect on respiratory health for a 
number of years. The role of vitamin D and its metabolites in bone and calcium 
metabolism is well established but there is increasing awareness of its importance in 
immune regulation 164-166. The overlap in the epidemiology of vitamin D insufficiency 
and asthma has led to intense interest in  its role(s) in inflammatory lung disease.  
1. 7. 1  Metabolic Pathway 
Vitamin D can be derived from the diet, however the majority of it is produced in the 
skin: once 7-dehydrocholesterol is photolysed into pre-vitamin D3 and processed into 
vitamin D3 it is converted in the liver to 25-hydroxyvitamin D by CYP27A1 
(25(OH)hydroxylase) and subsequently in the kidneys by CYP27B1 (25-
hydroxyvitamin-D-1-hydroxylase) to its biologically active form 1,25-dihydroxyvitamin 
D (hereafter calcitriol), a mechanism tightly regulated by PTH (Figure 1.2). Calcitriol is 
transported to target cells bound to vitamin D binding protein (DBP) or deactivated by 
24-hydroxylation by CYP24A1 which catabolizes calcitriol to its water-soluble inactive 
form calcitroic acid, excreted in the bile.  It further catabolizes 25(OH)D to 
24,25(OH)D. 1'-hydroxylation of 25-hydroxivitamin D also occurs at extrarenal sites 
such as brain, breast, colon, prostate and cells of the immune system. At site of 
inflammation, local synthesis of calcitriol (subject to availability of 25-hydroxyvitamin 
D substrate) can modulate immune responses in a paracrine fashion 167.  
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Figure 1.2 Synthesis of vitamin D: 
During exposure to UVB 7-dehydrocholesterol in the skin is converted to pre-vitamin D3, which 
is converted to vitamin D3 in a heat-dependent process.  
Vitamin D2 and D3 from dietary sources and vitamin D from the skin enter into the venous 
circulations, bind to vitamin D binding protein and are transported to the liver, where vitamin D is 
converted by CYP27A1 to 25-hydroxyvitamin D3 (25(OH)D). This is the major circulation form 
and is used to determine vitamin D status. 25(OH)D is biologically inactive though and is 
converted in the kidneys by CYP27B1 to the biologically active form 1,25-dihydroxyvitamin D 
(1,25(OH)2D3, calcitriol). 
 
Calcitriol binds to the nuclear vitamin D receptor  (VDR), a member of the superfamily 
of nuclear hormone receptors, which is found in most organs as well as monocytes, and 
activated T- and B-cells 168. The pleiotropic activity of the calcitriol – VDR complex has 
been widely studied and receptor polymorphism has been associated with various 
immune diseases 169-172. VDR is located within the region of q13-26 on chromosome 12, 
a region linked to asthma in genome-wide linkage analysis 173.  Binding of calcitriol to 
 44 
the VDR induces a conformational change allowing the VDR to bind to and form a 
heterodimer with the retinoid X receptor (RXR). This VDR-RXR complex then acts as a 
transcription factor and binds to vitamin D3 response elements (VDREs) within the 
promoter region of genes that respond to vitamin D3. Calcitriol is catabolised by 
CYP24A1 and excreted in the urine. 
1. 7. 2  Bioavailability  
25(OH)D serum levels are greatly influenced by exposure of the skin to sunlight with 
maximum synthesis achieved when UVB reacts with 7-dihydrocholesterol in the skin at 
wavelengths of 295nm. Very little vitamin D is produced in areas at beyond a latitude of 
35° from October to March and synthesis is greatly influenced by skin pigmentation, sun 
protection, (a sun protection factor of >15 will absorb UVB light to 99%), age and 
coverage by clothing 167. 
Numerous studies emerge reporting hypovitaminosis D in widespread areas of the world 
including temperate climates 174-179. Whilst serum levels of 25(OH)D as low as 25nmol/L 
will prevent rickets in children, it is often suggested that much higher levels are required 
for an adequate immune response.  
Only a few foods, such as oily fish, contain moderate amounts of 25(OH)D and unlike 
countries like the United States or Finland, dairy products in the UK and the rest of 
Europe are no longer fortified with vitamin D 167.  
 
It is therefore not surprising that Vitamin D deficiency is common and widespread. Over 
half of the British population has been found to have low levels of vitamin D during the 
winter months 180. Several reports are showing vitamin D deficiency not only in adults 
but in pre-pubertal populations: studies conducted in Buenos Aires, Southern Tasmania, 
Turkey, the US and Spain found vitamin D insufficiency (25(OH)D < 50nmol/L) in 10 – 
80% of the children with concerns raised over bone growth health and immune function 
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153, 181-183. Moreover, hypovitaminosis D has been linked to predisposition to chronic 
inflammatory lung disease, such as asthma and viral respiratory infections with higher 
rates of hospital admission for chest related diseases 184, 185. There is a high prevalence of 
low levels of vitamin D in medical inpatients, where an increased risk of bone fracture 
and muscle weakness potentially adds to a slower recovery 186. Also of interest are 
studies demonstrating an increased prevalence of cancers in countries at higher latitude 
including cancer of the colon, breast, oesophagus and prostate among others, suggesting 
an antiproliferative activity of vitamin D 125, 187, 188; similarly, latitude seems to confer an 
increased risk for certain autoimmune conditions such as multiple sclerosis 189, 
rheumatoid arthritis 190, inflammatory bowel diseases63 and type I diabetes mellitus 191.  
 
The importance of vitamin D for pulmonary health has been highlighted in many studies 
so far (reviewed in 192). Deteriorating asthma control and 25(OH)D levels have a similar 
seasonal oscillation and both have seen an increase in prevalence in the last decade. 
These observations have generated interest in exploring the link between the two 
conditions with a study by Black being one of the first to demonstrate a positive 
correlation between serum 25(OH)D and lung function 185. Many studies followed, and 
table 1.2 gives an overview of a number of observational studies examining the 
relationship between serum 25(OH)D levels and asthma. These studies vary in design, 
sample size and assessment of 25(OH)D status, which might explain the differing 
results.  
 
 
 
 
 
 
 46 
Author, Reference 
& Study Design Effect 
 
Beneficial 
Camargo 193 BC 
Cord blood vit D inversely associated with wheeze but not with asthma by 
age 5 
Camargo 194 BC 
High vit D intake during pregnancy associated with reduced risk of 
wheeze 
Miyake 195 BC High maternal vit D intake associated with reduced risk of wheeze 
Erkkola 196 
BC 
High maternal vit D intake associated with reduced risk of wheeze 
Devereux 197 BC High maternal vit D intake associated with reduced risk of wheeze 
Tolppanen 198 BC Vit D levels negatively correlate with wheeze 
Brehm 199 L 
Vit D levels negatively correlate with asthma severity and use of anti-
inflammatory medicine 
Brehm 200 CS Vit D levels negatively correlate with asthma exacerbations 
Chinellato 201 CS Vit D levels positively correlate with asthma control 
Searing 202 CS 
Vit D levels positively correlate with lung function and negatively with 
IgE and use of steroids 
Sutherland 203 CS 
Vit D levels positively correlate with lung function and glucocorticoid 
response 
Li 121 CS Vit D levels positively correlate with lung function 
Gupta 204 CS 
Vit D levels positively correlate with lung function in children with severe 
asthma 
Tolppanen 205 CS Vit D levels positively correlate with lung function 
Alyasin 206 CS 
 
Vit D levels positively correlate with lung function 
Montero-Arias 207 Vit D is negatively associated with asthma severity and hospitalization. 
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CS The association with lung function was not significant 
Wu 208 CS Vit D levels positively correlate with lung function 
Freishtat 209 CC Vit D levels negatively correlate with asthma 
Korn 37 CC 
 
Vit D levels negatively correlate with asthma control and severity 
 
 
No or adverse effect 
Menon 210 CC Vit D levels are not associated with asthma severity 
Pike 211 BC No association between maternal vit D levels and childhood asthma 
Gergen 212 CS No association between vit D levels and asthma 
Krobtrakulchai 213 
CC 
No association between vit D levels and asthma 
Devereux 214 BC No association between vit D levels and asthma 
Gale 215 BC Maternal vit D levels positively correlate with risk of childhood asthma 
Hollams 216 BC No association between vit D levels and asthma 
Table 1.2 Observational studies showing beneficial, no or adverse effect of vitamin 
D status on asthma 
Vit D: vitamin D: 25(OH)D. BC – birth cohort; L – longitudinal; CS – cross sectional; CC – case 
control 
 
Although birth cohort studies allow us to prospectively assess the relation between an 
vitamin D exposure and disease prevalence, significant loss to follow up and 
confounding factors will need to be taken into account when interpreting these results. 
Although most epidemiological studies show an association between lower vitamin D 
levels and increase asthma severity, there are alternative explanations for these findings. 
First, reverse causation is a potential concern in correlation studies. The vitamin D 
hypothesis states that lower vitamin D levels are causally associated with increased 
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asthma severity. It is possible that the association is causal, but in the opposite direction 
from the vitamin D hypothesis. For example, since vitamin D is synthesized in the skin 
by exposure to UV-B radiation, it is possible that children who are sicker due to their 
asthma may spend more time indoors and therefore have lower vitamin D levels. Brehm 
et al looked at the association between vitamin D levels and asthma exacerbations using 
a multivariate model, adjusting for time spent outdoors, racial ancestry as estimated 
from genetic data, and atopy (ref) All of these are potential confounders of the 
relationship between vitamin D and asthma, however the group found that even after 
adjusting for these exposures, there was still a strong relationship between vitamin D 
insufficiency and asthma exacerbations (ref) . 
Another potential issue is that vitamin D may be a negative acute phase reactant. Several 
studies have reported an acute drop in serum 25-hydroxy vitamin D levels with elective 
knee or hip arthroplasty, implying that the changes in vitamin D levels are simply a 
marker of inflammation Curr Allergy Asthma Rep (2014). While this is one possible 
explanation, there is no clear biological mechanism for how this would occur as an 
unrelated phenomenon. Another explanation, consistent with the vitamin D hypothesis, 
is that serum 25-hydroxy vitamin D is converted to active 1,25-dihydroxy vitamin D as 
an appropriate response to acute inflammation, acutely depleting the serum supply of 
25-hydroxy vitamin D (ref) . 
To answer this question, we need well-designed randomized clinical trials of vitamin D 
supplementation.. 
There are abundant studies, both epidemiological and immunological, reporting the 
detrimental effect vitamin D insufficiency may have on our health. Simultaneously, a 
vast number of reports across all medical sub-specialties suggest a potentially beneficial 
effect of normal – high serum 25(OH) levels. However, there is no absolute consensus 
on what physiological serum vitamin D levels are, or indeed what defines vitamin D 
deficiency.  In fact, a recent comprehensive review of intervention studies in a broad 
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range of diseases showed no beneficial effect apart from in elderly people where 
supplementation seemed to slightly reduce all cause mortality 217. It is noteworthy 
though that his review focused only marginally on respiratory health.   
To date there are few studies that investigated the effect of supplementing vitamin D in 
asthma and they vary considerably in terms of dose and treatment duration (see table 
1.3). One study, the VIDA trial of vitamin D supplementation in vitamin D insufficient 
asthmatics recently reported its outcomes 218. Although the primary outcome, time to 
first asthma treatment failure, was not met, patients in the treatment arm were 
significantly more likely to be able to reduce the dose of inhaled corticosteroids. One 
could conclude from this that supplementation with vitamin D might prove more 
successful when applied to a selected patient group, possibly in populations with a high 
prevalence of vitamin D deficiency at baseline, and using doses sufficient to induce 
sustained elevation of 25(OH)D concentrations. The aforementioned study proved 
successful in terms of steroid requirements to control disease and this is certainly 
interesting in relation to our interest and The Calcitriol Study.  
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 Population Treatment Outcome 
Majak 219 Mild asthma, aged 
5-18 years, n=48 
 
ICS$ +/- 500IU D3 
daily for 6 months 
Decreased exacerbation 
in D3 group 
Arshi 220 Mild-moderate 
asthma, aged 10-50, 
n=108 
ICS* +/- LABA +/- 
100’000 D3 i.m.  
Bolus, 50’000 orally 
weekly for 24 
weeks 
Improved FEV1 at 24 
weeks in D3 group 
Castro 218 Moderate asthma, 
aged  >18, n=408 
ICS$$ +/- 100’000 
D3  i.m. 4’000 daily 
for 28 weeks 
No change in FEV1 but 
D3 group able to reduce 
ICS further 
Nageswari 221 Moderate-severe 
asthma, aged 35-65, 
n=63 
ICS* +/- 1000 D3 
daily for 90 days 
Improved FEV1 in D3 
group 
Yadav 222 Moderate asthma, 
aged 3-14,  n=82 
ICS +/- 60’000 D3 
orally per month for 
6 months 
Improved Peak Flow, 
reduced ICS 
requirements and reduced 
exacerbation rate in D3 
group 
Table 1.3 Randomised controlled interventional studies in asthma and their 
outcomes 
 $ 800 mcg/d Budenoside; * Budenoside 400mcg twice daily +/- fermoterol 12mcg twice daily; 
i.m. intramuscular, FEV1 forced exspiratory volume in 1 second; 
$$ Ciclesonide 320mcg/day; 
D3: cholecalciferol 
 
There are a number of ongoing trials of vitamin D supplementation to prevent asthma or 
reduce asthma morbidity still to publish their results (see table 1.4).  
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Title / Design Target 
Population 
Hypothesis Treatment 
VDAART 
NCT00920621 
RCT 
Pregnant women 
and their children 
Vit D supplementation during 
pregnancy = reduced incidence of 
asthma during first 3 years of life 
D3 4000 IU/d vs 
placebo 
ABCvitaminD 
NCT00856947 
RCT 
Pregnant women 
and their children 
Vit D supplementation during 
pregnancy and 1 week after 
delivery prevents asthma 
symptoms in the first 3 years f life 
D3 2400 IU/d vs 
placebo 
ViDiAs 
NCT00978315 
RCT Vit D supplementation will 
influence time to severe asthma 
exacerbation in adult and 
adolescents over 1 year follow up 
D3 2-monthly oral 
doses vs placebo 
Table 1.4 Ongoing trials of vitamin D supplementation to prevent asthma or 
asthma exacerbations (taken from clinicaltrials.gov.identifier) 
RCT: randomised controlled trial. Vit D: vitamin d, D3: cholecalciferol. IU: international units 
 
Supplementation studies not only stem from the association of low vitamin D status and 
potentially poor respiratory health, but also from abundant evidence that vitamin D and 
its active metabolites have important immuno-modulatory functions - questions 
therefore arose as to how vitamin D might influence the innate and adaptive immune 
system. Research has focused on the immuno-modulatory properties of vitamin D 
following the observation that monocytes/macrophages from patients affected by the 
granulomatous disease sarcoidosis constitutively synthesize the active form of vitamin D 
from the precursor 25(OH)D and that the receptor for vitamin D (VDR) is detectable in 
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activated, proliferating lymphocytes. The next paragraph discusses the immunological 
effects of vitamin D with a focus on asthma. 
  
1. 7. 3 Immunological effects of vitamin D and its proposed effect in asthma 
There is abundant evidence that the active form of vitamin D is important for respiratory 
health 192. Chest (upper and lower respiratory tract) infections are the most common 
trigger for asthma exacerbations and are associated with a decline in lung function over 
time. The incidence of infections, in particular viral induced ones, peaks in the winter 
months when cutaneous vitamin D synthesis is weakened paving the way for many 
research studies to link vitamin D to the innate and adaptive immune system.  
Active vitamin D, (1,25(OH)2D3, hereafter calcitriol) induces antimicrobial activity in 
vitro in monocytes/macrophages 223, neutrophils 224, keratinocytes 225 and also respiratory 
epithelium 226 and has been shown to upregulate hCAP18, a human antimicrobial peptide 
precursor of the family of cathelicidins. Other antimicrobial peptides regulated by 
vitamin D are the cationic peptides defensin-# 2 and 4 224. The induction of cathelicidin 
by calcitriol results in autophagy, important for the killing of Mycobacterium 
tuberculosis in infected cells 227. Calcitriol upregulates the pattern recognition receptor 
Nucleotide-binding oligomerization domain containing 2 (NOD2) which, when activated 
in the presence of bacteria, leads to release of the antimicrobial peptide defensin-# 2 228. 
M. tuberculosis has also been shown to induce the expression of matrix 
metalloproteinases (MMPs), which degrade components of pulmonary extracellular 
matrix; calcitriol has been found to decrease the production of MMPs, thus reducing 
destruction of the lung by the mycobacteria 229.  
Treatment with calcitriol down-regulates monocyte expression of the toll-like receptors 
(TLRs) TLR2 and TLR4, which recognise non-specific pathogen-associated molecular 
patterns and are vital for the induction of early innate immune responses.  This 
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downregulation reduces production of the pro-inflammatory cytokine Tumour Necrosis 
Factor-' (TNF') when these TLRs are ligated 230.   
Calcitriol reduces dendritic cell (DC) expression of the antigen presenting molecules 
CD1a and MHC class II, and the co-stimulatory molecules CD40 and CD86.  Upon 
antigen stimulation, these DCs cannot upregulate MHC class I and II, CD80, CD86 and 
CD40 in order to fully mature, and their production of the pro-inflammatory cytokine 
IL-12 is impaired. Production of the anti-inflammatory cytokine IL-10 is enhanced.  
Consequently, calcitriol-treated DCs stimulate reduced T cell proliferation and appear to 
induce a state of hyporesponsiveness. Calcitriol-treated DCs have been described as 
being ‘tolerogenic’ with respect to T cells 231-233. 
Vitamin D has not only been linked to infection but also to autoimmunity. Several 
reports acknowledge an important role of calcitriol and VDR in Th2 driven disease, such 
as asthma. However, variable effects have been reported with some studies in mice 
describing reduced airway eosinophila, chemokine-induced T-cell migration and lung 
inflammation after injection with calcitriol 234, 235, whereas others reported no effect of 
calcitriol on lung pathology 236.  Other in vitro studies have shown that calcitriol inhibits 
T cell proliferation 168, 237 and IL-2 and IFN-" production by CD4+ T cells 238.  
The effect of vitamin D on cytokines key to asthma pathogenesis, Il-4, IL-5 and IL-13 is 
less clear: one study in mice observed that calcitriol reduced the frequency of IFN-" 
secreting CD4+ T cells but promoted IL-4, IL-5 and IL-13, suggesting calcitriol 
enhanced Th2 cell activity 239 whilst a human study reported an increase in IL-5 and IL-
13 following ex vivo treatment of PBMCs with calcitriol240. On the other hand, 
subsequent mouse and human studies found either no effect or an inhibitory effect of 
calcitriol on Th2 cells 238 among them an ex vivo cord blood study from neonates 
demonstrating inhibition of IL-4, IL-13 and IFN-" by calcitriol 241. These doscrepancies 
have partly been explained by a dosage effect with studies reporting that very high 
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concentration of 1calcitriol may fail to inhibit 160 or enhance 240 Th2 cytokine 
production. 
One way calcitriol may influence asthma pathogenesis is through modulation of CD4+ 
regulatory T cells. In vitro studies have demonstrated the ability of calcitriol to induce 
peripheral CD4+CD25- T cells to express FoxP3. Induced T regulatory cells are able to 
suppress the proliferation of effector CD4+CD25- T cells 242. In vivo studies in mice and 
humans reported similar findings: treatment with a calcitriol analogue resulted in disease 
regression in adult non-obese mice, autoimmune skin disease, rheumatoid arthritis and 
prevented transplant rejection by enhancing T regulatory cell activity 190.   
CD39 is an ectonucleotidase that catalyses the dephosphorylation of adenosine 
triphosphate (ATP) and adenosine diphosphate (ADP) into adenosine monophosphate 
(AMP). AMP is subsequently converted into the immuno-regulatory adenosine by CD73 
243. CD39 has been shown to be down-regulated in severe asthma and also to negatively 
correlate with IL-17A. Our previously published work has shown that in vitro calcitriol 
increases CD39 and hence reduces pro inflammatory IL-17A 244. 
There have been various reports about the immuno-modulatory and steroid sparing effect 
of vitamin D on Th17 mediated disease in in-vivo mouse and human models of 
experimental allergic encephalitis (EAE) 125, inflammatory bowel disease 245, rheumatoid 
arthritis 246 and autoimmune uveitis 247. To that extent several publications reported that 
vitamin D reduced the risk of MS with studies correlating the suppressive effect of 
vitamin D on Th17 cells with prevention of EAE 248. Joshi et al have shown that paralysis 
in EAE was reduced following treatment with active vitamin D3, which correlated with a 
reduction in IL-17A producing CD4+ cells 249. IL-22 is another pro inflammatory 
cytokine associated with asthma as described in paragraph 1.5 of this chapter. We and 
others have shown that calcitriol downregulates IL-22 244, 250.  One mechanisms by which 
calcitriol exerts it inhibitory effect on IL-17A could be by limiting expression of 
transcription factors RORC, RUNX1, and NFAT as well as the cytokine IL-6, all of 
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which promote the differentiation and maintenance of Th17 cells 251. Vitamin D has 
further been shown to affect the pro inflammatory IL-8, a key neutrophil attractant and 
relevant in severe, therapy resistant asthma. A study in colorectal cancer patients showed 
that daily supplementation with vitamin D significantly reduced IL-8 after 6 months.  
 
Vitamin D has also shown to modulate expression of matrix metallo-proteinases 
(MMP), such as MMP-7, MMP-9 and MMP-10. Extracellular matrix proteins are 
implicated in airway remodeling, which can lead to irreversible airways obstruction, 
often seen in longstanding and severe asthma, that is less responsive to steroid treatment. 
Increased airway smooth muscle mass (ASM) is also seen in airway remodeling and 
mouse models of asthma have shown that increased levels of vitamin D reduced ASM 
mass, subepithelial deposition and goblet cell hyperplasia 252. Serum 25(OH)D inversely 
correlates with ASM mass in paediatric asthmatics and addition of calcitriol to human 
ASM in vitro reduces cell proliferation204, 253. 
Our laboratory’s focus of interest has been the therapeutic response to steroids in 
asthmatics. In vitro dexamethasone inhibits Th2 associated cytokines via the proposed 
mechanism of IL-10 upregulation. CD4+ T cells from steroid resistant asthma patients 
fail to produce IL-10 when cultured in the presence of dexamethasone. However, when 
used in conjunction with calcitriol, dexamethasone induced a population of IL-10 
producing regulatory cells 163. In healthy controls, calcitriol alone did not lead to an 
increase in the expression of GR' but it prevented the dexamethasone dependent 
downregulation of GR' 163. These data provided a potential mechanism through which 
calcitriol enhanced dexamethasone induced IL-10 response and they led to the design of 
the proof of concept study termed ‘The Calcitriol Study’, which formed the base of this 
thesis. 
 
Chapter 2 
 
Rationale and Hypothesis 
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Steroid resistant asthma has been the focus of our laboratory’s research for a number of 
years. The work presented here discusses the results of a proof of concept clinical trial 
aimed at investigating the effect of calcitriol in steroid resistant and sensitive asthma 
patients in vivo and in vitro.  
 
It was hypothesised that calcitriol enhances clinical responsiveness to systemic 
(glucocorticoid) prednisolone therapy in asthma patients who are clinically insensitive to 
steroids.  
The immunological aim of the study was to utilise PBMC samples from the patients in 
this trial to further assess the immunophenotypes of SS and SR asthmatics at baseline, 
and following calcitriol therapy in the SR patients in order to identify potential 
immunophenotypes not only of steroid resistance but also the likely impact of treatment 
with calcitriol.  
Based on the association of severe, steroid resistant asthma and the cytokine IL-17A and 
in order to extend the laboratory’s earlier findings on the immunomodulatory effects of 
calcitriol on T cells and cytokines involved in asthma pathogenesis the study further 
hypothesised that calcitriol not only enhances IL-10 in culture but also inhibits elevated 
IL-17A production by blood Th17 cells from severe asthmatics independently of 
glucorticoids and independently of their clinical responsiveness to glucorticoid therapy 
in vivo.  
Chapter 3 
 
Materials and Methods 
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3. 1 Clinical Trial 
Recruitment into the “Calcitriol study” started in April 2009 and finished in July 2012.  
The trial was conducted in compliance with the principles of the Declaration of Helsinki 
and the principles of GCP. The study was approved by the NHS research ethics 
committee London Bridge (08/H0804/84) and to the MHRA EudraCT (2008-002244-
42) . 
We recruited patients form the asthma clinics at two local hospitals: Guys and St 
Thomas’ NHS Foundation Trust and Barts Health NHS Trust.  In an attempt to increase 
patient numbers we extended recruitment to the Homerton University Hospital NHS 
Foundation Trust, but were unable to enroll any patients into trial.  
Patients were approached under the following inclusion and exclusion criteria: 
3. 1. 1. Inclusion Criteria 
1. Male or female adults aged18 to 75 years. 
2. Documented history and typical symptoms of asthma for ( 6 months prior to 
 screening. 
3. Pre-bronchodilator FEV1 < 80% predicted and documented variability in 
airways  obstruction of 12% or greater within the previous 5 years or diurnal 
Peak Flow  variability of > 20%. 
4. Corticosteroid refractory asthma, as defined by a < 10% improvement in FEV1 
 following a 14 day course of prednisolone 40mg/1.73m2/ day29-31. 
5. Written informed consent received. 
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3. 1. 2 Exclusion Criteria 
1. Past or present disease, which, as judged by the investigator, may affect the 
study  outcome (other than asthma, rhinitis or eczema). 
2. Serum corrected calcium >2.66mmol/L 
3. Clinically significant deviation from normal (physical examination or laboratory 
 parameters) as judged by the investigator at the screening visit. 
4. Current smoker or an ex-smoker of less than 5 years with a greater than 5 pack 
year  history. 
5. Pregnant or lactating females or those at risk of pregnancy (women of 
childbearing age were offered a pregnancy test prior to recruitment). 
6. History of a respiratory tract infection and/or exacerbation of asthma within 4 
weeks of the screening visit requiring oral corticosteroid tablets. 
7. Participation in a study involving an investigational medicinal product in the 
previous 3 months or blood donation within the last year. 
8. Current or previous allergen immunotherapy. 
9. Concomitant treatment with lithium carbonate or calcium supplements. 
10. Inability to understand or comply with the research protocol 
Subjects were withdrawn from investigational product treatment if they developed 
hypercalcaemia (corrected serum calcium >2.66 mmol/l confirmed on two samples) 
during the course of the trial. This was monitored at each follow-up time point.  
Patients requiring rescue medication for exacerbation of asthma in the form of 
corticosteroids immediately before and during the trial were excluded or withdrawn 
from the trial (this included the four week wash out period).  
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Throughout the study the participants were allowed to continue their usual asthma 
medication as prescribed by their doctor (for example, short and long acting beta 
agonists (inhaled and oral form) including slow release, anticholinergics, inhaled 
corticosteroids, leukotriene receptor antagonists, theophyllines or antihistamines). 
 
3. 1. 3 Primary Outcome Measure/End Point: 
The primary outcome measure was the change in FEV1 at baseline compared to the end 
of the treatment period. 
 
3. 1. 4 Secondary Outcome Measures/End Points: 
The secondary outcome measures were  
1. Level of the ex-vivo production of cytokines by T cells 
2. Fraction of nitric oxide in exhaled air 
3. ACQ score (We obtained permission to use the Asthma Control Questionnaire 
by the author Professor Elisabeth Juniper.) 
3. 1. 5 Trial Design 
Screening Visit One 
Informed consent to take part was obtained before the screening start.  Suitable subjects 
underwent full assessment of their medical history (including a complete smoking 
history). Up to 100ml of venous blood was drawn for ex-vivo experiments. In addition, 
differential full blood counts were performed using a LH750 haematology analyser 
(Beckman Coulter, Brea, CA, USA). Albumin, phosphate and total serum calcium 
concentrations were determined using an Architect ci8200 analyser (Abbott Diagnostics, 
Chicago, IL, USA). Calcium concentration was corrected for serum albumin 
concentration using the formula: corrected calcium (mmol/l) = total calcium (mmol/l) + 
0.02 ) (40 – albumin [g/l]). Concentrations of 25(OH)D2 and 25(OH)D3 were 
determined by isotope-dilution liquid chromatography–tandem mass spectrometry and 
summed to give values for total 25(OH)D at the biochemistry laboratory under 
consultant Dr. Peter Timms at the Homerton University Hospital NHS Foundation Trust. 
Sensitivity for this assay was 10 nmol/l. Spirometry was performed using a PC based 
spirometer and software (MIR Medical International Research, Italy / WinspiroPRO).  
Reversibility was assessed by giving the subject 400mcg short acting beta agonist 
(salbutamol) followed by measuring the FEV1 pre- and 15 – 30 mins post-
bronchodilator. We measured FeNO using a Aerocrine NIOXMINO monitor, following 
the ATS/ERS guidelines. All these procedures were done in accordance to departmental 
Standard Operating Procedures.  Eligible subjects were entered into the second part of 
the screening process. These subjects received prednisolone (Wockhardt UK Ltd; 
40mg/1.73m2/day, where m2 = Body Surface Area, BSA). The dose was calculated as 
(patient's BSA (m2)/1.73)x 40mg and rounded down to the nearest 5 mg, to be taken at 
home.  
Screening Visit Two 
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The subject’s medical history and adverse events were reviewed at the start of the 
screening visit 2. Spirometry was performed and the FEV1 and FVC obtained as 
described for Screening Visit 1. Subjects demonstrating an increase of > 10% in the 
FEV1 when compared to baseline  (Screening Visit 1) were excluded. Subjects who were 
still eligible were entered into the main part of the trial. We repeated FeNO in exhaled 
air as described for Screening Visit 1. Up to 120ml of venous blood was taken to check 
that haematological and biochemical blood parameters were within normal range as 
described for Screening Visit 1, and for ex-vivo experiments.  
Treatment Visit One - Day One 
Following a 4-8 week washout period (from Screening Visit 2) participants attended 
Treatment Visit Day 1. The subject’s medical history and adverse events were reviewed 
at the start of this visit. Up to 100ml of venous blood was taken for safety haematology 
and biochemistry and for ex-vivo experiments as described for Screening Visit 1. 
Participants were randomised to receive either calcitriol 0.25*g soft capsules 
(Rocaltrol®; Roche) or organoleptically identical lactose placebo generated in house 
(Pharmacy Production Unit, St. Thomas’ Hospital NHS Trust, London, UK) twice daily. 
Patients were randomised in a 1:1 ratio using a computerised random plan generated by 
a physician not involved in the trial. Patients and trial investigators were blinded to 
treatment allocation.  
Treatment Visit Two - Day Fifteen 
On day 15 of treatment subjects attended Treatment Visit Day 15. The subject’s medical 
history and adverse events were reviewed at the start of this visit. Prior to dosing, up to 
120ml of venous blood was taken for safety haematology, biochemistry as described for 
Screening Visit 1 and for ex-vivo experiments. Subjects performed spirometry and 
fraction of nitric oxide in exhaled air (FeNO) pre-dose as described for Screening Visit 
1. A standard Asthma Control Questionnaire (ACQ) was completed by the subject 
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before prednisolone dosing. Subjects were then commenced on prednisolone 
40mg/1.73m2/day as a single daily dose for 14 days as described for Screening Visit 1.  
Final Visit - Day Twenty-Eight 
On day 28 of treatment subjects attended Treatment Visit Day 28. They had completed a 
28 day dosing period of treatment article and a 14 day dosing period of prednisolone. 
Medical history and adverse events were reviewed at the start of this visit. Following 
this, up to 120ml of venous blood were taken for safety haematology, biochemistry, as 
described for Screening Visit1 and for ex-vivo experiments. Subjects performed 
spirometry, and fraction of nitric oxide in exhaled air (FeNO) as described for Screening 
Visit 1. A standard Asthma Control Questionnaire (ACQ) was also be completed by the 
subject.  
Follow up - Day Fifty-Six 
After 1 month subjects were interviewed either during a routine visit to the asthma clinic 
or via telephone or email call to check medical history and adverse events.  Following 
this, subjects were discharged from the study.  
Figure 3.1 shows the study flowchart: 
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Figure 3.1: Calcitriol Study Flowchart 
Participants who fulfilled all inclusion criteria on Screening Visit 1 commenced a 2 
week course of oral prednisolone (Wockhardt UK Ltd; 40mg/1.73m2/day, where m2 = 
Body Surface Area, BSA). At screening visit 2 lung function tests were repeated and 
patients who had a > 10% improvement in FEV1 were excluded. All others were 
randomized after a 4 week wash out period to start either 0.25*g soft capsules 
(Rocaltrol®; Roche) or organoleptically identical lactose placebo generated in house 
(Pharmacy Production Unit, St. Thomas’ Hospital NHS Trust, London, UK) twice daily. 
After 2 weeks participants additionally took a further course of prednisolone the same 
dose as before for the remaining 2 weeks of the trial. 
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Table 3. 1 shows the tests performed each visit: 
 
Screening 
visit 1 
Screening 
visit 2 
Treatment 
visit 1 
Treatment 
visit 2 
Final 
visit 
Informed consent x     
Spirometry 
Exhaled FeNo 
x 
x 
x 
x 
 
x 
x 
x 
x 
Blood test x x x x x 
ACQ     x x 
TREATMENT: 
Calcitriol 
Prednisolone 
 
 
x 
 
 
x 
 
x 
x 
 
Table 3. 1:  Calcitriol Study: interventions at each visit.  
FeNO= fraction of exhaled nitric oxide. ACQ = Asthma Control Questionnaire. 
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3. 1. 6  Trial Statistics 
Sample Size calculation 
Although we could not anticipate the actual magnitude of enhancement of the FEV1 
response to prednisolone produced by calcitriol therapy in this study, we readily 
estimated our power to detect theoretical enhancements based on a previous study in 
which 23 moderate to severe asthmatics underwent a similar prednisolone trial31. Mean 
(SD) percent improvement in FEV1 was 15.0 (32.5%).  Power calculations predicted that 
the study of 40 glucocorticoid resistant participants would enable detection of an 
improvement in change in FEV1 from 0.4% to 10% with 80% power, tested at the 2-
sided 5% significance level. Because of difficulties with patient recruitment, however, 
the decision was made to terminate the study after 24 patients completed, giving 65% 
power. 
Statistical methods  
The differences in % predicted FEV1 at 28 days post randomisation between treatment 
groups was assessed using a linear regression model adjusted for screening values of % 
predicted FEV1 value and vitamin D status. The analysis was performed on the complete 
case population and statistical significance was assessed at the 5% level.   
For subsequent sub-analyses, data were assessed for Gaussian distribution and equality 
of variance after which the appropriate statistics were performed (see individual figure 
legends).  Data were presented as the mean ± 95% confidence intervals (CI). 
3. 1. 7   Randomisation 
A clinician not involved in the trial generated a randomised list with the help of a 
computerised randomisation plan generator (randomization.com). This was kept in 
Guy’s pharmacy and treatment was allocated accordingly. Allocation concealment was 
maintained and investigators and scientists as well as patients were blinded to the nature 
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of treatment. Guy’s and St Thomas’ NHS Foundation Trust and the clinician not 
involved in the trial kept a copy of the randomisation code. The investigator or treating 
physician was to unblind a participant’s treatment assignment only in the case of an 
emergency, when knowledge of the study treatment is essential for the appropriate 
clinical management or welfare of the subject. This situation did not arise. 
3. 1. 8 Investigational Medicinal Product and Placebo 
The investigational medicinal product in this study was calcitriol produced by Roche 
Products Limited, Marketing Authorisation Number PL/0031/0122, 0.25µg: soft 
capsules. The soft capsule was encapsulated into a hard capsule to have the same 
appearance as the placebo. 
Patients randomised to receive the investigational medicinal product received 0.25µg 
twice a day orally for 28 days. 
The placebo used was matching hard capsules with the same appearance and texture as 
the Investigational Medicinal Product and was produced by Guy’s Hospital pharmacy. 
Patients randomised to receive placebo received 1 capsule of matching placebo twice a 
day orally for 28 days. 
Patients also received prednisolone 40mg/1.73m2/day (where m2 = Body Surface Area, 
BSA) for 14 days, to be taken at home. The dose was calculated as (patient's BSA 
(m2)/1.73)x 40mg and rounded down to the nearest 5 mg. Prednisolone was produced 
by Wockhardt UK Ltd, Marketing Authorisation Number PL 29831/0178: flat faced 
tablets for 14 days. 
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3. 2 Experimental Work 
3. 2 .1 Isolation of Cell Populations from Human Peripheral Blood 
Peripheral blood (60-120mls) was collected by venepuncture into the anti-coagulant 
sodium citrate (Sigma-Aldrich Co. Ltd, Poole, UK) at a ratio of 10:1 and diluted 1:1 in 
Hank’s balanced salt solution (HBSS; Life Technologies, Gaithsburg, MD). This was 
layered at a ratio of 3:1 onto Lymphoprep® density gradient (Axis-Shield, Oslo, 
Norway) and centrifuged at 800g for 20 minutes at 4ºC. The peripheral blood 
mononuclear cells (PBMC) were removed from the Lymphoprep®:plasma interface and 
washed twice in HBSS supplemented with 2% foetal bovine serum (FBS; PAA 
laboratories, Pasching, Austria) (2%FBS/HBSS), first 600g for 10 minutes at 4ºC, then 
200g for 10 minutes at 4ºC.  PBMC pellets were then centrifuged at 6000rpm for 6 
minutes at room temperature, the supernatant was discarded and the pellets were snap 
frozen in liquid nitrogen and stored at -80°C. 
3. 2. 2 Isolation of CD4+ and CD8+ T cells by Positive Selection and CD4+ 
& APC cells by Negative Selection using Antibody coated Beads 
CD4+ and CD8+ T cells were isolated using Dynal® CD4 or CD8 Positive Isolation Kits 
respectively (Dynal, Oslo, Norway). PBMCs were incubated with CD4 or CD8 coated 
Dynabeads® (CD4 beads: 50µl per 107 PBMC, CD8 beads: 25µl per 107 PBMC) for 20 
minutes at 4ºC under continuous rotation. The sample was then placed on a magnet for 2 
minutes.  The supernatant containing the CD8 depleted cells was centrifuged at 200g for 
10 minutes at 4ºC. The cells were then resuspended in 10ml 10%FBS/HBBS. A 1:1 
dilution of 50µl of cell suspension and 50µl Trypan Blue was made and placed under a 
Haemocytometer. Viable cells were counted in 16 squares. The viable cell number was 
then calculated using the formula:  Cell number x Dilution Factor x 104 = viable 
cells/ml. 
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The bead-bound cells were washed six times with 2%FBS/HBSS by application to the 
magnet and were then resuspended in 500µl of 2%FBS/HBSS. DETACHaBEAD® 
(Dynal) was added (CD4 beads: 250µl, CD8 beads: 125µl) and the cells were incubated 
for 45 minutes at room temperature under continuous rotation. The sample was applied 
to a magnet and the supernatant containing the released, purified CD4+ or CD8+ cells 
was transferred to a fresh tube. The beads were washed twice in 2%FBS/HBSS to 
collect residual cells. The CD4+ or CD8+ cells were then washed twice in 
2%FBS/HBSS at 200g for 10 minutes at 4ºC to remove any of trace of the 
DETACHaBEAD® solution. Purity was routinely assessed by FACS analysis as 99% for 
CD4+ cells and 90% for CD8+ cells. 
Figure 3.2 shows representative plots demonstrating the purity of CD4+ & APC cells 
isolated by bead-based selection: 
  
Figure 3.2: Purity of CD4+ & APC cells isolated by bead-based selection 
CD4+ & APC T cells were isolated from PBMCs by negative selection using antibody-
coated Dynal beads. Purity was assessed by surface staining using CD19-FITC, CD3-
PerCP, CD8-PE, CD4-APC antibodies. 10000 live cells were analysed for fluorescence 
by FACS. Values shown are indicative of the percentage of positive cells within the 
relevant quadrant. 
 
Isolated cells were counted using a haemocytometer with dead cells excluded by the use 
of Tryphan Blue staining. Purified cells were resuspended at a concentration of 
1x106cells/ml 10%FBS/RPMI.  
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3. 2. 3  CD4+ & APC cell Cultures 
On day 0, cells were stimulated with plate-bound anti-CD3 (1mg/ml) (clone OKT3; 
purified in-house) and rIL-2 (50U/ml; Eurocetus, Harefield, UK).  Cells were incubated 
at 37ºC/5%CO2.  Feeding occurred on day 3; half the volume of culture medium was 
removed and replaced with 10%FBS/RPMI with 50U/ml rIL-2. 
On day 7 counting was performed by FACS analysis, using a FACScalibur (BD 
Biosciences). 0.4mg Propidium iodide (PI; Sigma-Aldrich) was added to exclude dead 
cells from the analysis.  Cells were then washed twice in 2%FBS/HBSS by 
centrifugation at 200g for 10 minutes at 4ºC and resuspended at 0.5x106cells/ml in 
10%FBS/RPMI. Cells were restimulated with plate-bound anti-CD3 (1mg/ml) and rIL-2 
(50U/ml).  On day 9 supernatants were collected and stored at -20°C for CBA analysis.   
1,25-dihydroxyvitaminD3 (also known as calcitriol, the active form of vitamin D3; 
BIOMOL Research Laboratories, Exeter, UK) and Dexamethasone was added to 
cultures on day 0 at the concentrations indicated. IL-4 was added to the cultures at 
10ng/ml; (NBS biological, Huntingdon U.K.). 
 
3. 2. 4 Quantification of mRNA Expression 
3. 2. 4. 1  RNA Extraction and Quantification 
Total RNA was isolated from cell pellets (previously ‘snap’ frozen in liquid nitrogen 
and stored at -80ºC) using the Qiagen RNeasy mini kit (Qiagen GmbH, Hilden, 
Germany), according to the manufacturers instructions. RNA was treated with RNase-
free DNase (Qiagen) to remove residual genomic DNA, before being re-purified using 
the RNeasy kit and eluted into 30ml of nuclease-free H20. RNA concentration was 
determined with a NanoDrop® ND-1000 spectrophotometer using ND-1000 software 
version 3.2.0. The purity and integrity of the RNA was assessed by A260/A280 
spectrophotometric measurements.  
3. 2. 4. 2  Reverse Transcription 
Two Hundred and Fifty nanogram RNA was reverse-transcribed into cDNA in a 30ml 
reaction. 0.2mg random hexamers (Amersham Biosciences, Buckinghamshire, UK) and 
250ng RNA were heated to 70ºC for 5 minutes, and allowed to cool on ice. A master 
mix containing a final concentration of 5x reverse transcriptase reaction buffer (MBI 
Fermentas, Sunderland, UK), 1mM 4dNTP (MBI Fermentas), 40U RNAguardTM 
(Amersham) and 200U of Revertaid Mouse Moloney Leukaemia Virus (M-MuLV) 
reverse-transcriptase enzyme (MBI Fermentas) was added per reaction. The samples 
were incubated at 25ºC for 10 minutes, 42ºC for 10 minutes, 70ºC for 10 minutes and 
held at 4ºC. The cDNA generated was stored at -20ºC until subsequent analysis by Real 
Time RT-PCR. 
3. 2. 4. 3  Real time RT-PCR 
Transcriptional expression of target mRNA transcripts were determined by PCR 
amplification, quantified by 5’-nuclease assay using fluorescent labelled TaqMan® 
probes and analysed using an ABI PRISM 7900HT Sequence Detection System thermal 
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cycler (Applied Biosystems, Foster City, USA).  All primers/probes sets were purchased 
from Applied Biosystems.  The sets used and the probe labels were IL-10 
(Hs00174086_m1), IL-17A (Hs00174383_m1), RORc (Hs01076112_m1) and FoxP3 
(Hs00203958_m1), BATF (Hs00232390_ml), IRF4 (Hs01056533_ml), STAT3 
(Hs00253714_ml). Reactions were performed in triplicate in 1 x TaqMan® Universal 
PCR MasterMix (Applied Biosystems) with 5ng reverse transcribed RNA, 0.5 x gene 
specific primer/probe set and 0.5 x 18S primer/probe set in a total volume of 10ml.  
Cycle parameters: 50ºC for 2 minutes; 95ºC for 10 minutes for 1 cycle followed by 45 
cycles of 95ºC for 15 seconds and 60ºC for 1 minute. 
3. 2. 4. 4 Validation of Multiplexed Reactions 
A TaqMan® probe has a fluorescent reporter dye (i.e. FAM or VIC) covalently linked to 
its 5’-end and a downstream non-fluorescent quencher. Fluorescence quenching depends 
upon the spatial proximity of the reporter and quencher. During the course of the PCR, 
Taq polymerase cleaves the reporter dye from the probe, thereby releasing it from the 
quencher and allowing it to fluoresce. The fluorescent dye released directly corresponds 
to amplification of the specific target sequence. The Real time RT-PCRs were internally 
controlled by an endogenously expressed gene (18S). The 18S probe has a VIC reporter 
dye whereas all of the other probes have a FAM reporter dye. These distinguishable 
reporter dyes allow amplification of 18S rRNA and the target gene of interest in a single 
well; known as a multiplex reaction. Validity of this approach was confirmed by 
performing serial dilutions of cDNA template in singleplex reactions with 18S or target 
primers/probe alone or in multiplex reactions with both 18S and target primers/probes. 
The relative quantification approach was used as the amplification efficiencies of both 
target and 18S primers/probes were found to be similar; both having slopes of within 0.5 
of -3.3 and an R2 value of greater than 0.98.  Multiplexing was performed only where it 
was determined to have no effect on the relative efficiencies of the primers/probe sets. 
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3. 2. 4. 5 !!Ct Analysis 
For each sample assayed, the Threshold Cycle (Ct) were determined for both the target 
gene and the 18S endogenous control, from the corresponding amplification plot 
according to guidelines from Applied Biosystems, using SDS software version 2.1 
(Applied Biosystems). Briefly, the baseline is set to incorporate the range of cycles in 
which the PCR product is not amplified.  The threshold line is set in the centre of the 
exponential phase of amplification to avoid the results being affected by the reaction 
components becoming limited in the plateau phase. The Ct value for each reaction is the 
cycle number at the point where the amplification curve crosses the threshold.  
The data is expressed as arbitrary units and calculated by first normalising the data by 
subtracting the Ct value of the endogenous control from the target gene Ct (+Ct). 
Samples from cell lines cultured with IL-2 but no VitD3 were chosen as reference 
samples. The +Ct of the reference or control sample was next subtracted from the +Ct of 
the other samples to give the ++Ct.  Finally, mRNA relative quantity of target genes was 
calculated using the equation: 2-(DDCt). 
3. 2. 5  Flow Cytometry 
Antibodies used for cell surface phenotyping were CD3 (BD Biosciences), CD19, CD4 
and CD8 (BD Biosciences). Please see graph below for gating strategy. For intracellular 
cytokine staining on day 7, cells were restimulated for 4 hours with 0.25 ng/ml PMA 
(Sigma-Aldrich) and 25 ng/ml ionomycin (Calbiochem), with monensin (Sigma-
Aldrich) added for the final 2 hours. Cells were washed, fixed, and permeabilized using 
Cytofix/Cytoperm kit (BD Biosciences) and triple-stained with fluorescently labeled 
monoclonal antibodies to IL-22 (ebiosciences 12-7229-42 PE anti-IL-22), IFN" (BD 
Pharmigen FITC anti-IFN" 554551), IL-13 (ebioscience PE anti-IL-13 55471), TNF' 
(BD Pharmingen PE anti-TNF' 554513), IL-10 (BD Pharmingen APC anti-IL-10 
554707), IL-17A (ebioscience APC anti-IL-17A 17-7179-42), IL-2 (BD Pharmingen 
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APC anti-IL-2 554567).  Dead cells (7-aminoactinomycin D [7-AAD] positive; Sigma-
Aldrich) were gated out and were analysed using a FACSCalibur flow cytometer 
(Becton Dickinson). Figure 3.3 shows the gating strategy chosen: 
 
Figure 3.3: Gating strategy 
Two representative plots showing the gating strategy. Firstly live cells were collected by 
7-AAD negative, lymphocytes were collected on forward (FSc) and side (SSc) scatters. 
 77 
3. 2. 6 Enzyme-Linked Immunosorbent Assay (Elisa) 
One of the techniques used to measure secreted cytokine levels from cell culture was 
ELISA (enzyme-linked immunosorbent assay), using matched antibody pairs (BD 
Biosciences). Antibody used: IL-22 (capture antibody 841990; biotinylated detection 
clone anti-hIL-22 clone 142928). 96 well plates were coated overnight with 1mg/ml 
specific catch antibody in coating buffer (0.1M bicarbonate buffer, pH9.7) at 4ºC. After 
which, the plates were washed four times with PBS buffer (PBS, 0.05% Tween-20 
(Sigma-Aldrich). The relevant cytokine was added to the plates at a final concentration 
of 0.5g/µml, along with the samples in duplicate, and incubated overnight at 4ºC. 
Standards were prepared in 10%FBS/RPMI or AIM V medium by serial 1:10 dilutions 
from the top standard 125000pg/ml. Each plate was then washed four times in PBS 
buffer and incubated with the appropriate biotin labelled detection antibody at 1mg/ml 
in detection buffer (PBS, 0.5% mouse serum (Sigma-Aldrich), 0.5% Tween-20, pH7.4) 
for 2 hours at room temperature. Following four further washes, Streptavidin HRP was 
diluted 1/200 in detection buffer and added to the plates for 30mins at room temperature. 
After that the plate was washed three times and TNB (Invitrogen 002023). The cytokine 
levels were measured using a Fusion Plate reader (Packard, UK) at an absorbance at 
450nm with 690nm control filter.  
The cytokine levels were measured using a Fusion Plate reader (Packard, UK) at an 
absorbance at 450nm with 690nm control filter. 
 
3. 2. 7 Cytometric Bead Array (CBA) 
An alternative method used to measure secreted cytokines in multiplex was by 
cytometric bead array (CBA), using the CBA flex set (BD Biosciences).  CBA is a flow 
cytometry based application using matched antibody pairs that allows for the 
quantification of multiple cytokines simultaneously within a sample.  Samples or 
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standards are firstly incubated with antibody-coated beads, which capture secreted 
cytokines, and following this step a fluorochrome-labeled detection antibody is 
incubated with the beads to bind to and quantify captured cytokine.  The beads fluoresce 
with a unique intensity within the allophycocyanin (APC) emission spectrum, to allow 
for discrimination between beads and the detection antibodies fluoresce within the 
phycoerythrin (PE) emission spectrum at an intensity determined by the quantity of 
captured cytokine.  A 16-point standard curve containing all relevant cytokines (rIL-5, 
riL-9, rIL10, rIL-13, rIL-17, rIFN-g; all R&D systems) was prepared in CBA sample 
buffer (BD Biosciences) by serial 1:2 dilutions from the top standard, which was 50000 
pg/ml for all cytokines. Standards or samples (50µl) were added to a 96-well plate and 
incubated with 50µl of capture beads (diluted 1/250 in ‘in house’ CBA buffer; 
FACSflow (BD Biosciences), 10% Bovine Serum Albumin (BSA, Fischer Scientific), 
0.5% TWEEN-20 (Sigma) and 2mM EDTA (Sigma)) for 3 hours at room temperature in 
the dark, with gentle shaking (500rpm) for the first 15 minutes.  After 3 hours the plate 
was centrifuged at 500g for 5 minutes at 4°C, the supernatant decanted and the beads 
resuspended with 200µl ‘in house’ CBA buffer.  The plate was then centrifuged for a 
further 5 minutes at 500g / 4°C and the buffer decanted.  The beads were then incubated 
with 50µl antibody-detection reagent (diluted 1/250 in ‘in house’ CBA buffer) for a 
further 2 hours at room temperature in the dark with gentle shaking (500rpm) for the 
first 15 minutes. Following this 2 hour incubation, beads were washed twice as 
described above and finally were resuspended in 150µl FACSflow (BD Biosciences) for 
analysis using a BD Fortessa flow cytometer.  Data were analysed using FlowJo 
(version 9.2, TreeStar Inc).  The lower limit of detection for all samples was 1.5pg/ml. 
3. 2. 8  Statistics 
Data were presented as the mean ± 95% confidence intervals (CI). Data were assessed 
for equivalence to a Gaussian distribution and equality of variance after which the 
appropriate parametric or non-parametric test was performed (see individual figure 
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legends). Differences were considered significant at the 95% confidence level. ). Box-
and-whisker plots represent the median, the box as inter-quartile range, and error bars as 
10th to 90th percentiles, with outliers outside the 10th to 90th percentiles shown as 
individual points. 
Chapter 4 
 
‘The Calcitriol Study’: A Randomized Placebo Controlled Trial 
to Investigate the Effects of Calcitriol Treatment in 
Glucocorticosteroid Resistant Asthma 
 
4. 1 Introduction: 
Steroids improve the clinical features of asthma and airways inflammation in a majority 
of patients; however they are not curative and they cause considerable side effects, 
particularly when taken at a high dose and over lengthy periods of time 130.  
Some patients with asthma do not improve with steroid therapy, many do so 
incompletely, even within a clinical trial, where clinical symptoms are seen in up to 20% 
of patients despite monitored adherence77. In clinical practice, account must be taken of 
poor compliance, incorrect diagnosis, poor inhaler technique, co-morbidity or 
continuous exposure to external trigger factors for inadequate asthma control. 
Considering this, there remains a small number of patients, who are clinically not 
responsive to steroid therapy. Patients with steroid resistance have a high risk of 
hospitalisation and suffer considerable morbidity and mortality and this group needs 
other agents or strategies both to control their disease and spare them from the side 
effects of systemic steroids. 
Overcoming steroid resistance, to improve the clinical response, is the focus of much 
basic and clinical research with many ongoing clinical trials. A number of mechanisms 
have been proposed to contribute to steroid resistant (SR) asthma (see also chapters one 
and five) 80, 83, 136, 254-258.  
Our laboratory has had an interest in the immune-modulatory effects of both IL-10 and 
vitamin D for a number of years: Richards et al showed that steroids induced T cell 
populations to synthesize high levels of IL-10 and greatly reduced amounts of disease-
promoting IL-4 and IL-5 158. Yet, CD4+ T cells from SR asthma patients showed an 
impaired in vitro response to steroids for the induction of IL-10 in comparison to cells 
from steroid sensitive (SS) asthmatics 259.  Subsequently, Xystrakis showed that the 
active form of vitamin D (1,25-dihydroxyvitamin D3, cholecalciferol; 1,25(OH)2D3,, 
thereafter calcitriol) when used in combination with dexamethasone restored the CD4+ 
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T cell response for the induction of IL-10 in SR asthma patients both in vitro and ex vivo 
163. 
The importance of vitamin D on pulmonary health has been highlighted in many studies 
so far (see chapter one and 192). Deteriorating asthma control and serum 25(OH)D levels 
peak during winter / early spring and both have seen an increase in prevalence in the last 
decade. These observations have generated interest in exploring the link between the 
two conditions. Black et al first demonstrated a positive correlation between serum 
25(OH)D and lung function 185 and many studies followed and Table 1.2 in Chapter one 
gives an overview of a number of observational studies examining the relationship 
between serum 25(OH)D levels and asthma. Notably, the results differ, which might be 
due to variations in design, sample size and assessment of 25(OH)D status. 
Nevertheless, it is interesting to see that those who focused on the role of 25(OH)D in 
improving disease control and treatment response to corticosteroids found that children 
with 25(OH)D levels below 75 nmol/L had increased use of inhaled and oral steroids 
relative to children with levels above 75 nmol/L,  suggestive of a potential for steroid 
enhancing properties of 25(OH)D 202. A different study in adults with persistent asthma 
found a significant association between reduced serum 25(OH)D levels and steroid 
sensitivity 203, a factor that considerably influences asthma severity and prognosis.  
Our laboratory’s earlier findings, together with epidemiological evidence that low levels 
of circulatory serum 25(OH)D is associated with a poor clinical response to steroid 
treatment in asthma174, 204, 260, 261, provided the rationale for this proof-of-concept trial 
termed ‘The Calcitriol Study’. We hypothesized that treatment with calcitriol would 
improve the clinical responsiveness to steroids in adult SR asthma patients.  
The primary outcome of the study was a change in lung function (!FEV1) from 
screening to the end of treatment period.  
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As secondary endpoints we choose to monitor asthma management via the asthma 
control questionnaire (ACQ) and measurements of fractional exhaled nitric oxide 
(FeNo).  The primary goal of asthma management is to optimise asthma control 
(minimisation of symptoms, activity limitation, and rescue ,2-agonist use) and thus 
reduce the risk of life-threatening exacerbations and long-term morbidity. The Asthma 
Control Questionnaire (ACQ) measures both - the adequacy and a change in asthma 
control, which occurs either spontaneously or as a result of treatment 262. There are many 
different questionnaires available to assess asthma control and studies have shown only 
a moderate agreement between five commonly used asthma controls scores. The ACQ is 
one of only a few fully validated questionnaires and has been shown to be particularly 
responsive to change in asthma control263. We chose the ACQ for its strong evaluative 
and discriminative properties is assessing asthma control.  
Measurement of FeNo is a quantitative method of measuring airway inflammation. 
Whilst FEV1 reversibility or provocation tests are only indirectly associated with airway 
inflammation, measurements of FeNo offer the advantage of detecting eosinophilic 
airway inflammation and to that extend allow monitoring of corticosteroid 
responsiveness or treatment adherence 264.  
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4. 2 Results 
4. 2. 1 Patient Characteristics 
Fifty patients were screened for eligibility between April 2009 and September 2012 (for 
inclusion and exclusion criteria see chapter two Materials and Methods). Figure 4.1 
shows a schematic of the trial design. All patients were seen by the principal investigator 
(myself) at their first screening visit and at their first treatment visit. Follow up visits 
were managed by myself or a clinical nurse specialist (Grainne Colligan). For an 
overview of the tests performed at each visit see table 3.1. 
Twenty-five patients were excluded before or during the screening period, which 
included a two-week course of oral prednisolone (at 40mg/1.73m2 body surface area; 
bsa): seven patients did not meet inclusion criteria, three declined to participate, three 
were non-compliant with the protocol and 12 were steroid sensitive (> 10% 
improvement in FEV1 compared to baseline). 24 severe asthmatics met the inclusion 
criteria for the study. They were randomly allocated, following a four-week washout 
period, to receive either twice daily 0.25µg calcitriol or identical placebo for a further 
four weeks. In the final two-weeks steroid treatment was repeated. 11 patients were 
allocated to placebo therapy and 13 to calcitriol. One patient in the calcitriol group 
withdrew from the study, due to constipation and back pain, leaving 11 placebo and 12 
calcitriol patients in each arm for full analysis.  
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Figure 4.1 Schematic of Clinical Trial Design 
Participants who fulfilled all entry criteria were screened at visit 1 then given a 2 week course of 
oral prednisolone. Lung function testing at screening visit 2 excluded all glucocorticoid sensitive 
asthmatics. Following a wash out period of 4 weeks, glucocorticoid resistant asthmatics began 
study treatment: At visit 1 the patients were commenced on either calcitriol or placebo, and at 
visit 2 (2 weeks later) the patients were additionally prescribed prednisolone at the same dosage 
as during the screening period. Two further weeks later, at visit 3, patients were seen again for 
assessment and lung function testing. At each visit blood tests were performed for safety 
monitoring and immunological analysis. 
 
 
Patients did not differ in terms of age, gender, FEV1, fractional exhaled nitric oxide 
(FeNo) and atopic status at screening. All had moderate to severe asthma with a mean 
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FEV1 of 56% (steroid sensitive patients) or 61.3% (steroid refractory patients) (table 
4.1). 
In our study SS patients had on average a 15% improvement of their FEV1 following an 
oral dose of prednisolone for 14 days, whereas SR patients had a mean deterioration on -
1.22%. Table 4.1 lists baseline characteristics of all patients completing the screening 
period and the patients who were randomized to receive placebo or calcitriol. There 
were no statistically significant differences in patient demographics including age, body 
mass index (BMI), atopic status (assessed by skin prick testing in the asthma clinic 
within the last five years), baseline FEV1 and inhaled steroid usage at randomisation. 
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Steroid Sensitive Steroid Resistant P value 
Age   49.0 (40.7-57.3) 51.8 (45.9-57.8)  
Ethnic Origin Caucasian 9 (75.0) 17 (73.9)  
  African 3 (25.0) 5 (21.7)  
  Asian 0 1 (4.4)  
Sex Male/ Female 4 (33.3)/ 8 (66.6) 14 (60.8)/ 9 (39.2)  
Atopic   10 (83.3) 19 (82.6)  
BMI (Kg/m2)   31.8 (28.0-35.6) 28.2 (26.2-30.2) p = 0.06 
Inhaled Corticosteroid 
dose (BDP)   
1113 (798-1469) 1225 (985-1520) p = 0.60 
Pre-steroids 1.7 (1.4-1.9) 1.9 (1.7-2.1) p = 0.13 
FEV1 (L)  
Post-steroids 2.1 (1.8-2.4) 1.8 (1.6-2.1)  
Pre-steroids 56.0 (47.4-64.6) 61.3 (55.3-67.3) p = 0.97 
FEV1 (%) 
Post-steroids 70.8 (62.6-79.0) 59.7 (52.8-66.5)  
Serum 25(OH)D 
(nmol/L)   
38.8 (27.6-50.1) 36.9 (27.6-46.2) p = 0.51 
  n=12 n=23 
Table 4.1 Patient Characteristics 
Data are shown as the mean and 95% confidence interval. Where applicable, data are shown as 
the mean with 95% confidence intervals or frequency (%). Where p values shown for non-
categorical clinical parameters assessed by an unpaired t-test. Atopy was defined by skin prick 
testing with a panel of local aeroallergens. BDP: Beclometasone dipropionate; BMI: body mass 
index; 25(OH)D: 25-hydroxyvitaminD.  
Compliance to therapy is of significant importance in placebo-controlled trials. Our 
patients were handed out diary cards to help them remember to take their treatments (see 
supplementary material).   
Corticosteroids induce neutrophil leukocytosis. Studies looking into the mechanism 
behind this have shown decreased adhesions of marginated neutrophils and/or a reduced 
capacity of neutrophils to migrate from the vasculature. Additionally, the induction of 
granulocyte-colony stimulating (GCS) factor is thought to contribute to neutrophil 
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production and release into the circulation 265. Furthermore, corticosteroid treatment 
leads to reduced eosinophil adherence and decreased chemotaxis, with both effects 
resulting in eosinopenia 266.    
As a measure of compliance we assessed peripheral blood total and differential 
leukocyte counts before and after prednisolone therapy in the screening and treatment 
phases. In each phase, prednisolone therapy resulted in similar and significant increases 
in blood neutrophils and reductions in blood eosinophils (Figure 4.2 B and 4.2 C).  
 
  
Figure 4.2 Prednisolone therapy-associated changes in blood total and differential 
leukocyte counts 
A, Whole Blood Count (WBC), B, Neutrophils, C, Eosinophils, and D, Lymphocytes in placebo 
group (open symbols) and calcitriol (closed symbols) pre- and post-prednisolone during the 
Screening Visits (left) and Treatment Visits (right). A-D, analysed by paired t-test. 
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All patient were monitored for hypercalcaemia and hyperphosphataemia, well-
described, potential side effects of calcitriol. Mean corrected serum calcium and 
phosphate concentrations were not significantly altered by active therapy (table 4.2). 
Table 4.2 Corrected serum calcium and phosphate levels at each study visit 
Data shown as mean (+95% confidence intervals). 
 
Adverse events during the study are listed in Table 4.3. There were no serious adverse 
events, and all events were self-limiting. One patient reported constipation and back 
ache after 3 days into the treatment phase. She was asked to stop the treatment 
immediately and when reviewed on day 5 was symptom-free and clinical examination as 
well as blood tests (including calcium levels) were unremarkable. Upon unblinding at 
the end of the study it transpired that she was taking the active study drug and her 
symptoms, albeit mild, may have been attributable to calcitriol.   
Table 4.3 Side effects documented throughout the trial 
All effects were non severe and resolved spontaneously. 
 
Adverse Event! Study Phase Study Drug Related to study drug!
Mild indigestion! Screening Prednisolone Yes!
Nausea! Screening Prednisolone Possible!
Increased hunger! Screening Prednisolone Yes!
Coryzal symptoms Treatment No - wash out No!
Diarrhoea Treatment Placebo No!
Coryzal symptoms Treatment Calcitriol No!
Coryzal symptoms Treatment Calcitriol No!
Coryzal symptoms Treatment Calcitriol No!
Constipation, Back pain Treatment Calcitriol Possible!
Bang to head! Treatment Calcitriol No!
Pre-steroids Post-steroids Pre-treatment Post-treatment         Pre-steroids
Post-treatment         
Post-steroids
Calcium (mmol/L) Placebo 2.30 (2.23-2.37) 2.33 (2.27-2.40) 2.28 (2.16-2.40) 2.26 (2.17-2.34) 2.30 (2.20-2.41)
Calcitriol 2.22 (2.15-2.28) 2.19 (2.08-2.30) 2.15 (2.01-2.29) 2.23 (2.13-2.34) 2.21 (2.15-2.27)
Phosphate (mmol/L)Placebo 0.95 (0.81-1.08) 1.01 (0.85-1.17) 1.09 (0.94-1.24) 0.97 (0.88-1.05) 1.09 (0.84-1.33)
Calcitriol 1.07 (0.92-1.21) 1.24 (0.98-1.51) 1.09 (0.94-1.25) 1.02 (0.87-1.17) 1.21 (1.07-1.34)
Screening Visits Treatment Visits
 91 
4. 2. 2 Primary Outcome 
Based on the primary clinical outcome of comparing lung function at screening and at 
the end of treatment, we saw no significant difference in % predicted FEV1 between the 
two groups (p=0.82): placebo start 59.9 (48.8-71.0) and final 65.9 (55.0-76.8); calcitriol 
start 62.5 (55.2-69.8) and final 68.1 (55.4-80.7). FEV1 (%; mean +/- 95%CI) (table 4.4). 
Table 4.4 Primary endpoint 
Change in FEV1 in absolute Litres (L) or % predicted: Data shown as mean (+ 95% confidence 
intervals).  
 
Nevertheless, a within group comparison of mean absolute and predicted FEV1 showed a 
modest but statistically significant improvement in response to prednisolone only in 
those receiving calcitriol (Figure 4.3 (i) p=0.03 and (ii) p=0.03 respectively).  
Figure 4.3 Effects of calcitriol versus placebo on the clinical response to oral 
prednisolone therapy 
Comparison of changes in (i) absolute and (ii) % predicted FEV1 in individual patients in 
response to 2 weeks of oral prednisolone in the screening and treatment phases of the study in 
patients randomised to receive calcitriol or placebo. Assessed by Student’s paired t-test. 
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Screening 1 Screening 2 Treatment 2 Treatment 3
FEV1 (L) Placebo 1.82 (1.44-2.21) 1.82 (1.79-2.44) 1.83 (1.42-2.23) 2.01 (1.61-2.41)
Calcitriol 1.98 (1.67-2.29) 1.88 (1.52-2.23) 1.96 (1.58-2.34) 2.20 (1.64-2.75)
FEV1 (% predicted)Placebo 59.9 (48.8-71.0) 59.9 (48.3-71.3) 60.6 (46.7-74.7) 65.9 (55.0-76.8)
Calcitriol 62.5 (55.2-69.8) 59.5 (49.8-69.2) 61.6 (53.3-69.9) 68.1 (55.4-80.7)
4. 2. 3 Secondary Outcomes: 
 
A.  ACQ (Asthma Control Questionnaire)  
 
Patients rated their asthma control and quality of life through the Asthma Control 
Questionnaire (ACQ) where a lower score predicts better asthma control. The table 
below shows ACQ score before and after treatment; there was no significant difference 
between the two groups (p=0.46, table 4.5). However in sub analyses it was observed 
that those patients showing the greatest increase in predicted FEV1 (after 2-weeks 
prednisolone; treatment phase) were those individuals who showed the greatest 
improvement in ACQ (Figure 4.4).  
Table 4.5 ACQ 7 scores of patients prior to and after prednisolone treatment 
during the treatment phase 
Data shown as the mean and 95% confidence interval. 
 
 
 
 
   
 
 
 
pre-steroids post - steroids
ACQ 7 Placebo 2.15 (1.14-3.17) 1.48 (0.97-1.98)
Calcitriol 2.15 (1.38-2.94) 1.80 (1.04-2.55)
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Figure 4. 4 Change in ACQ score post-steroids correlates with change in lung 
function  
Correlation between absolute changes in lung function (% predicted) following oral prednisolone 
therapy in the treatment phase of the study and corresponding changes in ACQ 7 scores. ACQ >0 
is improvement in asthma symptoms; ACQ <0 is a worsening of asthma symptoms. Open Circles 
– Placebo, Closed Squares – Calcitriol. Analysed by Spearman’s rank correlation test, r = -0.518, 
p = 0.0113. 
p = 0.01
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B.  FeNo; Fractional exhaled nitric oxide 
Nitric oxide (No) plays a key role in lung biology and has been implicated in the 
pathophysiology of asthma267. Patients with asthma have high levels of No in their 
exhaled breath. No originates in the airway epithelium as a result of inflammation 268. 
Thus, exhaled No may be regarded as an indirect marker of airway inflammation.  
Table 4.6 shows fractional exhaled nitric oxide (FeNo) values throughout the trial. We 
saw no statistical differences between treatment groups whether the patient was on 
placebo or calcitriol. Unexpectedly patients in the placebo group had much lower 
baseline values. A reason for the discrepancy is likely the small numbers recruited. 
However it was very interesting to see that steroid sensitive patients had lower levels 
after prednisolone treatment: FeNO showed on average a greater than 40% reduction 
compared to baseline values. This response is, in accordance to the ATS guidelines, a 
minimally important decrease of 10ppb and indicative of treatment (steroid) response 
(see discussion of this chapter).  
 
Table 4.6: Fractional exhaled nitric oxide throughout the trial  
Data presented as mean values and 95% confidence intervals. 
 
Screening 1 Screening 2 Treatment 2 Treatment 3
FeNo Placebo 19.4 (16.8-22.0) 23.1 (11.8-34.5) 21.9 (13.2-30.5) 19.7 (8.7-30.7)
FeNo Calcitriol 34.1 (19.5-48.8) 30.7 (17.1-44.3) 34.9 (20.7-49.1) 32.4 (20.1-44.8)
FeNo SS 33.75 (16.8-50.7) 19.75 (12-27.5)
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4. 2. 4 Serum (25(OH)D) levels 
Patients enrolled into the study had their serum 25(OH) levels measured on the first 
screening visit. All but three patients were vitamin D insufficient with the majority 
being deficient (figure 4.5). The three highest levels were from patients having recently 
returned from a holiday in Australia, a keen gardener and an outdoor cyclist.  
 
Figure 4.5: Serum 25(OH)D levels at baseline (Screening Visit 1): 
Serum 25(OH)D levels of all patients who completed the screening period and were identified as 
steroid sensitive (SS closed squares) and of patients who successfully completed the treatment 
period (steroid resistant, SR, open circles) are shown. The figure also shows the month the 
patients were recruited into the study and suggest seasonal differences in levels. Serum was 
analyzed by 2-dimensional high performance liquid chromatography system – tandem mass 
spectrometry (2D LC-MS-MS): All but three patients were insufficient of deficient of 25(OH)D. 
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At baseline, we saw no difference between patients who were steroid resistant and those 
who were steroid sensitive (figure 4.6 A). Patients of African or Asian origin had 
significantly lower levels as compared to Caucasians (figure 4.6 B). 1,25(OH)D3 has a 
negative feed back effect on 25(OH). Serum levels of 25(OH were measure at the start 
and at the end of the study. There was no difference seen whether the patient was on 
placebo or calcitriol (figure 4.6 C).  
Figure 4.6 Serum 25(OH)D in SS vs SR patients, according to ethnic origin and 
before and after treatment with 1,25(OH)2D 
A: No significant difference was seen in SS (n =12) versus SR (n=23) patients. Whiskers = 5-
95th percentile. Assessed by unpaired t-test, p = 0.792. B: the African / Asian population had 
significantly lower serum 25(OH)nmol/L levels as assessed by unpaired t test: p = 0.04. C: 
Calcitriol had no effect on serum 25(OH) levels, analyzed by paired t-test, Placebo p = 0.204. 
Calcitriol: p = 0.635 
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4. 2. 5 Sub-analysis of the Placebo arm 
In the placebo cohort four out of the 11 patients showed a >10% improvement in their 
lung function post-prednisolone in the treatment, as compared to the screening, phase. 
Retrospective analysis of serum concentrations of 25(OH)D of the 11 patients showed 
that six patients experienced elevation of their baseline serum 25(OH)D concentrations 
from start to final visit of study (Figure 4.7 A). It was interesting to see that there was a 
clear trend towards a positive correlation between serum 25(OH)D concentrations and 
change in predicted lung function following prednisolone (r=0.56, p=0.08; figure 4.7 B). 
Despite the very low numbers, a trend (p=0.09) towards a greater improvement in FEV1 
following prednisolone in those with relatively high (>50 nmol/L; n=6) as compared 
with low (<50 nmol/L; n=5) serum concentrations of 25(OH)D was seen (Figure 4.7 C). 
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Figure 4.7  Association of final serum 25(OH)D concentration with clinical 
responsiveness to oral prednisolone in patients randomised to receive placebo 
A: Serum 25(OH)D concentrations in placebo treated asthmatics at screening visit 1 as compared 
to the final visit (treatment visit 3). Boxes delineate “low” (black) and “high” (dotted) serum 
25(OH)D concentration groups. B: correlation between final serum 25(OH)D concentrations and 
absolute changes in lung function (predicted %) following oral prednisolone in the treatment 
phase. C: comparison of change in lung function post-glucocorticoids during treatment phase 
(Treatment 3 compared to Treatment Visit 2) shown as means ±95% CI. B, analysed by 
Spearman’s rank correlation C, analysed by paired t-test. 
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 4. 3  Discussion 
The results of this chapter discuss the clinical outcome data of ‘The Calcitriol Study’. 
They are in support of the hypothesis that the clinical responsiveness of asthma patients 
to steroid therapy is subject to manipulation, at least in the short term. The most notable 
observation was that a four week course of calcitriol improved the clinical response to 
steroids in patients classified as clinically steroid resistant (SR) in a within group 
comparison of changes in FEV1 (figure 4.3).  
Yet, the primary study outcome of a between group difference was not significant.  
Considering why the primary outcome was not met, a number of potential explanations 
may contribute to the observations made. We may have failed to detect a difference due 
to the small number of patients recruited and studied; the treatment period may have 
been relatively short for what is a chronic disease - many patients have suffered from 
asthma for many years and could likely have developed airway remodeling and possibly 
fixed obstructive airways disease to some extent. As a proof of concept and safety study 
the design of this trial was short term rather than over a lengthy treatment period. 
The rationale for the present study was based on the laboratory’s earlier immunological 
data demonstrating that steroid- induced T cell synthesis of the anti-inflammatory 
cytokine IL-10, impaired in adult SR asthmatics, was restored by calcitriol not only in 
vitro, but also ex vivo 163. This has influenced the clinical approach, and the choice of 
calcitriol rather than cholecalciferol supplementation. The alternative supplementation 
with cholecalciferol may be more practical and attractive, offering a relatively cheap, 
and safe option. Also, long term treatment with calcitriol would almost certainly raise 
concerns about the risk of drug induced hypercalcaemia. However, the combination of 
calcitriol and a steroid, known to reduce circulating calcium levels and the expression of 
Cyp27B1, the catalytic enzyme that converts circulating 25(OH)D into active calcitriol 
(1,25(OH)2D3), could potential reduce the risk sufficiently. An interesting in vitro study 
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of a murine model of colitis used a combination of the steroid dexamethasone and 
calcitriol and demonstrated a promotion of Treg cell functions with distinct increases of 
the regulatory set of IL-10, TGF- and FoxP3 and inhibition of entero-antigen specific T-
cell differentiation and as such significantly reduced the clinical severity of this chronic 
inflammatory disease 269. It is noteworthy however that the majority of these studies use 
doses of calcitriol that are 100-200 times greater than therapeutic doses in humans and 
the immuno-modulatory effects described in in vitro studies required local 
concentrations of calcitriol of 10-6 M – 10-10 M.  Maintaining such concentrations in vivo 
would require supraphysiological dosing prescriptions and there remain uncertainties on 
how to achieve this, via supplementation of vitamin D or calcitriol, and indeed whether 
it is safe to do this.  
The concept however extends others’ and our own observations of the potentially 
promising additive effect of calcitriol and dexamethasone. The antimicrobial activity of 
calcitriol further makes it an attractive adjunct to steroids in view of the increased risk of 
infections that come with chronic steroid treatment.   
Looking at our secondary endpoints, we did not see a significant difference in the ACQ 
score whether or not the patient was on placebo or calcitriol (table 4.5). This again may 
be because of the low numbers recruited or the relatively short treatment period. The 
fact that all patients were subject to a two-week course of prednisolone, a drug the 
majority of the patients were rather reluctant to take, might have influenced their quality 
of life adversely. We issued diary cards and we measured cortical levels as means to 
optimize and check compliance.  Those patients who experienced the strongest 
improvement in FEV1 had the lowest ACQ score, strengthening the questionnaire’s 
predictability of asthma control (figure 4.4). 
There was no difference seen in FeNo values between the placebo and calcitriol group 
(table 4.6). However, it was interesting to find, that SS patients showed a significant 
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reduction in FeNo levels after prednisolone treatment whereas SR patients did not. 
According to the ATS guidelines a decrease of more than 10ppb (for baseline values 
lower than 50ppb, or > 20% for baseline values higher than 50ppb) is clinically 
important and indicative of steroid responsiveness 267. Our data are in agreement with 
this and support the fact that measurements of FeNo could be an attractive adjunct to 
help identifying SS or SR patients. An independent, retrospective study in 295 patients 
with asthma found that a threshold of 42 ppb discriminates between eosinophilic and 
non-eosinophilic asthma 270. Pérez-de-Llano et al aimed to evaluate the accuracy of 
baseline FeNO to recognize individuals with difficult-to-treat asthma who have the 
potential to achieve control with a guideline-based, stepwise strategy: a FeNO cut point 
greater than or equal to 30 ppb demonstrated a sensitivity of 88% and a specificity of 
91% for the identification of steroid responsive individuals with asthma, and a value less 
than or equal to 30ppb had a negative predictive value for steroid response of 92% 271. 
The difference in FeNo levels seen between SS and SR patients is striking and FeNo 
measurements are an attractive, non-invasive tool to identify steroid sensitivity amongst 
patients with difficult to control asthma. Randomized controlled trials have so far failed 
to show improvement in asthma control based on using regular FeNo measurements for 
adjusting the dose of inhaled corticosteroid therapy 272. One of the reasons for this might 
be the fact that there are inconsistencies with regards to the dose–response relationship 
of the drugs used in relation to the outcomes measured, the fact that treatment adherence 
and non-adherence is poorly documented, and a lack of agreement on the selection of 
FeNo cut points/decision points. Whilst disease monitoring via FeNo measurements so 
far lacks evidence that it improves asthma control, measurements to better identify 
steroid responsiveness are a valuable option.  
As pointed out above, The Calcitriol Study was not designed to assess impact of 
25(OH)D status on asthma control, nevertheless it provided interesting data as all 
patients had serum 25(OH)D levels measured upon entering the study. All but one 
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participant was vitamin D insufficient (<75nmol/L) at the start of the trial (figure 4.5).  
This is in keeping with epidemiological studies assessing vitamin D status in the British 
population and in fact across the globe including countries exposed to sunshine all year 
round 200, 273,167.   
The basis for the current adult vitamin D recommendation has been more than arbitrary 
and was substantiated on the basis of seven women with severe nutritional osteomalacia, 
whose bones showed a response when given 100IU/day 274. Currently the Department of 
Health recommends ‘that people not exposed to much sun should take a daily 
supplement containing 400IU’ but also advises us not to take more than 1000IU a day 
275.  Food and Nutrition Board guidelines specify 2000IU/d as the highest vitamin D 
intake that healthy adults can consume without risking hypercalcemia, this is the upper 
limit, or what has been termed as the no adverse effect level (NOAEL). A prolonged 
intake of 95 µg vitamin D/d is said to be the lowest observed adverse effect level 
(LOAEL), a dosage that causes hypercalcemia in healthy adults. There are few data 
from which to establish vitamin D safety and toxicity limits. Some studies that might be 
considered relevant because they include data on serum calcium, urinary calcium, or 
both have major shortcomings, eg, -6 subjects, follow-up times -3 months, 
nonspecification of the form of vitamin D used (vitamin D2 or vitamin D3) or 
nonverification of the accuracy of the stated dose. 2000IU/d dosage of vitamin D3 has 
been shown to effectively increase 25(OH)D levels to high-normal concentrations with 
serum 25(OH)D within the physiologic range and is therefore considered to be a safe 
intake. 
The proposed benefits of normal – high serum vitamin D levels on the frequency of 
asthma exacerbations and respiratory infections, the most frequent overall precipitant of 
asthma exacerbation276, 277, has prompted numerous initiatives to study the impact of 
vitamin D supplementation - with mixed outcomes 184, 277-281.  
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A subanalysis of our data showed that over a third of the patients randomised to placebo 
had a considerable improvement of their serum 25(OH) levels from the start of the study 
to the final visit (from insufficient/deficient to sufficient). Although the patient numbers 
were indeed very low, these patients demonstrated what was a near significant trend for 
improvement in lung function alongside changes in circulating vitamin D levels (figure 
4.7). The increase in serum 25(OH)D levels was surprising and reasons for this may 
include exposure to sunlight, dietary intake or supplementation (despite the fact that all 
patients were asked not to take any vitamin supplements during the trial period).  
The association between serum 25(OH)D concentrations in our placebo cohort and 
clinical steroid responsiveness was very interesting to find. Other investigators have 
found similar positive results. An independent study on asthma exacerbations as a 
clinical outcome showed that children who were treated with inhaled corticosteroids 
(ICS) plus cholecalciferol (500IU) had fewer exacerbations than children on ICS only 
219. It is noteworthy that the two groups didn’t differ in their serum 25(OH) levels after 
treatment, which might be due to the relatively low supplementation dose or a possible 
lack of treatment adherence. Another recent placebo controlled supplementation study 
(the intervention group received 100 000 IU once, followed by 4000 IU/d for 28 weeks) 
found that although the primary outcome, time to first asthma treatment failure, was not 
significantly affected by vitamin D supplementation, patients in the treatment arm were 
more likely able to reduce their inhaled steroid dose (p = 0.05) 218. The study was 
underpowered, with a lower than expected event rate in the placebo arm, which might 
explain the reasons the primary endpoint wasn’t met. Furthermore, not all patients in the 
supplementation groups achieved sufficient serum 25(OH) levels. Although these data 
support our findings suggesting a possible steroid enhancing role for vitamin D, studies 
of larger sample size and longer duration are needed. Results from trials that are 
heterogeneous in baseline vitamin D status of the study populations and in dosing 
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regimens will inevitably be conflicting and there is a real need for standardized trial 
designs.  
The findings presented here raise important questions about the design of future studies. 
The decision to study a well-characterized cohort of steroid resistant asthma patients 
produced significant challenges with recruitment and retention, but on the other hand 
may have facilitated to achieve significance despite the low numbers of asthmatics 
studied. I made attempts to increase participant numbers by extending the study to three 
different sites. We were fortunate to be able to employ a dedicated specialist nurse for 
patient recruitment after the first year. Future studies will need to expand recruitment to 
a wider cohort of asthma patients, and to consider study criteria, in particular treatment 
with prednisolone. Notably, it was reassuring that no significant adverse events were 
observed.  
The results of this trial complement and expand previous studies that showed a positive 
association between serum vitamin D status and the use of anti-inflammatory medication 
in asthma174, 204. Steroids continue to be the most commonly prescribed drugs to treat 
asthma, and in the case of systemic steroids to combat exacerbations and to ameliorate 
disease in those suffering from the most severe form 130. Maintenance oral steroid 
treatment has further been shown to be the key factor driving healthcare cost in 
asthma282.   
Trials with biologicals directed at targets such as IgE, IL-5, IL-4 and IL-13, and non-
pharmacological therapies such as bronchial thermoplasty show some promise at least in 
subgroups of severe asthmatics and allow for a reduction in steroid dose 58, 283-285. Unlike 
vitamin D, however, none of these strategies are likely to be universally effective, 
affordable or convenient.  
Given the continuous increase in asthma prevalence across the globe, finding a steroid 
sparing drug that is a safe, cheap and is easy to administer could have a substantial 
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socioeconomic impact, not withstanding the benefit for asthma patients, whose lives are 
blighted by poor asthma control and numerous steroid induced side effects. The data 
discussed here are encouraging and warrant further investigations in larger, ideally 
clinically well-defined cohorts, including in paediatric asthma patients where 
epidemiological data are arguably strongest. Studies looking at supplementation during 
pregnancy or during early life will shed light on the important questions as to whether 
vitamin D can manipulate disease development or activity. If beneficial effects of 
vitamin D are confirmed future trials will need to address the optimal delivery, dosing 
and safety of vitamin D supplementation.  
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Chapter 5 
 
Immunological and Clinical Differences between 
Steroid Resistant and Steroid Sensitive Asthma Patients 
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5. 1 Introduction 
Asthma is characterized by clinical and immunological heterogeneity encompassing 
different phenotypes that require different treatment plans. Indeed, three decades ago 
Schwartz and colleagues described a subgroup of patients who demonstrated clinical 
responsiveness to beta-2-agonists but who had persistent airways hyper-reactivity 
despite intravenous administration of hydrocortisone 286,287. In vitro studies followed 
showing that proliferation of PBMCs stimulated by PHA was not inhibited by steroids in 
vitro in patients with treatment refractory asthma79.  
Steroid resistant (SR) asthma has rapidly become an accepted entity and has since driven 
research into finding more effective treatments for this patient group 80, 287. Several 
mechanisms accounting for decreased anti-inflammatory activity of steroids have been 
proposed and are discussed in chapter one. The exact mechanisms of steroid resistance 
are still unknown. In order to improve asthma control it is crucial to explore all 
possibilities driving therapy refractoriness and find ways to enhance treatment responses.  
Early investigations of cytokine expression in studies with lymphocytes from SR patients 
in culture revealed that steroids failed to inhibit IL-2 and IFN-" secretion in SR patients 
as compared to SS individuals 80. Our laboratory has previously shown that SR 
asthmatics have an impaired expression of anti-inflammatory IL-10 by CD4+ T cells in 
response to steroids in culture, and in keeping with this our data collected from the 
earlier parts of ‘The Calcitriol Study’ showed the frequency of circulating Foxp3+ CD4+ 
T regulatory cells is significantly lower in SR than in SS asthmatic patients 288. 
The active form of vitamin D, calcitriol, increases the production of the immuno-
regulatory IL-10 both directly and through enhancing steroid-induced IL-10 responses 
from CD4+ T cells in vitro, as previously shown by our laboratory and published by 
Xystrakis 163.   Calcitriol has also been found to improve steroid responsiveness via 
inhibition of LPS-induced cell activation and IL-6 production in SR asthmatics 289.  
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‘The Calcitriol Study’ was designed to primarily test the effect of calcitriol on lung 
function in SS and SR asthmatics (as discussed in chapter four) and to that extent was a 
proof of concept study of Xystrakis’ earlier findings 163. Furthermore, it also offered the 
opportunity to investigate the cellular mechanisms driving this effect in a larger cohort of 
patients than studied before 163.  
The aim of the experiments presented in this chapter was to identify specific cytokines 
associated with steroid responsiveness. All patients enrolled into the study had 
spirometry performed upon entering the trial and this allowed us to investigate the 
association between cytokine synthesis in culture, lung function and treatment response. 
We chose to investigate the production of Th2 cytokines IL-5 and IL-13, classically 
associated with steroid sensitive asthma, and Th1 cytokines IFN" and TNF', whose role 
in asthma to date is less clear but there has been an association with COPD, a chronic 
inflammatory lung disease mostly described as being steroid resistant 290. Elevation of 
serum IL-17A concentrations appears to be both a marker 291 and an independent risk 
factor for severe asthma 129-132, 292.  Involvement of Th17 cells in severe steroid resistant 
asthma is proposed from murine and human studies and in addition to IL-17A, IL-22 is 
commonly produced by Th17 cells. 135, 293. Studies were further performed looking at the 
anti-inflammatory IL-10 to complement our earlier observations. 
We hypothesized that pro-inflammatory cytokines such as IL-17A, IL-22 and Th1 
cytokines are associated with poor lung function and reduced response to steroid 
(prednisolone) treatment and that anti-inflammatory cytokines such as IL-10 positively 
correlate with improved treatment response.  
We further hypothesized that treatment with calcitriol has the potential to manipulate 
cytokines towards an immuno-protective milieu in the peripheral blood. 
To investigate this, CD8-depleted PBMCs, as used in our original studies 158, were 
isolated from patients recruited into the clinical trial as described in chapter two 
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(Materials and Methods). Intracellular cytokine production was assessed by flow 
cytometry and cytokine production in cell culture supernatants by Cytometric Bead 
Array (CBA) and following in vivo  (oral prednisolone) and in vitro (dexamethasone in 
culture) treatment. 
Each patient performed lung function tests as described in chapter two and absolute 
values (L) and % predicted values of FEV1 were analysed and compared against 
cytokine synthesis in culture. 
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5. 2 Results 
Patients were assessed for their corticosteroid responsiveness by means of FEV1 prior to 
and after a two-week course of prednisolone at a dose of 40mg/1.73m2 body surface area 
(BSA). Notably the two patient groups exhibited comparable disease severity, based on 
impairment of lung function, and were taking comparable doses of inhaled steroids (total 
dosages based on beclomethasone dipropionate (BDP) equivalence) (for patient’s 
characteristics see table 3.1 in chapter three). 
Figure 5.1 demonstrates how clearly different the two patient groups responded to 
treatment: SR patients showed no improvement in their FEV1 (mean pre: 1.90L/s, post: 
1.75L/s) whereas SS patients had on average an improvement of 14.8% in their FEV1 
(mean pre: 1.65L/s, post: 2.01L/s). Figure 5.1 B shows the change in lung function 
(FEV1) in both groups. 
Dr Emma Chambers and I performed experiments to determine whether any significant 
differences existed in the numbers of lymphocytes between SS and SR patients, prior to 
and after oral prednisolone treatment. Cell surface staining was performed on peripheral 
blood cells isolated from SS and SR asthmatics before and after treatment. There were 
no significant differences seen in the numbers of circulating total B cells, total T cells, 
CD4+ T cells and CD8+ T cells between SS and SR patients prior to oral prednisolone 
treatment (see Supplementary Figure 1 A). Following oral prednisolone, although there 
was no significant change in the total numbers of circulating lymphocytes in both the SS 
and SR asthmatic patients, the total number of circulating B cells significantly increased 
in both groups without significant change in the numbers of circulating total T cells, 
CD4+ T cells or CD8+ T cells (Supplementary Figure 1B). This resulted in a significant 
reduction of the median T:B cell ratios in both groups (Supplementary Figure 1C). 
Prednisolone therapy was also associated with a trend towards an increase in the number 
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of circulating Foxp3+ T regulatory cells in the SS, but not the SR asthmatics 
(Supplementary Figure 1D). 
     
 
Figure 5.1 Predicted FEV1 prior to and after a two week course of prednisolone at 
40mg/1.73m2. A: Steroid sensitive (SS) patients had a mean improvement of their FEV1 of 
14.8% (p = 0.0006, assessed by t test) whereas steroid resistant (SR) patients had a mean 
deterioration of their FEV1 of -1.22%. B: The change in FEV1 was significantly different between 
the two patient groups; p < 0.0001; Graph with 10-90 percentile, outliers staggered. Assessed by 
Mann Whitney test. 
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5. 2. 1    In vitro Cytokine Profiles at Baseline  
5. 2. 1. 1 SR patients have significantly higher protein levels of IFN"  and IL-
17A 
The capacity of PBMCs from SS and SR patients to synthesize the anti-inflammatory 
cytokine IL-10, the Th17 cytokine IL-17A, the Th1 cytokine IFN", and the Th2 
cytokines IL-5 and IL-13 in culture was compared at baseline, i.e. peripheral blood was 
collected from patients at screening visit 1.  CD8 T cells were depleted from PBMCs 
using magnetic beads as described in chapter two and efficacy of depletion was 
routinely assessed with typical purity 97%. Cells were cultured at a cell density of 
1x106/ml in RPMI containing 10% FCS for 7 days with anti-CD3 (1µg/ml) and IL-2 
(50IU/ml). At day 7 phorbol 12-myristate 13-acetate (PMA; 5ng/ml) and Ionomycin 
(500ng/ml) was added for 4 hours, with the final 2-hours containing Monensin (2µM) to 
allow intracellular cytokine production to be assessed by flow cytometry. In parallel 
cultures cells were also recounted at day 7 and re-cultured at 1x106/ml in the presence of 
anti-CD3 and IL-2 for a further 48-hours to account for differential cell loss. Culture 
supernatants were collected and cytokine production was assessed using Cytometric 
Bead Array (CBA).  Comparisons were made between the two patient groups at baseline 
(screening visit 1). Culture supernatants from SR asthma patients contained significantly 
higher quantities of secreted IL-17A and IFN" (IL-17A: p=0.006; IFN" p=0.02). There 
was no significant difference seen in Th2 cytokines or IL-10 between the two groups 
(Figure 5.2 A).  When comparing IL-17A and IFN", there was a non significant trend 
seen for patients with high IFN" to have lower IL-17A and vice versa (Figure 5.2 B). 
Having demonstrated elevated culture levels for IFN" and IL-17A in SR patients, the 
sensitivity and specificity of baseline IL-17A and IFN. for glucocorticoid-
responsiveness was next analysed. The combination of IL-17A and IFN. production 
produced a significant predictability to test for glucocorticoid resistance with ROC 
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analysis showing p=0.0002, sensitivity of 86.4% and specificity of 75.0%, with a cutoff 
for IL-17A+IFNg of >27.2 ng/ml.   
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B     C 
 
Figure 5.2 A, B and C Cytokine production in cell culture supernatants from SS 
and SR asthma patients at baseline. PBMCs depleted of CD8+ T cells were stimulated in 
vitro with anti-CD3 (1µg/ml) and IL-2 (50IU/ml) for seven days. At seven days cells were 
harvested and re-cultured at equal cell densities for 48h with anti-CD3 and IL-2 at which time 
cell culture supernatants were harvested for cytokine analysis using cytometric bead array 
(CBA). A: SR patients synthesized significantly higher levels of IL-17A and IFN". Graph with 
10-90 percentile, outliers staggered, assessed by unpaired t test. IL-17A: p = 0.006; IFN": p = 
0.02. SS: white, n = 12, SR: grey, n= 23. B: Comparison of culture levels of IL-17A and IFN", 
SS: open circles, SR: closed squares. C: ROC curve of IL-17A and IFN": ROC analysis 
p=0.0002, sensitivity 86.6% and specificity 75.0% with a cutoff for IL-17A+IFN" of >27.2ng/ml. 
 
 
SS SR
0
10
20
30
40
50
ng
/m
l
IFN-y
*
SS SR
0
500
1000
1500
2000
4000
6000
pg
/m
l
IL-5
SS SR
0
50
100
150
200
ng
/m
l
IL-17A
**
SS SR
0
2
4
6
8
12
24
ng
/m
l
IL-13
SS SR
0
2
4
6
8
ng
/m
l
IL-10
IL-17A (ng/ml)
IF
N
! (
ng
/m
l)
0 50 100 150 200
0
10
20
30
40
50
SR
SS
100-%Specificity
Se
ns
iti
vi
ty
 (%
)
0 50 100
0
50
100
IL-17A + IFN!
 115 
 
Intracellular cytokine expression was assessed in eight SS and 14 SR patients. Once the 
trial was up and running it became clearer what type of experiments were feasible to 
perform given the time and staff we had available to care for the patients and therefore 
the extent of laboratory work performed on visit days. Experiments looking at 
intracellular protein were started some time into the trial, resulting in lower numbers as 
compared to the assessment of protein in supernatants. PBMCs depleted of CD8+ T 
cells were treated as stated above and were stained with fluorescently labeled 
monoclonal antibodies to the Th1 cytokines IFN", IL-2 and TNF', the Th2 cytokine IL-
13, for IL-10 and for the Th17 cytokines IL-17A and for IL-22. In contrast to the 
secreted cytokines data there was no significant difference seen between the two patient 
groups for the frequency of cells expressing any of the cytokines as shown in Figure 5.3 
A and B. There was a significant variability in values between patients seen as can be 
seen by in the cumulative data presented in 5.3 B and one example of each a SS and SR 
patient presented in 5.3 A.  
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Figure 5.3 Intracellular protein expression of SS and SR patients at baseline 
PBMCs depleted of CD8+ T cells were isolated from human peripheral blood and stimulated for 
seven days with anti CD3 and IL-2 as described in Figure 5.2. At day seven, cells were 
stimulated with 5ng/ml PMA and 500ng/ml ionomycin for four hours and 2µM Monensin for the 
final two hours and stained for the expression of intracellular IL-10, IL-17A, IL-22, IFN", IL-13, 
IL-2 and TNF' as fully described in Materials and Methods. A: representative dot plots of one 
SS patient and one SR patient. B: cumulative data of % cytokine positive cells within the 
lymphocyte gate (see Materials and methods Figure 2.3). No significant difference was seen 
between the two patient groups for any cytokine as assessed by unpaired t test. Graph with 10-90 
percentile, outliers staggered.  IFN": p=0.79, IL-13: p=0.70, IL-10: p=0.84, IL-22: p=0.26, 
TNF': p=0.95, IL-2: p=0.97, IL-17A: p=0.31. SS: white, n = 8, SR: grey, n = 14.  
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5. 2. 2  The Effect of in vivo Treatment on Cytokine Profiles in Culture 
5. 2. 2. 1 Cytokine expression in supernatant cultures of SS and SR patients 
Following a two-week course of prednisolone (40mg/1.73m2 BSA) the in vitro cytokine 
levels in culture supernatants of all SS and SR patients who successfully completed the 
screening visits 1 and 2 were measured, using the same protocol and methodology as 
used for the initial (visit 1) experiments. 
There was no significant difference seen in absolute cytokine levels synthesized in 
culture between the two patient groups after prednisolone (visit 2; Table 5.1) in contrast 
to the data from the start of the trial (visit 1; Figure 5.2)) where statistically significantly 
increased secretion of IL-17A and IFN" was observed in SR cultures as compared to SS 
ones.  The median values of each cytokine (and range) are shown in Table 5.1.  
However, by assessing the change from baseline versus post prednisolone treatment, a 
significant difference in IL-17A levels was seen (Figure 5.4). In comparison to SS 
patients, SR patients had a greater reduction of IL-17A following oral corticosteroid 
treatment (p = 0.003). A reason for this could be in vivo trafficking of the cells to the 
disease site, explaining lower levels in the peripheral blood. No significant difference 
was seen for all other cytokines studied (IFN", IL-10, or IL-13) between the two patient 
groups (Figure 5.4). Table 5.1 shows the median values of change in cytokine 
production after steroid treatment.  
 
 SS SR 
Cytokine 
 
Pre Steroids 
ng/ml 
(range) 
Post Steroids 
ng/ml 
(range) 
Pre Steroids 
ng/ml 
(range) 
Post Steroids 
ng/ml 
(range) 
IFN" 10.11 
(5.01 – 20.75) 
9.81 
(2.65 – 27.85) 
15.1 
(3.92 – 41.27) 
12.36 
(3.72 – 40.85) 
IL-10  
 
0.64 
(0.18 – 6.31) 
0.46 
(0.03 – 2.34) 
0.61 
(0.07 – 2.75) 
0.58 
(0.05 – 4.8) 
IL-5 
 
0.34 
(0.02 – 1.75) 
0.13 
(0.01 – 2.89) 
0.23 
(0.01 – 3.69) 
0.25 
(0.02 – 1.02) 
IL-13 
 
1.8 
(0.18 – 16.04) 
1.64 
(0.4 – 16.04) 
1.63 
(0.19 – 20.64) 
1.64 
(0.31 – 8.47) 
IL-17A 
 
6.37 
(1.12 – 53.99) 
13.59 
(0.79 – 252.9) 
37.28 
(1.83 – 157.5) 
16.6 
(0.52 – 91.97) 
Table 5.1 The effect of in vivo steroid treatment on in vitro cytokine secretion 
following culture in SS and SR patients 
A comparison of median values (and range) of cytokines (ng/ml) synthesized in culture before 
and following a two-week course of systemic corticosteroid treatment (prednisolone). See Figure 
5.4 for experimental details. 
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Figure 5.4 A comparison of the effect of in vivo steroid treatment on in vitro 
cytokine secretion in cell cultures of SS and SR patients expressed as change (delta) 
from baseline (visit 1) to after treatment with prednisolone (visit 2). 
PBMCs depleted of CD8+ T cells were stimulated in vitro with anti-CD3 and IL-2 for seven days 
as  described in Figure 5.2. At seven days cells were harvested and re-cultured at equal cell 
densities for 48h with anti-CD3 and IL-2 alone, when CBA was used to assess cytokine content 
of culture supernatants. Results are shown as change in cytokine production (!; ng/ml cytokine 
pre-prednisolone – ng/ml cytokine post prednisolone). In comparison to baseline the reduction in 
IL-17A levels observed after prednisolone was significantly greater in SR patients (n=23), as 
compared to SS (n=12) patients (p = 0.003). Graph with 10-90 percentile, outliers staggered. 
Assessed by Mann-Whitney test.  
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5. 2. 1. 2 Intracellular cytokine expression in SS and SR patients 
The intracellular expression of IL10, IL-17A, IFN, IL-13, IL-2 and TNF' following 
culture was also assessed in SS and SR after prednisolone. This treatment did not result 
in a significant change of the frequency of cells expressing the above cytokines 
compared to baseline. Table 5.2 lists the median values (and range) of each cytokine. 
Figure 5.5 shows the change in % cells expressing cytokines. 
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 SS SR 
Cytokine 
 
Pre Steroids 
% cells 
(range) 
Post Steroids 
% cells 
(range) 
Pre Steroids 
% cells 
(range) 
Post Steroids 
% cells 
(range) 
IL-10+ 
 
0.68 
(0.35 – 1.78) 
0.62 
(0.08 – 3.63) 
0.77 
(0.01 – 1.93) 
0.76 
(0.11 – 4.59) 
IFN"+ 10.16 
(3.93 – 51.21) 
13.43 
(4.84 – 47.53) 
23.06 
(5.41 – 53.88) 
12.24 
(1.82 – 49.79) 
IL-17A+ 
 
2.03 
(0.59 – 7.15) 
1.58 
(0.13 – 12.16) 
2.39 
(0.25 – 19.21) 
1.35 
(0.1 – 16.23) 
IL-22+ 
 
0.56 
(0.29 – 6.98) 
0.97 
(0.18 – 1.41) 
3.47 
(0.51 – 9.83) 
1.46 
(0.38 – 13.22) 
IL-17A&IL-
22+ 
 
0.13 
(0.1 – 2.89) 
0.21 
(0.01 – 1.18) 
0.35 
(0.01 – 4.56) 
0.17 
(0.01 – 6.44) 
IL-13+ 
 
1.34 
(0.57 – 2.63) 
0.98 
(0.39 – 7.71) 
1.46 
(0.55 – 9.99) 
1.34 
(0.23 – 2.74) 
IL-2+ 
 
8.03 
(2.22 – 16.89) 
8.49 
(3.05 – 44.33) 
8.24 
(0.5 – 21.34) 
9.8 
(1.38 – 27.41) 
TNF' 
 
15.12 
(3.47 – 40.37) 
16.79 
(6.2 – 66.56) 
16.42 
(3.9 – 39.17) 
11.66 
(0.88 – 66.3) 
Table 5.2 The effect of in vivo steroid treatment on intracellular protein expression 
following culture in SS and SR patients 
A comparison of median values (and range) of cytokines (% cytokine positive cells) before and 
following a two-week course of systemic corticosteroid treatment (prednisolone). See Figure 5.5 
for experimental details. 
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Figure 5.5 Change in intracellular protein expression following culture of PBMC 
from SS and SR patients following (in vivo) treatment with prednisolone 
Before and after a two-week course of prednisolone PBMCs depleted of CD8+ T cells were 
isolated from peripheral blood and stimulated for seven days with anti CD3 and IL-2 as described 
before. At day seven, cells were stimulated with PMA and ionomycin for four hours, with 
monensin added for the final 2 hours, and stained for the expression of intracellular IL10, IFN", 
IL-17A, IL-22, IL-17&IL-22, IL-13, IL-2 and TNF'. Results shown as change (!) in % 
lymphocytes expressing cytokines. Graph with 10-90 percentile, outliers staggered. Assessed by 
Mann-Whitney test. SS: white, n = 8, SR: grey, n = 14.  
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5. 2. 3 The Effect of in vitro Treatment on Cytokine Profiles in Culture 
5. 2. 3. 1 Cytokine expression in supernatant cultures of SS and SR patients 
The effect of in vitro exposure to the synthetic steroid dexamethasone on cytokine 
synthesis by cultures of PBMC from SS and SR patients was studied next. PBMCs 
depleted of CD8+ T cells were stimulated in vitro with anti-CD3 and IL-2 as described 
before, in the absence or presence of dexamethasone at the dose indicated (10-9M – 10-
6M), and with or without 10ng/ml IL-4 in culture (Figure 5.6 ).  
The SR asthmatics show significantly greater IFN. and IL-17A production in culture as 
compared to the SS across the concentration range of dexamethasone. No difference was 
seen in between patient groups for IL-10 and the Th2 cytokines IL-5 and IL-13.  
The production of IFN. was significantly reduced by dexamethasone in the presence or 
absence of IL-4; additionally IL-13 was inhibited by dexamethasone in the presence of 
IL-4. Interestingly the SR asthmatics showed a significant increase in the production of 
IL-17A in the presence of 10-7M dexamethasone, an effect that was not observed in the 
SS asthmatics. There was a highly significant interaction between steroid sensitivity 
status and dexamethasone concentration on IL-10 production in IL-4 treated cultures, 
with significant dexamethasone-induced IL-10 only in the SS group, in line with our 
earlier observations (Figure 5.6). Historically the laboratory’s experiments demonstrated 
highest induction of IL-10 and Th2 cytokines by CD4+ T cells following treatment with 
dexamethasone when IL-4 was added to the culture media and therefore the same 
protocol of addition of IL-4 was used in the current study. However, earlier experiments 
revealed that IL-17A was undetectable with IL-4 in culture and IL-17A was therefore 
only measured in culture media with no added IL-4. 
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Figure 5.6 The effect of dexamethasone in culture on cytokine production of SS and 
SR asthma patients 
PBMCs were stimulated with anti-CD3 + IL-2 and dexamethasone (10-xM) as described before 
with (right column) or without (left column) the addition of 10ng/ml IL-4 in culture. Treatment 
with dexamethasone significantly increased IL-10 synthesis at 10-6M and, whith IL-4 in culture, 
at 10-6M and 10-7M. IL-17A was significantly increased at 10-6M. IFN", IL-5 and IL-13 were 
significantly inhibited by dexamethasone Data presented as mean with SEM. Assessed by two-
way ANOVA with Dunnett’s multiple comparison’s test of cytokine production in presence of 
different concentrations of dexamethasone compared to no dexamethasone. *p = <0.05, **p = 
<0.01, ***p = <0.001 ****p = <0.0001. SS: open circles, SR: closed squares. 
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5. 2. 3. 2 Intracellular cytokine expression in SS and SR patients 
Experiments were also performed to assess the change in frequency of lymphocytes 
expressing IL-10, IL-17A, IL-17A+IL-22 double positive cells, IL-22, IL-13, TNF' and 
IL-2 for both patient groups after treatment of cells in culture with dexamethasone 10-
7M. PBMCs were treated as described for Figure 5.3 and flow cytometry was performed. 
Figure 5.7 A shows a representatives FACS plots of cytokine expression by single 
representative SS and SR patients; Figure 5.7B shows cumulative data of % cytokine 
positive cells and Figure 5.7C p values for these data. 
There were significant differences seen for cytokines IL-10, IFN", IL-17&IL-22, IL-13 
and TNF' following in vitro treatment with dexamethasone. Both patient groups 
showed a significant increase in intracellular expression of IL-10 after treatment. 
However, only SR patients demonstrated a higher frequency of lymphocytes co-
expressing IL-17A+ IL-22+ cells after dexamethasone treatment. 
Dexamethasone treatment significantly reduced expression of IL-13 in both groups, 
which was more significant in SR patients likely due to the greater number of patients 
studied in this group. Dexamethasone treatment also reduced expression of IFN" and 
TNF', but only in SR patients.  
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IL-10 p = 0.0078 p = 0.0034 
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IL-22 p = 0.484 p = 0.454 
IFN"  p = 0.742 p= 0.018 
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Figure 5.7 A, B and C The effect of in vitro dexamethasone treatment on 
intracellular cytokine expression in SS and SR patients  
PBMCs depleted of CD8+ T cells were treated as before and stained for the expression of 
intracellular IL-10, IL-17A, IL-22, IFN", IL-13, IL-2 and TNF'. SS: white, n = 8, SR: grey, n = 
14. A: representative dot plots of one SS patient and one SR patient. B: Graph: SS patients had a 
significant increase in IL-10+ and a significant decrease in IL-13, SR patients had a significant 
increase in IL-10, IL-17A&IL-22+, and a significant decrease in IFN", IL-13 and TNF'. Graph 
with 10-90 percentile, outliers staggered. C: Table showing all p values. Analysed by Wilcoxon t 
test.  
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5. 2. 4 The Effect of in vivo Steroid Treatment on in vitro Response to 
Dexamethasone 
The effect of in vivo treatment with steroids (prednisolone 40mg/1.73m2 BSA) on the in 
vitro response to dexamethasone was investigated next: Following a two-week course of 
prednisolone study participants attended for a trial visit. PBMCs depleted of CD8+ T 
cells were isolated as described before and stimulated in vitro with anti-CD3 and IL-2 
and dexamethasone at the dose indicated (10-9M – 10-6M) with or without 10ng/ml IL-4 
in culture. Cytokine levels were assessed by CBA.  
Following prednisolone treatment, the previously significantly increased secretion of IL-
10 after treatment with 10-6M dexamethasone was not seen any longer although there 
remained a trend towards an increase in cytokine production.  
 
Cytokine levels of IL-5 and IL-13 in culture were significantly reduced in both patient 
groups (Figure 5.8).  
 130 
 
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
6
12
ng
/m
l
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
50
100
150
ng
/m
l
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
8
16
24
ng
/m
l
SS
SR
IL-10
-
IL-17A
IFN!
+Dexamethasone 10-xM
+ Prednisolone
+Dexamethasone 10-xM
+Dexamethasone 10-xM
+Dexamethasone 10-xM+Dexamethasone 10-xM
+Dexamethasone 10-xM
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
50
100
150
ng
/m
l
*
**
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
6
12
ng
/m
l
**
**
-
10
-9 M
10
-8 M
10
-7 M
10
-6 M
0
8
16
24
ng
/m
l
*** ***
****** *
 131 
 
Figure 5.8 The effect of in vivo steroids (prednisolone) and in vitro dexamethasone 
in culture on in vitro cytokine production: differences between SS and SR 
After a two–week course of oral prednisolone (40mg/1.73m2 BSA) participants attended for 
blood tests and PBMCs were stimulated with anti-CD3 + IL-2 and dexamethasone (10-xM) as 
described before. The previously significant difference in IL-17A and in IFN" between the two 
patient groups (left column) was abolished following in vivo prednisolone treatment (right 
column). Data presented as mean with SEM. Assessed by two-way ANOVA with Dunnett’s 
multiple comparison’s test of cytokine production in presence of different concentrations of 
dexamethasone compared to no dexamethasone. *p = <0.05, **p = <0.01, ***p = <0.001; SS: 
open circles, SR: closed squares.  
 
When IL-4 was added to the culture media SS patients had a significant induction for 
IL-10 synthesis in culture following stimulation with in vitro dexamethasone as 
compared to SR patients. This effect was not further augmented after in vivo treatment 
(Figure 5.9). 
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Figure 5.9 The effect of in vivo prednisolone treatment and in vitro dexamethasone 
on in vitro cytokine production in culture: results with IL-4 in culture media 
PBMCs were stimulated with anti-CD3 + IL-2 and dexamethasone (10-xM) with the addition of 
IL-4 in culture as described before. The difference in IL-10 synthesis in culture after in vitro 
treatment with 106 M dexamethasone was no longer significant between SS and SR patients. Data 
presented as mean with SEM. Assessed by two-way ANOVA with Dunnett’s multiple 
comparison’s test of cytokine production in presence of different concentrations of 
dexamethasone compared to no dexamethasone. *p = <0.05, **p = <0.01, ***p = <0.001. Left 
column - before prednisolone treatment, right column - after prednisolone treatment. SS; open 
circles, SR; closed squares.  
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5. 2. 5  The Correlation between Lung Function and Cytokine Levels 
SS and SR patients who fulfilled the study criteria performed spirometry at Screening 
Visit 1 using a PC based spirometer and software (WinspiroPRO) and as described in 
chapter two. Also, PBMCs from each patient were isolated and stimulated with anti-
CD3 and IL-2 with or without IL-4 as described in Figure 5.2. Cytokine synthesis in 
culture supernatants was analysed by CBA. 
There was no significant correlation seen when data of all patients (SS and SR) was 
analysed. SR patients alone showed a significant positive correlation between IL-10 
levels in culture supernatants and FEV1  (L) (p = 0.037, r = 0.448) at Screening Visit 1. 
There was a trend towards significance for SR patients with high levels of IFN" being 
associated with worse lung function (p = 0.072) (Figure 5.10).   
When IL-4 was added to the culture media SR patients showed a significantly positive 
correlation between IL-5 and FEV1 values. Table 5.3 shows r and p values of the 
correlation between cytokine levels in culture and FEV1 in absolute values (L) with and 
without IL-4 in culture media. 
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Figure 5.10 The correlation between lung function (FEV1 in L) at baseline 
(Screening Visit 1) and cytokine synthesis in culture at Screening Visit 1 (graphs 
without IL-4 in culture) 
PBMCs were stimulated with anti-CD3 and IL-2 as described before; cytokine levels in culture 
were measured by CBA. Lung function was measured at Screening Visit 1 using a PC based 
spirometer and software (WinspiroPRO). The graph shows FEV1 in L (absolute values) and 
cytokines measured in supernatants. Correlation assessed by Spearman’s rank statistical test. SS 
open circles, SR closed squares. 
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 - with IL-4 
 Cytokine  SS  SR  All Severe  SS  SR  All Severe 
IL-10 
r=0.141 
p=0.661 
r=0.448 
p=0.037 
r=0.194 
p=0.273 
r=0.127 
p=0.695 
r=0.237 
p=0.289 
r=0.249 
p=0.155 
IL-17A 
r=0.136 
p=0.674 
r=0.122 
p=0.331 
r=0.281 
p=0.107 not done not done not done 
IFN. 
r=0.350 
p=0.266 
r=-0.382 
p=0.072 
r=-0.117 
p=0.502 
r=-0.203 
p=0.528 
r=-0.107 
p=0.635 
r=-0.192 
p=0.277 
IL-5 
r=0.063 
p=0.852 
r=0.215 
p=0.336 
r=0.175 
p=0.323 
r=0.546 
p=0.088 
r=0.614 
p=0.002 
r=0.549 
p<0.001 
IL-13 
r=-0.119 
p=0.716 
r=-0.183 
p=0.404 
r=-0.107 
p=0.541 
r=0.188 
p=0.607 
r=-0.169 
p=0.476 
r=-0.040 
p=0.838 
Table 5.3 The correlation between cytokine synthesis in culture and FEV1 (L) at 
Screening Visit 1 with or without IL-4 in culture 
PBMCs were isolated and stimulated as described in Figure 5.2 and cytokine levels in culture 
were measured by CBA. Spirometry was performed using a PC based spirometer and software 
(WinspiroPRO).  A significant correlation was seen between the production of IL-10 and 
absolute values for FEV1 (L) in SR patients. When IL-4 was added to the culture media all 
patients together and SR patients as a group had a significant correlation between lung function 
(FEV1) and IL-5 in culture media. Assessed by Spearman’s rank correlation statistical test.  
 
Following two weeks of oral prednisolone participants attended for Screening Visit 2. 
PBMCs were cultured and stimulated as described before. Patients repeated spirometry 
using the same protocol as for Screening Visit 1. Cytokines in culture were assessed by 
CBA. Change in FEV1 (L) was calculated as FEV1 (L) Screening visit 2– FEV1 (L) 
Screening Visit 1.  Patients who showed the greatest improvement in lung function had 
significantly lower levels of IL-17A and higher levels of IL-10 in culture supernatants 
assessed using PBMCs from study Screening Visit 1 (Figure 5.11 and Table 5.4). SS 
patients had a positive correlation between IL-13 in culture and change in FEV1 (L). 
When assessing for cytokines IL-17A and IFN", which were highest at baseline, a 
significant negative correlation was seen. 
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Figure 5.11 Correlation between change in lung function (FEV1 in (L)) after 
prednisolone treatment and cytokine synthesis in culture at Screening Visit 1 
(graphs without IL-4 in culture) 
PBMCs were isolated and stimulated as before and cytokine levels in culture were measured by 
CBA (see Figure 5.2).  Change in lung function was calculated as FEV1 (L) Screening Visit 2 – 
FEV1 (L) Screening Visit 1.  Assessed by Spearman’s rank correlation statistical test. * p = 
<0.05, ** p = < 0.01 
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- with IL-4 
Cytokine SS SR All Severe SS SR All Severe 
IL-10 
r=0.830 
p=0.002 
r=-0.259 
p=0.244 
r=0.488 
p=0.004 
r=0.777 
p=0.005 
r=-0.151 
p=0.504 
r=-0.026 
p=0.887 
IL-17A 
r=-0.132 
p=0.558 
r=-0.03 
p=0.937 
r=-0.354 
p=0.044 not done not done not done 
IFN. 
r=0.118 
p=0.735 
r=0.196 
p=0.369 
r=-0.136 
p=0.445 
r=0.082 
p=0.818 
r=-0.102 
p=0.651 
r=-0.208 
p=0.246 
IL-5 
r=0.527 
p=0.100 
r=-0.025 
p=0.911 
r=0.071 
p=0.694 
r=-0.224 
p=0.537 
r=-0.021 
p=0.924 
r=-0.136 
p=0.460 
IL-13 
r=0.618 
p=0.048 
r=-0.100 
p=0.658 
r=0.158 
p=0.370 
r=0.500 
p=0.178 
r=-0.157 
p=0.508 
r=0.023 
p=0.905 
IL-17A + 
IFN" 
r=0.003 
p=0.991 
r=-0.052 
p=0.816 
r=-0.511 
p=0.002    
Table 5.4 The correlation between cytokine synthesis in culture at screening visit 1 
and change in lung function (FEV1 (L)) following prednisolone 40mg/1.73m2; FEV1 
(L) Screening visit 2 – FEV1  (L) Screening Visit 1 
Significant correlations were seen for the synthesis of IL-13 and IL-10 in culture in SS patients 
and IL-17A in all patients combined. When IL-4 was added to the culture media, IL-10 culture 
levels correlated significantly positive in SS patients with change in lung function. FEV1 (L). 
Assessed by Spearman’s rank correlation statistical test. 
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5. 2. 6 The correlation between serum 25(OH)D levels and cytokine levels 
It has previously been reported that low levels of serum 25(OH)D is not only associated 
with poor asthma control (see chapter one) but in particular with reduced lung function 
203, 294. We have not seen a significant association between lung function and serum 
25(OH)D levels in our cohort. This might be due to the fact that we have small patient 
numbers, a selected patient group of severe asthma with low FEV1 and the fact that the 
majority of our patients were deficient of serum 25(OH)D.  
Having demonstrated a significant correlation between cytokine levels in culture and 
change in lung function it was next investigated whether there was a correlation between 
serum 25(OH)D levels and patients’ cytokine levels in culture supernatants at Screening 
Visit 1. 
We hypothesised that cytokine levels are amenable to manipulation by vitamin D status 
in that higher levels of 25(OH)D correlate with anti-inflammatory cytokines such as IL-
10. 
SS and SR patients were assessed for their circulating serum 25(OH)D levels by isotope-
dilution liquid chromatography–tandem mass spectrometry. CD8 depleted PBMCs were 
isolated and cultured with anti-CD3 and IL-2 with or without IL-4 as described before. 
Cytokines in culture supernatants were measured by CBA. Figure 5.12 demonstrates a 
positive correlation between IL-13 and 25(OH)D.  Table 5.5 shows r and p values of the 
correlation between cytokines in culture with and without IL-4 in the culture media and 
serum 25(OH)D levels. Measured at baseline (Screening visit 1). 
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Figure 5.12 The correlation between serum 25(OH)D levels and cytokine levels 
PBMCs were cultured with anti-CD3 and IL-2 as described before. The graphs shows cytokine 
from cultures without IL-4. Serum 25(OH)D was measured at screening visit 1 by  isotope-
dilution liquid chromatography–tandem mass spectrometry. There was a positive correlation seen 
between IL-13 and serum 25(OH) (p = 0.024). Assessed by Spearman’s rank correlation 
statistical test. 
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r=0.532 
p=0.079 
r=-0.155 
p=0.488 
r=-0.120 
p=0.500 
r=0.183 
p=0.569 
r=0.205 
p=0.373 
r=0.13 
p=0.46 
IL-5 
r=0.490 
p=0.101 
r=0.050 
p=0.840 
r=0.080 
p=0.657 
r=0.581 
p=0.065 
r=0.119 
p=0.606 
r=0.299 
p=0.091 
IL-13 
r=0.559 
p=0.063 
r=0.254 
p=0.266 
r=0.393 
p=0.024 
r=0.697 
p=0.031 
r=0.594 
p=0.005 
r=0.55 
p=0.002 
IL-10 
r=0.133 
p=0.683 
r=0.156 
 p=0.498 
r=0.22 
p=0.22 
r=0.357 
p=0.256 
r=-0.136 
p=0.558 
r=-0.165 
p=0.351 
IL-17A 
r=0.497 
p=0.104 
r=0.007 
p=0.972 
r=0.046 
p=0.796 not done not done not done 
Table 5.5 The correlation between cytokine production in culture and serum 
25(OH)D levels assessed at Screening Visit 1 
All (SS and SR) patients had a significant positive correlation between IL-13 in culture and 
25(OH)D serum levels at Screening Visit 1. When IL-4 was added to the culture media 
significant correlations were seen in steroid sensnitive (SS) patients for IL-5 and IL-13, for 
steroid resistant (SR) patient for IL-13 and for all patients (SS and SR) for IL-13. Assessed by 
Spearman’s rank correlation statistical test. 
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5. 2. 7 The Effect of Calcitriol on Steroid Resistant Asthma 
The second part of this chapter discusses data from the treatment period of ‘The 
Calcitriol Study’. Steroid resistant asthma is currently inadequately managed let alone 
understood. Based on the important findings of Xystrakis et al on the effect of calcitriol 
for the induction of IL-10 in culture and the clinical improvement in lung function 
associated with this, the aim was to investigate the effect of a four-week course of 
calcitriol (0.25*g twice a day) on in-vitro cytokine production.  
Patients who successfully completed the screening period of a two week course of 
prednisolone and who failed to improve their lung function (FEV1) by > than 10% were 
characterized as steroid resistant and were double-blinded and randomised to receive 
either calcitriol or a matching placebo. Eleven patients received calcitriol and 12 patients 
received placebo. After two weeks all patients started a two week course of 
prednisolone, at the same dose they had received during the screening period and which 
they took alongside the calcitriol / placebo until the end of the treatment period. Blood 
tests were performed at the beginning of the calcitriol / placebo treatment and before and 
after corticosteroid treatment. PBMCs depleted of CD8 cells were isolated and 
stimulated with anti-CD3 and IL-2 as described before. Supernatants were assessed for 
cytokine production by CBA as described before.  
5. 2. 8 The Effect of Calcitriol on in vitro Cytokine Production  
At the Final Visit, after a four-week treatment course with calcitriol / placebo and two 
weeks of prednisolone, there was no statistical difference seen on in-vitro cytokine 
production in culture as compared to the start of the study (Screening Visit 1) between 
the two treatment groups (Figure 5.13). However, there was a trend towards decreased 
IL-17A levels in the patient group receiving calcitriol (p = 0.34). 
  
 
Figure 5.13 Cytokine production in culture by SR patients at baseline (Screening 
Visit 1) and after treatment with placebo/calcitriol and prednisolone (Final Visit) 
PBMCs were isolated and treated as before. Cytokine production in cell culture supernatants was 
assessed by CBA. There was no statistical significance seen. Data presented as mean + SEM. 
Assessed by multiple t-test corrected for multiple comparisons using the Holm-Sidak method. 
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It was next investigated whether calcitriol treatment on its own without steroid treatment 
had an effect on cytokine synthesis in cultures. Figure 5.14 shows cell culture cytokine 
levels after two weeks of calcitriol / placebo but before prednisolone.  There was no 
significant difference seen. There was a trend for reduced IL-17A levels after treatment 
(p  = 0.133). 
 
  
 
Figure 5.14 Cytokine production in culture by SR patients at baseline (Screening 
Visit 1) and after treatment with placebo/calcitriol (Treatment Visit 2) 
PBMCs were isolated and treated as before. Cytokine production in cell culture supernatants was 
assessed by CBA. There was no statistical significance seen. Data presented as mean + SEM. 
Assessed by multiple t-test corrected for multiple comparisons using the Holm-Sidak method. 
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5. 2. 9 The effect of Calcitriol on the in vitro Response to Dexamethasone 
The final data presented here discusses the in vitro production of cytokines in response 
to in vitro dexamethasone following in vivo treatment with calcitriol. Our understandig 
of cytokines involved in the pathogenesis of asthma has greatly evolved in the last years 
and it is now well accepted that different T helper cell subsets are driving the disease. 
Our aim was to investigate the effect of calcitriol on the in vitro response to 
dexamethasone treatment in culture. We hypothesised that calcitriol enhanced the anti-
inflammatory properties of dexamethasone by increasing IL-10 and inhibiting pro-
inflammatory cytokines such as Th2 and Th17 cytokines IL-17A, IL-5 and IL-13. 
CD8+ depleted PBMC of all SR patients were collected and stimulated with anti-CD3 
and IL-2 and co-cultured with dexamethasone at the dose indicated (10-9M – 10-6 M), (as 
described in Figure 5.2), after in vivo treatemnt with calcitriol / placebo for four weeks 
including oral prednisolone for the last two weeks.  
Figure 5.15 shows that after four weeks calcitriol or placebo and a repeat two week 
course of prednisolone, there was significant induction of IL-17A by dexamethasone in 
the placebo control group but not in the calcitriol treatment group. Furthermore, 
calcitriol treated SR asthmatics showed a significant increase in dexamethasone-induced 
IL-10 (when IL-4 was added to the culture media only), an effect that was not observed 
in the placebo group. There was no significantly difference seen between the two patient 
groups for the induction of IL-13 or IL-5. Similarly, there was no significant effect of 
calcitriol treatment on IFN. production.  
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Figure 5.15 The effect of Calcitriol / Placebo treatment on the in vitro response to 
dexamethasone 
CD-8 depleted PBMCs were stimulated as described before with dexamethasone at the dose 
indicated (10-6M – 10-9M) and without (left column) or with (right columns) IL-4 added to the 
culture media. Cytokines in culture supernatants were assessed by CBA. Calcitriol significantly 
increased the synthesis of IL-10 in cultures stimulated with dexamethasone 10-7 M and 10-6M. 
When IL-4 was added to the culture media the effect was significant at 10-8M, 10-7 M and 10-6M 
for patients on calcitriol treatment. There was no significant difference in between patiet groups 
seen for IFN", IL-5 and IL-13. Data presented as mean with SEM and assessed by two-way 
ANOVA with Dunnett’s multiple comparisons tests. p = <0.05, **p = <0.01, ***p = <0.001; 
Calcitriol open squares, placebo closed circles. 
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5. 3.  Discussion 
There is currently significant interest in better defining asthma phenotypes, both 
clinically and mechanistically, in order to improve treatment outcomes and hence 
asthma control.  Indeed recent clinical trials using biologics have reported successful 
outcomes when treatments were targeted at specific subgroups 59, 285. The detection of 
differences in cytokine production is a valuable approach to obtain information about 
the distinct nature of a chronic inflammatory process. The focus of this work was to 
assess the cytokine profiles of clinically characterised steroid sensitive (SS) and steroid 
resistant (SR) asthma patients and to identify whether distinct profiles could be defined, 
that were biomarkers of steroid responsiveness.  
The results presented here demonstrate significant differences between the two patient 
groups with the most striking data centering around anti-inflammatory IL-10 and pro-
inflammatory IL-17A synthesis in culture and the correlation of those cytokines with the 
patient’s clinical response to steroids. The data further highlights a potential role for IL-
17A and IFN" to predict steroid resistance in vitro. 
The dichotomy in IL-10 and IL-17A synthesis observed between SS and SR patient’ 
cultures is novel and exciting. Notably, whilst there was no correlation seen between 
cytokine production and lung function at baseline, patients who had the biggest 
improvement in lung function after a course of oral prednisolone were found to have the 
highest IL-10.  In contrast, patients whose lung function failed to improve, and in some 
in whom it deteriorated, had significantly greater production of IL-17A, suggestive of a 
potentially deleterious effect of steroids in those patients (Figure 5.11).  
In SR patients higher synthesis was not only seen for IL-17A but also for IFN" (Figure 
5.2). A difference in the in vitro synthesis of IFN" between SS and SR patient in PBMC 
cultures was first described by Corrigan in 1991 295, thus the present data confirm and 
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extend those initial findings. Higher frequencies of IFN. producing cells have also been 
well described in patients with chronic obstructive pulmonary disease (COPD) 290, 296.  
Severe, and in particular, SR asthma has many features similar to COPD, such as airway 
neutrophilia, a poor response to steroids, and also decreased IL-10 synthesis.  SR asthma 
may to that extent represent a phenotype more closely related to COPD as opposed to 
the classical Th2 high atopic asthma.  The asthma-COPD overlap syndrome, postulated 
over 50 years ago by the ‘Dutch hypothesis’, suggested that asthma and COPD have 
genetic and environmental risk factors such as allergens, infections, air pollution and 
smoking in common 297. It is believed that up to a fifth of patients with chronic airways 
disease may have overlap syndrome; characteristics include increased airway 
neutrophilia, accelerated decline in lung function and more frequent and severe 
exacerbations 298. Patients with overlap syndrome classically have less bronchial 
reversibility and are smokers or ex-smokers of less than 5 years.  
There is also a link between higher IFN. levels, recurrent infections and severe asthma. 
The role of respiratory viral infections in the development and particularly progression 
of asthma is well described. IFN. is a central factor involved in antiviral and 
antibacterial responses and detected clinically in association with many respiratory 
infections.  
It was interesting, and unexpected, to find that whilst both IFN" and IL-17A cytokine 
synthesis in culture were elevated in SR patients as compared to SS individuals, those 
patients with high IFN" expression did not have high IL-17A and vice versa (Figure 5.2 
B), defining the SR subgroup further. ROC analysis of IL-17A and IFN" synthesis in 
culture at baseline revealed a sensitivity of 86.4% and specificity of 75% to predict SR, 
rendering these cytokine valuable biomarkers to identify patients in whom steroid 
treatment on its own could have deleterious effects (Figure 5.2 C). This would certainly 
be worth exploring in more depth in the future. It has been suggested that T cells that co-
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express IL-17A and IFN" may represent more pathogenic cells than single cytokine 
positive cells 120, 299.  Unlike for IL-17A, there was no evidence of steroid mediated 
enhancement of the IFN" response. In fact, the response was inhibited by 
dexamethasone in culture in either patient group. This suggests that there are SR patients 
who produce high levels of IFN" in culture, that is amenable to in vitro steroid 
inhibition, whereas SR patients with IL-17Ahigh are clinically and immunologically SR. 
There was no difference seen at baseline for IL-10 or for the Th2 cytokines IL-5 and IL-
13 between SS and SR patients (Figure 5.2 and 5.3). This is in contrast to other studies 
that have found higher levels of Th2 cytokines in SS patients 300. However, unlike our 
data, these results represent cytokine expression in the airways as opposed to peripheral 
blood and in mild asthma, whereas our patients, SS and SR, suffered from moderate to 
severe asthma. Importantly Th2 cytokines were strongly inhibited in both patient groups 
following in vitro treatment with dexamethasone. On the other hand, a significant 
steroid-induced increase in IL-10 synthesis in culture was observed in SS patients only. 
In agreement with our previous findings this was significant with IL-4 in the culture 
media only. Steroid treatment resulted in significant reduction of the Th2 cytokines IL-5 
and IL-13 (Figure 5.6).  
We have previously shown an association between steroid sensitivity and IL-10 
synthesis in culture and a strong inhibitory effect of in vitro steroids on Th2 cytokine 
such as IL-13 301. I have briefly mentioned the landmark study by Woodruff in chapter 
one before. They identified periostin (POSTN), chloride channel regulator 1 (CLCA1), 
and serpin peptidase inhibitor, clade B, member 2 (SERPINB2) as epithelial genes that 
were specifically induced in asthma and directly regulated by IL-13 in vitro44. The group 
further identified patients with distinctly higher levels of IL-13, termed Th2-high 
asthma. This was in contrast to patients with cytokine expression including the Th1 
IFN", who was significantly lower in the Th2-high group. Of particular interest was 
 151 
their observation of corticosteroid responsiveness:  lung function of Th2-low asthmatics 
failed to improve following treatment with inhaled corticosteroids, in fact patients’ FEV1 
deteriorated suggesting a detrimental effect of corticosteroids in Th2-low asthma44. IL-
13, a key driver of airway hyper-responsiveness is increased in sputum and bronchial 
biopsy specimens of patients with severe asthma, which makes it an attractive target for 
new asthma treatments59, 302, 303. Recent clinical trials have seen a therapeutic success of 
anti-IL-13 antibodies in selected patients only, namely patients with high levels of 
FeNo, eosinophils, IgE and serum periostin levels 59. Each of these biomarkers has been 
associated with Th2 inflammation in the airway and steroid responsiveness.  
Collectively these data highlight that it is the Th2-low asthma cohort that remain 
clinically challenging and for whom new and improved treatments are needed. 
The balance between Th1 / Th17 versus regulatory cytokines is likely to be important in 
the attenuation of airway inflammation in asthma. Whilst IL-17A is associated with 
more severe disease and poor response to treatment, IL-10 has been found to limit 
inflammation as a result of bacterial and viral infections, one of the most common 
causes for asthma exacerbations and a known factor associated with the progressive 
decline in lung function seen in severe asthma 304.  Patients with asthma have been found 
to have lower levels of IL-10 mRNA and protein as compared to healthy controls 151, 155 
and there is a clear association with disease severity and lower levels of IL-10 152, 305. IL-
10 down-regulates IL-17A production from Th17 cells 306, 307 and dampens T cell 
activation via antigen-presenting cells 61, 62, 308.  Promoting an anti-inflammatory 
environment by boosting IL-10 production is an attractive concept and has been 
successful in for example allergen immunotherapy 309, 310.  
There is epidemiological evidence linking low serum 25(OH) levels with poor 
respiratory health, asthma development and treatment response 192. Our previous data 
has shown that in vitro calcitriol improved steroid sensitivity via increasing IL-10 
synthesis in culture. We have also shown that the steroid dexamethasone failed to 
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suppress the pro inflammatory IL-17A in culture. In this study, in vivo treatment with 
calcitriol, but not with placebo, resulted in diminished culture levels for IL-17A after 
stimulation with in vitro dexamethasone (Figure 5.15). Conversely, there was a trend in 
the absence, but a significant effect in the presence of IL-4 in culture of enhanced 
steroid-induced IL-10 synthesis after ingestion of calcitriol - reproducing the original 
Xystrakis observations 163 (Figure 5.15 A & B). This finding is exciting as it suggests a 
steroid-sensitizing effect of calcitriol by attenuating the pro-inflammatory activity of 
Th17 cells via up-regulation of IL-10 secreting cells.  
Historically, our laboratory has found that under all but optimal conditions of 
stimulation, namely priming with both IL-4 and dexamethasone, CD4+ T cells 
synthesized the greatest amount of IL-10, implying that endogenously produced IL-4 
synthesis can regulate T cell phenotype development.  
My results showed a positive correlation between serum 25(OH)D levels and synthesis 
of the Th2 cytokine IL-13 (Figure 5.12). A large body of conflicting scientific literature 
exists describing the capacity of vitamin D to variously inhibit or enhance Th2 responses 
in culture and in animal models (reviewed in 166, 192, 311). Importantly IL-13, and Th2 
cytokines in general, are highly sensitive to steroid inhibition (as seen in Figure 5.10) 
further implying the capacity of vitamin D to skew towards a state of steroid 
responsiveness.  The recently published paper by Castro 218 has been discussed in the 
previous chapter; together with our own data on the capacity of calcitriol to improve the 
clinical response to prednisolone. Castro et al showed that supplementation with vitamin 
D in asthma patients led to a small but significant reduction in the overall dose of 
inhaled steroids required to maintain asthma control. In addition a large body of 
epidemiological evidence demonstrate an association between low vitamin D status and 
response to treatment 192. Our data offer immunological support to Castro’s and other 
findings and pave the way for more, well-conducted clinical trials addressing the role of 
vitamin D as an adjunct to current treatments. 
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Limitations to the study design exist. The Calcitriol study only assessed peripheral blood 
cytokines. It would have been beyond our available resources to assess for BAL 
cytokines, and certainly more difficult recruitment processes but this would have been 
interesting to look into. The data presented in this chapter represents data from severe 
asthmatics only and not from healthy controls. I will discuss the role of IL-17A in severe 
asthma further in chapter six, where I investigated its expression in the healthy 
population and in patients. It would undoubtedly be interesting to compare some of the 
above data with data from healthy individuals.  
 
There are other limitations in our experimental approach; the study was designed to 
investigate the effect of calcitriol in SR patients only. SS patients were excluded after 
the second screening visit and by targeting severe steroid resistant patients specifically 
during recruitment; the number of SS patients is much lower (12 versus 23 SR patients). 
This carries the risk for some of the data being skewed. In hindsight one would want to 
recruit equal numbers throughout the trial. 
 
Cell cultures use for this proof of concept study were based on the laboratories earlier 
experiments with CD4+ T cells and APCs.  It is well known that IL-17A is also secreted 
by CD8 cells, "( T cells and others 96 and in future experiments it would be good to look 
at cytokine expression in different cell types.  Other cytokines involved in steroid 
resistance have emerged recently, namely IL-6, which is involved in the differentiation 
and maintenance of Th17 cells, or IL-8, a key neutrophil chemoattractant, that has 
previously been shown to be sensitive to vitamin D treatment 312 and it would have been 
interesting to study the effect of calcitriol on more cytokines with more time and 
funding available. Interpretation of data after in vivo and in vitro stimulation with 
steroids is difficult potentially due to inter individual differences in absorption and 
metabolism of prednisolone and calcitriol and its effect on cell signaling in vitro. The 
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focus of our results centered on cytokine levels in culture at baseline and following 
either in vivo or in vitro treatment instead. 
 
In conclusion, the data discussed here show that SR patient were distinct in expressing 
high culture levels for IL-17A and IFN", providing a possibility for in vitro testing for 
steroid resistance. Patients with high levels of IL-17A, that is less responsive to steroid 
treatment, could be in a chronic pro-inflammatory state with IL-17A potentially 
sustaining higher IFN" levels hence poor asthma control. This is certainly reflected in 
the clinical response to steroids in terms of lung function, where best outcomes are seen 
in patients with low levels of IL-17A and high levels of the immuno-modulatory 
cytokine IL-10. 
Calcitriol has the potential to enhance steroid activity through promotion of an anti-
inflammatory environment with IL-10high and IL-17Alow.  Although our numbers are 
small, the data also showed that patients with high serum 25(OH)D had higher levels of 
the strongly steroid responsive IL-13 giving weight to the concept that 25(OH)D could 
lead to a shift in Th -cell balance by altering the immunophenotype away from a steroid 
resistant Th17 phenotype towards a more responsive Th2 immunophenotype. Thus, 
while calcitriol does not improve lung function in asthma directly it does improve 
responsiveness to steroid therapy.  
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Supplementary Data 
Figure 1: 
A 
B C 
        D 
Figure S1 Absolute lymphocyte counts in the peripheral blood of steroid sensitive 
(SS) and steroid resistant (SR) asthma patients before and after a 2 week course of 
oral prednisolone. 
A, total lymphocytes B, total B cells (CD19+), T cells (CD3+), CD4+ and CD8+ T cells C, the 
ratio of CD3+:CD19+ cell ratios and D, total Foxp3+ CD4+ T cells in the peripheral blood of 
steroids sensitive (SS) and resistant (SR) severe asthmatics. Data assessed by Wilcoxon matched-
pairs test *=p<0.05, ** p<0.01 ***= p<0.001. 
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Chapter 6 
 
 
Enhanced production of IL-17A in Severe Asthma is Inhibited 
by Calcitriol in a Steroid-Independent Fashion 
 157 
6. 1 Introduction 
Studies of recent years demonstrated, and indeed the results of the previous chapter are 
in support of this, that the immune mechanisms involved in asthma cannot be explained 
by a Th1/Th2 imbalance only, but that a complex interplay exists between different 
innate and adaptive immune cells. Depending on the cytokine milieu present at the time 
of antigen presentation and T cell activation, T cells differentiate into effector T cell 
subsets, which secrete various cytokines, such as IFN" (Th1 cells), IL-10 (iTreg cells), 
IL-22 (Th22 cells) and IL-17A, IL-17F, IL-22 (Th17 cells). Understanding the role of 
the many different cytokines involved in asthma pathogenesis is important for the 
development of new therapies. 
The previous chapter has highlighted that steroid resistant (SR) asthma patients recruited 
into ‘The Calcitriol Study’ were found to have significantly higher culture levels of the 
pro inflammatory cytokine IL-17A than steroid sensitive (SS) patients. These data are in 
agreement to previous reports, showing that increased IL-17A cytokine concentrations 
are both an indicator and a risk factor for severe asthma 131, 132, 291, 292, 313.   Furthermore, 
Th17 cells and IL-17A were implicated in steroid non-responsiveness in a murine model 
of allergic asthma 135. In vitro and in vivo experiments have shown that transfer of Th17 
or Th2 cells could both initiate airway hyperresponsiveness, but only Th2 cells were 
inhibited by steroid treatment 135.  
Similarly, the cytokine IL-22 has been demonstrated to be important in sustaining 
inflammation in autoimmune disease and, as well as being elevated in patients with 
severe asthma 145, has been described to augment the pro-inflammatory activity of IL-
17A 144, 147, 314.  
Monoclonal antibodies against IL-17A have been trialled in asthma but not all were able 
to improve disease control. Furthermore there is a concern that blocking IL-17A could 
lead to an increase in infection 58, 72.  Genetic deficiency in IL-17RA is associated with 
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recurrent or persistent mucocutaneous infections caused by Candida albicans and, to a 
lesser extent, by Staphylococcus aureus 315. Treatments with anti-IL-17A antibodies in 
psoriasis and arthritis were generally well tolerated in the reported phase 2 studies but 
the duration of these studies was relatively short and the probable side effects associated 
with anti-IL-17A treatments need to be evaluated further in studies to come and the aim 
should be to find treatments directed at controlling inflammation whilst maintaining host 
defense. 
Previous studies have shown that the active from of vitamin D, 1,25(OH)2D3  (hereafter 
calcitriol) represses mRNA and transcription of several pro-inflammatory cytokines 
including IL-17A 249, 316, 317 while others have highlighted the capacity of calcitriol to 
inhibit Th17 responses247, 318, 319.  
Vitamin D is also known to have antimicrobial activity 320-323. There is an interest in the 
potential of vitamin D to regulate autoimmune diseases and to reduce the amount of 
anti-inflammatory (=steroid) medication required for disease control without affecting 
host defense mechanisms negatively. Studies have highlighted the capacity of calcitriol 
to inhibit Th17 proliferation and function in mouse models of autoimmunity and also in 
human keratinocytes and T cells in vitro 247, 249, 318, 319. 
Therefore, expanding on above studies and following our observations of higher levels 
of IL-17A in cultures of severe asthma patients this chapter discusses IL-17A and IL-22 
cytokine levels in culture between healthy control subjects and patients and the role 
dexamethasone and calcitriol might have in controlling the synthesis of these cytokines. 
To address this IL-17A and IL-22 cytokine production from PBMCs of healthy controls 
and asthma patients were stimulated in culture in the absence and presence of 
dexamethasone and calcitriol. 
The experiments in this chapter were performed whilst the clinical trial was ongoing and 
patients’ in vitro data started to emerge. The results complement and expand data 
 159 
discussed earlier. Time and funding restrictions limited the number of in vitro 
experiments that were performed on patient’s and healthy control subject’s material.  
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6. 2  Results 
6. 2. 1 The Expression of IL-17A and IL-22 in Healthy Controls and 
Asthma Patients 
The results of chapter five demonstrated that PBMCs from SR asthma patients 
synthesized significantly higher levels of IL-17A in culture than those of SS patients 
(figure 5.2) and that this effect was not abrogated by in vitro steroid treatment (figure 
5.6) suggesting a role for IL-17A in steroid resistant asthma. IL-17A levels in culture 
also inversely correlated with a change in lung function after in vivo steroid treatment 
(figure 5.11). 
To assess the in vitro production of IL-17A in healthy controls and severe asthma 
patients CD8-depleted PBMCs were isolated from the peripheral blood and stimulated 
with anti-CD3 and IL-2 for seven days. Cells were cultured at a cell density 1x106/ml in 
RPMI containing 10% FCS with anti-CD3 (1µg/ml) and IL-2 (50IU/ml). At day 7 
phorbol 12-myristate 13-acetate (PMA) (5ng/ml) and Ionomycin (500ng/ml) was added 
for 4 hours, with the final 2-hours containing Monensin (2µM) to allow intracellular 
cytokine production to be assessed by flow cytometry. In parallel cultures cells were 
also recounted at day 7 and re-cultured at 1x106/ml in the presence of anti-CD3 and IL-2 
for a further 48-hours to account for differential cell loss. Culture supernatants were 
collected and IL-17A cytokine production was assessed using Cytometric Bead Array 
(CBA), IL-22 cytokine production was assessed by ELISA.  
Initial experiments investigated whether there was a difference in cytokine production in 
culture between healthy controls and patients enrolled into ‘The Calcitriol Study’ (SS 
and SR patients). Figure 6.1demonstrates significantly greater percentages of IL-17A+ 
..control subjects. When patients were divided according to their response to 
prednisolone treatment after the initial screening phase in the trial, only SR patients 
showed a significant difference in IL-17A and IL-22 immuno-reactivity   (IL-17A: SR p 
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= 0.003; SS p = 0.142; IL-22: SR p = 0.037; SS p = 0.701), compared to control subjects 
(Figure 6.1 B).  
Cells co-expressing IL-17A and IL-22 are proposed to represent the more pathogenic 
population, and it was interesting to find they were significantly increased in all 
asthmatics and SR asthmatics as compared to healthy control subjects (all asthmatics 
p=0.029; SR p=0.009).  Culture supernatants from asthma patients contained 
significantly higher quantities of secreted IL-17A and IL-22 as compared to healthy 
controls (Figure 6.1 C). Production of IL-17A and IL-22 was significantly increased in 
all severe asthmatics as compared to controls (IL-17A: p=0.009; IL-22: p=0.036). 
Supernatants from SR had significantly more IL-17A as compared to SS (p=0.016), 
whereas culture supernatants from SS and SR patients contained comparable levels of 
IL-22. 
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Figure 6.1 Severe asthma patients express higher levels of IL-17A and IL-22 
CD8-depleted PBMCs were stimulated for 7-days with anti-CD3 and IL-2. Control and asthmatic 
cultures were assessed for IL-17A and IL-22 production by intracellular flow cytometry and 
cytometric bead array (CBA) and ELISA respectively. A, Representative dot plots of one healthy 
control and one asthma patient. B, Cumulative data of cytokine positive cells (healthy n=8; SS 
n=8 and SR n=14) and C, secreted cytokines (healthy n=10; SS n=10 and SR n=14). Analysis by 
unpaired t-test, * p<0.05; ** p<0.001. SS: open circles; SR: closed squares; healthy controls: 
closed circles.  
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6. 2. 2 Dexamethasone Increases IL-17A and IL-22 Synthesis in Culture of 
Healthy Controls 
 
Steroids are the most widely used therapy for asthma. Having found a significantly 
higher production of IL-17A in cultures of asthma patients as compared to healthy 
controls, the effect of in vitro dexamethasone treatment on IL-17A synthesis in culture 
was next investigated.  PBMCs of healthy donors and asthma patients were isolated and 
stimulated as before with the addition of dexamethasone in cultures at the dose indicated 
(10-9  – 10-6M). IL-17A and IL-22 cytokine production was assessed by flow cytometry 
where dexamethasone was used at a concentration of 10-7M only due to a limited 
amount of blood available for experiments relating to the clinical trial and based on 
earlier observations in our laboratory for an optimum induction of IL-17A and other 
cytokines 301. IL-17A cytokine production in culture supernatants was assessed by 
cytometric bead array (CBA) and IL-22 was assessed by ELISA. 
Figure 6.2 shows that dexamethasone failed to inhibit IL-17A and IL-22. In fact, in 
healthy controls, there was a significant increase in the frequency of IL-17+ cells in 
cultures containing 10-7M dexamethasone (Figure 6.2 B). IL-17A production in culture 
supernatants was significantly increased in a dose dependent manner (Figure 6.2 C). 
Cytokine levels in asthma patients were around 10-fold higher but did not further 
increase following treatment. Dexamethasone had no significant effect on the frequency 
of IL-22+ cells in culture or IL-22 in culture supernatants. 
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Figure 6.2 In vitro dexamethasone treatment increases IL-17A in cultures of 
healthy controls and has no effect in asthma patients.  
CD8 depleted PBMCs from healthy controls and asthma patients were assessed for IL-17A and 
IL-22 production following stimulation with anti-CD3 and IL-2 as described before and 
dexamethasone at the indicated concentration. Intracellular flow cytometry and CBA for IL-17 
and ELISA for IL-22 were performed following cell cultures as they are described in figure 1. A, 
Representative dot plots of healthy control. B, Cumulative cytokine positive IL-17A (n = 8) and 
IL-22 (n = 8) cells in healthy controls C, secreted IL-17A (healthy controls n = 10, asthma 
patients n = 20); D, IL-22 (healthy controls n = 5, asthma patients n = 20). Analysis by one way 
ANOVA with Tukey’s multiple comparison post-test, * p<0.05; ** p<0.001, *** p<0.0001 
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6. 2. 3 The Effect of Inhaled Steroids on IL-17 Cytokine Levels 
 
In vitro steroid treatment significantly increased IL-17A levels in cultures from healthy 
control subjects whereas in asthma patients the difference was small. One explanation 
could be that cytokine levels in patients were already significantly higher with limited 
scope to increase further. Another factor to consider was that all patients were on high 
doses of inhaled corticosteroid treatment.  
To explore this further, a retrospective analysis of the relationship between inhaled 
steroid dose (equivalent to beclomethasone dipropionate) and IL-17A levels in culture 
supernatants was performed. This proved to be significantly positive (Figure 6.3) and 
raises the question of a possibly deleterious effect of steroids in certain patient groups. 
 
Figure 6.3 The correlation between inhaled corticosteroid (ICS) dose and IL-17A 
cytokine levels 
SR and SS patients’ inhaled corticosteroid dose was calculated to the equivalent of 
beclomethasone dipropionate (BDP). IL-17A was measured with cytokine bead array as 
described for figure 1. SS: open circles, SR: closed squares. Pearson Correlation r = 0.437, p = 
0.016. 
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6. 2. 4 Calcitriol Inhibits IL-17A and IL-22 Expression in Severe Asthma 
Patients 
 
Data in chapter five demonstrated that in patients treated with calcitriol in vivo, the 
stimulatory effect of dexamethasone on IL-17A cytokine levels in SR cell cultures was 
abolished, an effect that was not seen in patients on placebo. Hence the impact of 
calcitriol and dexamethasone in vitro was assessed in CD8-depleted PBMCs isolated 
from the peripheral blood of healthy donors and asthma patients to investigate for Th17-
associated cytokine production. Cells were cultured as described before and intracellular 
cytokine production was assessed by flow cytometry and cytokine production in culture 
supernatants was assessed by Cytometric Bead Array (CBA) for IL-17A and ELISA for 
IL-22.  
The data presented in Figure 6.4 demonstrates that not only did in vitro treatment with 
calcitriol significantly reduce IL-17A synthesis in culture levels, but it could overcome 
the stimulatory effect induced by dexamethasone in healthy controls and asthma 
patients.  
There was a significant increase in the frequency of IL-17A+ cells in cultures containing 
10-7M dexamethasone and there is a similar trend observed in IL-22+ cells (Figure 6.4 A 
and B). When 10-7M calcitriol is present in the cultures there was a significant decrease 
in the frequency of IL-17A+ and IL-22+ cells as compared to dexamethasone. Inhibition 
of IL-17A by calcitriol occurred independently of whether dexamethasone was present 
or not. There was a trend towards increase in the amount of IL-17A secreted in culture 
in the presence of dexamethasone (p = 0.12) which was significantly decreased with the 
presence of calcitriol. This effect was also seen for IL-22 (Figure 6.4 C). 
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Figure 6.4 Dexamethsone fails to inhibit whereas calcitriol significantly decreases 
IL-17A production 
CD8-depleted PBMCs stimulated for 7-days with anti-CD3 and IL-2 (no drugs: - ) or additionally 
with the indicated concentration of calcitriol (V-7 ; 10-7M) and/or dexamethasone (D-7 ; 10-7M), 
assessed for IL-17A and IL-22 production by intracellular flow cytometry and CBA for IL-17A 
and ELISA for IL-22. A, representative dot plots of a healthy control subject. B, cumulative data 
of intracellular staining of cytokines. Healthy Controls: IL-17A n=5 and IL-22 n=4. Asthma 
Patients IL-17 n = 24; IL-22 n = 21. C, cumulative cytokine secretion data from CD8-depleted 
cells Healthy Controls: n=5. Asthma Patients: IL-17A: n=30, IL-22: n=28. B, and C, assessed by 
repeated-measures one-way ANOVA with Tukey’s multiple comparison post-test * p - 0.05, **p 
- 0.01 ***p - 0.001. 
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6. 2. 5  Mechanisms of IL-17 Regulation 
6. 2. 5. 1 The role of calcitriol on transcription factors   
In order to investigate the mechanisms that could potentially be involved in the calcitriol 
induced inhibition of IL-17A, transcription factors were studied by PCR amplification.  
PMBCs were isolated and stimulated as described above. At day seven, cells were 
harvested. RNA was isolated and 250ng of RNA was reverse-transcribed into cDNA as 
described in chapter two. Transcriptional expression of RORC, STAT3, IRF4 and BATF 
mRNA transcripts were determined by PCR amplification and qRT-PCR analysis 
performed. 
STAT3 has a direct role in Th17 specification: the major cytokines that induce IL-17 
(and to that extent, also IL-6, IL-23 and IL-21) all activate STAT3. It is also involved in 
signaling upstream and downstream of IL-22 expression. Patients with Hyper IgE 
syndrome (HIES), a primary immunodeficiency syndrome, suffer from a dominant 
negative mutation of STAT3 and have severely impaired ability to produce Th17 cells 
and have lower IL-22 production 324,325 resulting in overwhelming bacterial and fungal 
infections.  ROR"t (hereafter RORC) is a master regulator of Th17 cell differentiation 
and STAT2 and RORC each regulate the other gene’s transcription and both induce IL-
17 expression 326. BATF, a member of the AP-1 transcription family, has been shown to 
be essential in Th17 differentiation and is increased in response to viral infection or IL-6 
stimulation. BATF synergises with RORC to induce IL-17 expression through 
interaction with the IL-17 gene promoter 327. IRF4 regulates IL-17 and IL-21 production 
and there is a strong association between IRF4 and STAT3 326. Figure 6.5 gives an 
abbreviated overview of the complex transcriptional regulation of IL-17A (adapted from 
Hwang E, Transcriptional regulation of T helper 17 cell differentiation 2010: 
Transcription factors regulating Th17 cell differentiation 328):
 Figure 6.5 adapted from Hwang E, Transcriptional regulation of T helper 17 cell 
differentiation 2010: Transcription factors regulating Th17 cell differentiation 328 
T cell receptor stimulation activates BATF and stimulates IL-17 gene transcription. IL-6 or IL-21 
activates STAT3 and induces IL-21 as well as autocrine regulation of Th17 cell differentiation. 
IL-21 also induces IRF4 which in turn induces IL-17 gene transcription. ROR.C is strongly 
induced by IL-6 or IL-21 in the presence of low amounts of TGF-,. The induction of ROR.C is 
dependent on STAT3, which is preferentially activated by IL-6, IL-21, and IL-23 and plays an 
important role in the regulation of IL-17 production in T cells. T-bet antagonizes ROR.C activity 
and suppresses Th17 development. TGF-, stimulation induced both FoxP3 and ROR.C: high 
TGFb increases FoxP3 whereas the presence of IL-6 and IL-21 activates STATs and hence IL-
17. 
 
I therefore investigated the effects of calcitriol on ROR"t, STAT3, BATF and IRF4 gene 
expression. CD8+ depleted PBMC cells were isolated from the peripheral blood of 
healthy donors and cultured for 7-days with anti-CD3 and IL-2 in the presence or 
absence of drugs as indicated; cell pellets were harvested at day seven and PCR 
performed after isolation of RNA and reverse transcription. RORC was significantly 
reduced following treatment with a combination of calcitriol at 10-7M and 
dexamethasone 10-7M in culture. There was no effect seen on any of the other 
transcription factors (Figure 6.6). 
 
 Figure 6.6 Gene expression following stimulation with calcitriol and / or 
dexamethasone in culture: 
CD8 depleted PBMC cells from healthy volunteers were cultured for seven days with anti-CD3 
and IL-2 as described before and +/- drugs as indicated: - = no drug; V-7  = calcitriol 10-7M, D-7  
= dexamethasone  10-7M and (V/D)-7 = calcitriol & dexamethasone 10-7M. Relative mRNA 
expression was significantly reduced for RORC following treatment (V/D)-7: p < 0.0001; 
treatment had no significant effect on STAT3, IRF4 or BATF; assessed by one-way ANOVA. n 
= 5. 
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6. 2. 5. 2 The role of IL-10 in calcitriol induced inhibition of IL-17A 
The effect of calcitriol on IL-10 has been described in the past and has been published 
by our laboratory. To investigate whether the inhibitory effect on IL-17A is dependant 
on IL-10 I used an anti-IL-10 antibody during culture of PBMCs prior to intracellular 
staining for IL-17A: The inhibitory effect of calcitriol was not abrogated by anti-IL-10 
and this implies that this effect is IL-10 independent (Figure 6.7). 
 
 
Figure 6.7 The inhibitory effect of calcitriol is not mediated via IL-10: 
CD8 depleted PBMC cells from healthy volunteers were cultured for seven days with anti-CD3 
and IL-2 +/- drugs as indicated: - = no drug; V-7 = calcitriol treatment 10-7M, D 10-7 = 
dexamethasone 10-7 M and (V/D)-7 = calcitriol & dexamethasone 10-7M +/- the addition of 
500µg/mL of anti-IL-10 in culture media. After seven days cells were harvested and assessed for 
IL-17A production by intracellular flow cytometry. There was no significant difference seen with 
or without anti-IL-10 in culture as assessed by paired t test, n = 3. 
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6. 3 Discussion 
The data presented in this chapter demonstrate that the production of IL-17A and IL-22 
by human PBMCs is elevated in severe asthma patients as compared to healthy subjects 
and that treatment with calcitriol significantly reduced cytokine synthesis in culture.  
Dexamethasone failed to inhibit IL-17A or IL-22 production in asthmatic patients in 
vitro, but significantly enhanced IL-17 synthesis in healthy control cultures and, to a 
lesser extent, in asthma patients (Figure 6.2). Calcitriol not only significantly reduced 
cytokine level synthesis compared to no treatment, but also overcame the stimulatory 
effect of dexamethasone.  
IL-17A was approximately 10-fold greater in asthmatics as compared to healthy controls 
(Figure 6.1).  These data extend earlier observations showing an association between 
elevated IL-17A and IL-22 production and chronic lung disease 145.  The results are 
novel in terms of our ability to further characterise asthma patients as being either SS or 
SR. Strikingly, while blood T cells from all asthmatics demonstrated elevated IL-17A 
and IL-22 synthesis, the greatest differences were observed for SR patients whereas 
comparison of cytokine production between SS patients and healthy controls 
demonstrated a non-significant trend only for enhanced IL-17A and IL-22 production in 
SS.  
Assessing SS versus SR asthmatics, the most notable differences were in the frequency 
of the levels of secreted IL-17A+ IL-22+ double positive cells (Figure 6.1 B). Double 
positive conventional T cells are proposed to represent the more pathogenic population 
with studies showing that IL-22 enhances the pro-inflammatory properties of IL-17A 145, 
319. In animal models IL-22 has been shown to act in synergy with IL-17A to promote 
pathological airway inflammation. Likewise, deficiency in IL-17A rendered IL-22 
unable to promote airway inflammation. Instead, in the absence of IL-17A, IL-22 
promoted essential tissue repair and homeostasis of the airway epithelium.  
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The association between IL-17A and steroid responsiveness has been discussed in 
previous chapters. IL-17A has been proposed to affect global corticosteroid 
responsiveness through effects on the glucocorticoid receptor (GR). GR-! is 
ubiquitously expressed and is responsible for the induction and repression of target 
genes, while GR-ß is expressed at much lower levels and is a dominant negative 
inhibitor of GR-!. Increased expression of GR-ß has been linked with severe asthma in 
some studies 333, 334, and a recent study suggested that IL-17A and IL-17F increase the 
expression of GR-ß, an effect that was more prominent in asthmatics than in healthy 
controls 293. With hindsight it would have been interesting to investigate the expression 
of GR'/# in our patient cohort and healthy control subjects and assess whether there is a 
correlation with cytokine response. 
Independent studies have suggested that Th17 cytokine production plays a mechanistic 
role in reducing corticosteroid sensitivity and, as a result of this, increasing asthma 
severity 135. The data presented here is broadly complementary of studies in animal 
models, demonstrating that IL-17A production was not inhibited by dexamethasone in 
culture (see introduction to this chapter) 129. It is difficult to fully exclude the possibility 
that elevated IL-17A production could be associated with inhaled corticosteroid 
administration. Certainly, culture of blood PBMCs from control subjects with 
dexamethasone resulted in significantly increased IL-17A production (and a trend seen 
for higher IL-22) from a very low baseline as compared to baseline levels in patients. On 
the other hand, dexamethasone did not further enhance PBMC Th17 cytokine 
production significantly in patients in whom it was already greatly elevated. In a post 
hoc analysis of the dose of inhaled corticosteroids the study patients were on, a 
significant association between inhaled corticosteroid dosage (beclomethasone 
equivalent prior to the trial of oral prednisolone therapy) and the amounts of blood 
PBMC IL-17A released in vitro (Pearson correlation r=0.459; p=0.014) was observed 
(Figure 6.3), suggesting that some of the IL-17A produced by PBMCs in asthmatics may 
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result from corticosteroid exposure. Interestingly a study in steroid naïve patients with 
mild asthma and relatively normal spirometric parameters found considerable 
heterogeneity in induced sputum cell counts with isolated neutrophilic inflammation and 
an impaired response to a treatment trial with steroids 335.  Neutrophilic asthma has also 
been associated with bacterial colonisation in the airways resulting in increased amount 
of oxidative stress and steroid insensitivity in some patients 336. An unbiased cluster 
analysis done by the US National Institutes of Health Severe Asthma Research Program 
found that amongst patients with the most severe form of the disease more than a third 
had a mixed granulocytic inflammatory sputum profile. This implies that neutrophils 
might be an important biomarker for severe asthma, but also that concomitant 
persistence of airway eosinophilia might be a fundamental finding in participants with 
therapy refractory asthma.  
RORC plays an important role in the production of IL-17A and is known to be co-
operating with other transcription factors such as STAT3, BATF and IRF4; reviewed in 
337 and illustrated in Figure 6.5. RORC expression was inhibited by the combination of 
calcitriol and dexamethasone in culture. However no effect was seen for the expression 
of STAT3, IRF4 and BATF. This suggests that the calcitriol-mediated effects on IL-17A 
are not predominantly genetically orchestrated.  
We and others have shown that both calcitriol and dexamethasone increased the 
expression of the anti-inflammatory cytokine IL-10 in vitro, and IL-10 has been shown 
to inhibit IL17A production 338. This implies a possible IL-10 dependent mechanism for 
the inhibition of IL-17A seen in our results. However, Figure 6.7 demonstrates that the 
use of an anti IL-10 antibody did not significantly alter the inhibitory effect of calcitriol 
on IL-17A expression. 
Dr Chambers, the principal scientist working alongside me on ‘The Calcitriol Study”, 
investigated a possible mechanism for the inhibition of T cell IL-17A synthesis by 
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calcitriol and the ectonucleotidase CD39, which is expressed by memory T cells as well 
as Foxp3+ regulatory T cell and which has previously been reported to inhibit IL-17A 
synthesis 332, 339, 340. Figure 6.7 shows that treatment with calcitriol increased the mean 
intensity of CD39 expression by human CD4+ T cells, while the CD39 antagonist POM-
1 partially abrogated calcitriol -mediated inhibition of the IL-17A production, 
supporting a mechanistic role for this pathway but not excluding others. In contrast, 
dexamethasone tended to reduce CD39 expression.  
I have mentioned Dr Chamber’s data here to complement my own data and demonstrate 
a possible mechanism involved in the results shown here. This certainly needs to be 
explored further and in greater detail and unfortunately we were unable to do this due to 
time restrictions. 
Together our data are consistent with the hypothesis that calcitriol, through inhibition of 
IL-17A, has the potential to improve disease control in asthmatics independently of their 
clinical steroid responsiveness.  
Trials at blocking IL-17A cytokines in patients with asthma have to date shown mixed 
results as discussed in chapter one. IL-17A is important in host defense and blocking 
this cytokine might come with an increased risk of infections. The relationship between 
IL-17A and calcitriol is of interest. It has been shown in patients with atopic dermatitis 
that oral supplementation with cholecalciferol resulted in lower frequencies of IL-17-
producing memory T cells 341. Further animal and human studies have shown an 
inhibitory effect of calcitriol on IL-17A cytokine production in experimental 
autoimmune uveitis 247, Behçet’s disease 342 or Vogt-Koyanagi-Harada disease 343. 
This chapter discusses results that emerged whilst data for the calcitriol study were 
being collected. It is a small chapter and mechanistically incomplete. Once more 
patients entered and went through the clinical trial, producing a wealth of material, the 
focus of our laboratory work fully shifted onto the study and experiments with blood 
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from healthy controls were postponed. The findings of this chapter support a role for 
calcitriol in down regulating pro inflammatory cytokines such as IL-17A and IL-22 but 
with taking a smaller risk of infection related side effects than seen with IL-17A 
blocking antibodies and future studies are warranted to verify these results in an in vivo 
setting. 
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Chapter 7 
 
General Discussion 
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Asthma is one of the most common chronic diseases worldwide, affecting up to 10% of 
adults and 30% of children in developed countries; the number of people affected by 
asthma in the UK is among the highest in the world 344.  Whilst many people with 
asthma have well controlled disease that seldom requires unscheduled visits to their GP, 
or indeed hospital admission, some patients suffer from daily symptoms ranging from 
breathlessness, cough and chest tightness to numerous and uncontrolled exacerbations; 
this might be because their asthma is difficult to control, complicated by co-morbidities, 
or because it is at the severe end of the disease spectrum - defined by a poor response to 
medication, in particular corticosteroids (steroids). All these patients have a greater risk 
of dying of their disease and their lives are often blighted by their condition, 
notwithstanding the disproportional amount of healthcare resources spent.  
A recent national review analysed data from 192 asthma deaths in 2012-2013 20. The 
report shed light on some alarming facts.  In 59% of patients who died, asthma treatment 
guidelines were not fully adhered to and many of those who died were undertreated. One 
reason for this may be a lack of awareness among doctors and patients on the severity of 
their disease. Suboptimal treatment occurs for several reasons including, doubt about the 
benefit, patient and physician reticence in prescribing long-term steroid therapy or poor 
adherence. The report underpins the fact that patients with severe asthma remain a 
substantial unmet clinical need.  
Over the past years research has focused on the immune-mechanisms that drive asthma 
and significant effort has been directed at defining its endotypes or phenotypes in order 
to improve asthma management 345. A phenotype is defined as the apparent 
characteristics of an organism resulting from its interactions of the environment, its 
genetic make up and distinct immune pathological mechanisms leading to clinically 
variable responses to treatment 18.
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Vitamin D and Asthma 
The reason to consider vitamin D and asthma came from a large number of 
epidemiological studies that highlighted the associated between low serum 25(OH) 
levels and the prevalence and/or severity of asthma 200, 204, 346. Also numerous in vitro 
models have provided compelling supporting evidence and potential mechanisms for 
how vitamin D may influence asthma pathogenesis, as reviewed in 192. If the association 
between low levels of serum 25(OH) and asthma severity could be causation, could it be 
reverse causation in that patients with severe asthma may be less likely to spend time 
outdoors in sunshine? Not according to a study by Brehm which found that even after 
adjusting for confounders such as time spent outdoors, race and atopy, there was still a 
strong relationship between vitamin D insufficiency and asthma exacerbations 200, 347. 
To investigate these epidemiological associations and in vitro studies, only a few 
randomised controlled trials of vitamin D supplementation have so far been conducted 
(see table 1.3, chapter 1). Of particular interest in terms of overcoming steroid resistance 
is the previously mentioned VIDA study, which showed that treatment modestly 
decreased the overall dose of steroids used 218. In line with that is a paediatric study by 
Yadav who found that supplementation with 60,000 U per month for six months allowed 
for a reduction in the dose of ICS in children with moderate to severe asthma 348.   
The question of dose, formulation and duration will likely be important, and studies 
investigating the effect of vitamin D supplementation have to date used different drugs, 
concentrations, dosing regimens and varying periods of treatment time. In several 
studies many patients were not, or were borderline, vitamin D deficient, which may 
impact on the efficacy of vitamin D treatment. Based on findings to date, and when 
placed in the context of experimental data, beneficial effects of vitamin D 
supplementation are likely to be observed in individuals who are vitamin D deficient. 
Within VIDA, an exploratory analysis of patients showed that those who responded to 
vitamin D therapy with a rise in serum 25(OH) levels to > 30ng/ml had an overall lower 
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rate of treatment failure and exacerbations. This provides support to the hypothesis that 
flexible regimes of D replacement guided by serum 25(OH) D levels may have more 
therapeutic promise. 
Another potential confounding matter is the observation that there may be racial 
differences amongst patient groups, a recent study has highlighted significant variations 
in vitamin D binding protein levels (to which most serum vitamin D is bound) between 
white and black North Americans, resulting in similar levels of bioavailable free 25(OH) 
D despite blacks having lower total 25(OH) D serum levels 347.  Hence, these data may 
also need to be taken into account when conclusions are being made with regards to 
serum 25(OH) levels and supplement requirements; however with an eye to clinical 
practicality, assays for total 25(OH) D are robust, cheap and available, this is not the 
case with free assays. 
Calcitriol and Asthma – This Thesis 
This thesis presents data of the clinical trial termed ‘The Calcitriol Study’, which I 
helped design, I obtained ethical approval for and of which I was the main clinical 
investigator. The study tested the efficacy of calcitriol, or active vitamin D, to improve a 
patient’s response to steroid treatment and offered the opportunity to investigate the 
immunological characteristics of steroid resistant, severe asthma. The laboratory’s 
earlier in vitro studies with calcitriol influenced the clinical approach and the choice of 
calcitriol rather than cholecalciferol supplementation. The alternative supplementation 
with cholecalciferol may be more practical and attractive, offering a relatively cheap, 
and safe option. Also, long term treatment with calcitriol would almost certainly raise 
concerns about the risk of drug induced hypercalcaemia. However, the combination of 
calcitriol and a steroid, known to reduce circulating calcium levels and the expression of 
Cyp27B1, the catalytic enzyme that converts circulating 25(OH)D into active calcitriol 
(1,25(OH)2D3), could potential reduce the risk sufficiently.  Calcitriol is a well tolerated 
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drug, that is easy to administer and cheap compared to many novel biological drugs; 
calcitriol is comparable in cost to oral prednisolone - a two-week course of 40mg 
prednisolone daily and calcitriol 250ng twice daily are £5.32 and £5.41 respectively. 
This trial has shown that treatment with calcitriol increased steroid sensitivity (see 
Chapter 4). The proposed steroid enhancing capacity of calcitriol, allowing for an 
overall reduction of prescribed oral steroids, would not only have significant effects on 
healthcare spending but most importantly spare patients of considerable side effects due 
to long term and often high dose steroid treatment frequently leading to complications 
such as osteoporosis, diabetes mellitus, hypertension, and adrenal insufficiency. 
This study failed to show an improvement in lung function or asthma quality of life 
following treatment with calcitriol. More well designed clinical trials are needed to 
determine whether vitamin D supplementation improves asthma control and thus allows 
for a reduction in standard treatments such as inhaled or oral steroids. Alongside 
improving asthma control there are studies considering whether vitamin D may 
influence the development of the disease. The role of vitamin D in foetal lung 
development is well described 349, 350 and studies have shown that lower maternal intake 
of vitamin D is associated with increased risk of wheeze/asthma in the offspring during 
childhood, both in individual studies and in meta-analyses 193-195, 197.  
The ongoing VDAART (Vitamin D Antenatal Asthma Reduction Trial) trial is 
supplementing pregnant women to either high (4400 IU daily) or low (400 IU daily) 
vitamin D and the results of this study will provide more information as to whether 
vitamin D has a preventative role in asthma. 
The Importance of Defining the Immunophenotype 
A Th2-high signature with elevated IL-4, IL-5 ad IL-13 cytokine levels and steroid 
responsiveness in patients (as opposed to Th2-low asthmatics, who failed to improve 
following treatment with inhaled corticosteroids) was first described by Woodruff  44. In 
our study, cells from those asthmatics with the greatest response to prednisolone therapy 
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produced a significantly elevated median quantity of IL-13 at baseline, in line with 
Woodruff‘s data. 
Mepolizumab and reslizumab - monoclonal antibodies directed against the cytokine IL-5 
- have shown significant benefit in patients with severe asthma, having identified and 
selected those with refractory airway eosinophilia 54. The same applied to antibodies 
directed against IL-13; in trials with the humanized IgG4 antibody lebrikizumab, 
patients selected for their high periostin levels experienced greatest treatment success 59. 
After the initial lack of clinical efficacy in earlier trials with biological treatments, it has 
been shown that success of cytokine-targeted treatments is closely linked to the ability to 
define a patient’s disease characteristics or endotype. 
Patients with a Th2-low signature have so far remained a more complicated challenge. 
Th17 cytokines, such as IL-17A, have been associated with severe asthma 291. A number 
of trials using antibodies directed against IL-17A in autoimmune diseases have been 
published with some success seen, for example in psoriasis 138, but studies in asthma 
have to date not only been disappointing but complicated by an increase in infections 72.  
The ‘Calcitriol Study’ offered the unique opportunity to further identify the 
immunological phenotype of a clinically well-recognized and relevant population of 
steroid treatment refractory patients on the basis of their in vitro cytokine expression and 
found steroid resistance to be associated with an IL-17Ahigh phenotype. The results also 
imply that steroids might potentially be detrimental for these patients, but that treatment 
with calcitriol abrogated the IL-17Ahigh profile in a steroid-independent manner.  
Treatment of steroid resistant asthma with calcitriol is a novel therapeutic approach 
without taking the risk of an increase in infection rates as seen with anti-IL-17A 72.  The 
data supports the concept that calcitriol improves responsiveness to steroids at least 
partly by altering the immune phenotype away from a steroid resistant Th17 phenotype 
towards a more responsive Th2 immune phenotype.  
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There are several possible ways in which the results of the ‘Calcitriol Study’ could be 
taken further. It would be interesting to test whether treatment with calcitriol and 
prednisolone during an asthma exacerbation leads to a better clinical response allowing 
for a reduced steroid dose and/or treatment period. It would also be interesting to see 
whether asthma patients, in particularly those with SR asthma have improved control of 
their disease after vitamin D supplementation to high-normal 25(OH) serum levels. 
Further research is anticipated to reveal a more feasible way to test for biomarkers of IL-
17high SR asthma similarly to the development of periostin as a biomarker of Th2high 
asthma. With the substantial investment and development in immunotherapy and novel 
biological treatments against specific cytokines, there is acute focus on both accuracy 
and precision on the individual patient’s endotype. Large, randomised controlled trials 
with clearly defined outcomes will provide new insights into the pathogenic role of 
various Th cell subsets and their cytokines and on the development and maintenance of 
the inflammatory condition that is asthma, its response to therapy and even its 
modulation.   
With the global burden of asthma rising, the prospect of a therapeutic agent that will 
benefit the most severely affected patients has immense clinical and financial 
implications. To that extent is is worth exploring further whether vitamin D, in its active 
form or as readily available, easily tolerated and affordable cholecalciferol has a role in 
the management, or indeed prevention of asthma.  
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1 Background & Rationale 
 
Glucocorticosteroids represent the cornerstone of asthma therapy and are safe and 
effective in most patients. However, 10-20% of the 5.2million UK asthma patients are 
characterised as glucocorticosteroid refractory, either failing to gain any clinical 
benefit from glucocorticoid therapy or requiring prolonged systemic treatment and are 
most at risk of their asthma1. 
 
The anti-inflammatory actions of IL-10 have been extensively documented2,3. IL-10 
inhibits many functions relevant to asthma, it is acting on macrophages and dendritic 
cells to inhibit pro-inflammatory cytokine production and the capacity to activate T 
cells, including Th2 cells. IL-10 inhibits mast cells and eosinophil function and 
favourably modulates IgE to IgG4 ratios. IL-10 is proposed to play a role in 
maintaining immune homeostasis in the lung (reviewed in 4 ). Studies of IL-10 
production in the lung and of polymorphisms in the IL-10 gene promoter suggest that 
individuals who make low IL-10 have more severe asthma4-6. Inverse correlations 
between IL-10 and disease severity are also observed in allergic patients7-9. These 
data have generated considerable interest in the therapeutic potential of IL-10 
secreting T regulatory cells (IL-10-Treg) in allergy and asthma4,10,11.  We believe that 
the principal mechanism of the anti-asthma effect of glucocorticoids is through the 
induction of IL-10. 
 
The role of vitamin D and its metabolites in bone and calcium metabolism is well 
established, but there is increasing awareness of its importance in immune regulation 
12-14. 1-!-hydroxilase is expressed in leukocytes at site of inflammation, allowing local 
synthesis of calcitriol (subject to availability of 25{OH}D substrate), which can 
modulate immune responses in a paracrine fashion15.  
Vitamin D deficiency is very common16 and predisposes to chronic inflammatory 
conditions, poor lung function and asthma17-19. Bioavailability of vitamin D in the body 
is greatly influenced by exposure to sunlight. Hypponen et al. 16 reported in their 
study that half of the British population that low levels of vitamin D during the winter 
months. This is not surprising given Great Britain’s latitude, a cloudy climate and 
lifestyle, which involves working indoors or the use of protective clothing and sun 
screen. In a complementary body of work, we have demonstrated very high rates of 
vitamin D deficiency among individuals of South Asian origin living in London19-21, 
who experience high rates of hospital admission for asthma22. Administration of a 
single dose of 2.5mg (100’000IU) vitamin D elevated 25(OH)D levels above 
27.5nmol/ 23, and increased IL-10 production in whole blood stimulated ex-vivo 
(unpublished data). 
 
Our published findings to date provide the rationale for this current study. We have 
shown that: 
(i) Glucocorticosteroids induce the synthesis of the anti-inflammatory 
cytokine IL-10 by human CD4+ T cells24; 
(ii) T cells from steroid insensitive asthma patients fail to respond to 
glucocorticoids for induction of IL-10 synthesis, implying that induction of 
IL-10 contributes to the clinical efficacy of glucocorticoids25; 
(iii) Combining steroids with calcitriol greatly boosts IL-10 synthesis by T-cells 
(IL-10-Treg) from healthy donors, inducing a regulatory phenotype in 
these cells26; 
(iv) Dexamethasone and calcitriol induced IL-10-Treg inhibit proliferation and 
cytokine production by autologous T cells, including allergen specific Th2 
cell lines27;  
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(v) The treatment of T cells from steroid insensitive asthma patients with 
glucocorticoids plus calcitriol restores induction of IL-10 synthesis to 
levels observed in steroid sensitive patients treated with glucocorticoids 
alone27; 
(vi) Calcitriol prevents ligand induced down regulation of the glucocorticoid 
receptor27, which may contribute to its efficacy in restoring steroid induced 
IL-10 synthesis in insensitive asthmatic patients; 
(vii) A small pilot study has demonstrated that ingestion of calcitriol by steroid 
insensitive asthma patients greatly enhances the subsequent capacity of 
their T cells to respond to dexamethasone for induction of IL-10 
synthesis28. This response appeared maximal by 3 days, in agreement 
with the known kinetics of calcitriol28. 
 
2 Trial Objectives, Design and Statistics 
Calcitriol (1-!-25-dihydroxyvitamin D3, the active form of vitamin D3), enhances 
clinical responsiveness to systemic glucocorticoid therapy in asthma patients who 
are clinically insensitive to steroids. Induction of IL-10 secreting T-cells through the 
combined effects of glucocorticoid and 1-!-25-dihydroxyvitamin D3 is implicated in 
mediating this effect. 
 
 
2.1 Trial Objectives 
 
 
1.         Our primary aim is to perform a clinical trial to determine whether 1-!-25 
dihydroxyvitamin D3 (calcitriol at recommended pharmacological dosage) 
enhances the clinical response to systemic glucocorticoids in 
glucocorticoid refractory asthma patients. 
 
2.  We will monitor changes in IL-10, Th2, pro-inflammatory cytokines and 
other immunological markers during the course of the study to test their 
value in predicting or confirming drug action and efficacy for use in future 
clinical trials and to further implicate IL-10-Treg induction in the anti-
asthma mechanism of glucocorticoids.  
 
3.  Identification of specific markers for drug-induced IL-10-Treg will facilitate 
monitoring of steroid responsive status, identification of non-responsive 
individuals, and tracking of drug-induced IL-10-Treg cells in vivo. We are 
using Affymetrix gene profiling, quantitative (q)RT-PCR and flow 
cytometry to analyse genes specifically expressed in human drug 
induced CD4+ IL-10-Treg cells, Th1 and Th2 cells. Markers of interest 
include Toll-like receptor (TLR)9, which is increased in vitro and in vivo 
by calcitriol and TLR2 which is upregulated by glucocorticoids. We also 
intend to store blood cells for further transcript analyses of biomarkers 
associated with vitamin sufficient and insufficient patients pre- and post 
supplementation of vitamin D. 
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2.2.1 Trial Design 
 
Screen Visit 1 
Informed consent will be obtained before screening starts.  Suitable subjects will 
undergo full assessment of their medical history (including a complete smoking 
history) and laboratory evaluation for safety haematology and biochemistry 
profile, as well as baseline cortisol. Up to 120ml of venous blood will also be 
drawn for ex-vivo experiments. Spirometry will be performed and the FEV1 and 
FVC obtained. Reversibility will be assessed by giving the subject a short acting 
beta agonist and measuring the FEV1 pre- and 15-30mins post-bronchodilator. 
We will measure FeNO using an Aerocrine NIOXMINO monitor, following the 
ATS/ERS guidelines. A peak flow meter and a diary card will be given to the 
subject to record morning and evening peak flows throughout the study. 
All these procedures are done in accordance to departmental Standard 
Operating Procedures.  
 
Eligible subjects will be entered into the second part of the screening process. 
These Subjects will receive prednisolone 40mg/1.73m2/day (where m2 = Body 
Surface Area, BSA). The dose will be calculated as (patient's BSA (m2)/1.73)x 
40mg and rounded down to the nearest 5 mg, to be taken at home.  
 
 
Screen Visit 2 
The subject’s medical history and adverse events will be reviewed at the start of 
the screening visit 2. Spirometry will be performed and the FEV1 and FVC 
obtained. Subjects who demonstrate an increase of > 10% in the FEV1 when 
compared to baseline (screen visit 1) will be excluded. Subjects who are still 
eligible will be entered into the main part of the trial. We will repeat FeNO in 
exhaled air. Up to 120ml of venous blood will be taken for safety haematology 
and biochemistry, repeat cortisol and prednisolone levels to confirm compliance, 
and for ex-vivo experiments.  
 
Treatment Visit Day 1 
Following a 4 week washout period (from screen visit 2) participants will attend 
Treatment Visit Day 1. Under special circumstances Christmas breaks, summer 
holidays, for example) the wash out period can be extended for a maximum of 4 
weeks (20 working days). The subject’s medical history and adverse events will 
be reviewed at the start of this visit. Up to 100ml of venous blood will be taken 
for safety haematology and biochemistry and for ex-vivo experiments.  
Participants will be randomised to receive either calcitriol or placebo. The first 
dose will be done under supervision. Subjects will be discharged following first 
dosing and will take the subsequent doses at home. 
 
Treatment Visit Day 15 
On day 15 of treatment subjects will attend Treatment Visit Day 15. Subjects will 
be asked to withhold their Day 15 treatment dose prior to attending. The 
subject’s medical history and adverse events will be reviewed at the start of this 
visit Prior to dosing up to 120ml of venous blood will be taken for safety 
haematology, biochemistry and cortisol, and for ex-vivo experiments.  
Subject will also undergo spirometry and fraction of nitric oxide in exhaled air 
(FeNO) measurement pre-dose. These will be done in accordance to 
departmental standard operating procedures. A standard Asthma Control 
Questionnaire (ACQ)32 will also be completed by the subject pre-dose. 
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FeNo measurements are highly correlated with eosinophilic airway inflammation; 
eosinophilic inflammation is correlated with response to steroid treatment33,34 . 
We will measure FeNO using an Aerocrine NIOXMINO monitor, following the 
ATS/ERS guidelines. 
 
Subject’s who are still eligible to continue in the study will be commenced on 
prednisolone 40mg/1.73m2/day as a single dose for 14 days. The first dose of 
prednisolone and Day 15 dose of treatment article will be done under 
supervision. Subjects will be discharged following dosing and will take 
subsequent doses of treatment and prednisolone at home. 
 
Treatment Visit Day 28 
On day 28 of treatment subjects will attend Treatment Visit Day 28. Subjects will 
have completed a 28 day dosing period of treatment article and a 14 day dosing 
period of prednisolone. The subject’s medical history and adverse events will be 
reviewed at the start of this visit. Following this up to 120ml of venous blood will 
be taken for safety haematology, biochemistry, cortisol and prednisolone, and for 
ex-vivo experiments. The subject will perform spirometry, and fraction of nitric 
oxide in exhaled air (FeNO). A standard Asthma Control Questionnaire (ACQ)32 
will also be completed by the subject. A physical examination will also be 
performed.  
 
Follow up Day 56 
After 1 month subjects will be interviewed either during a routine visit to the 
asthma clinic or via telephone call to check medical history and adverse events. 
Following all these procedures subjects will be discharged from the study. 
 
 
Immunological studies 
A central aim of this work is to further underpin the role of IL-10 in mediating the 
immunomodulatory effects of steroids and vitamin D. Our recent study clearly 
demonstrates a correlation between expression of IL-10 by T cells and their 
inhibitory functions relevant to asthma27. We aim to identify immunological 
responses to steroids and 1-!-25-dihydroxyvitamin D3,  in the asthma patients 
under study 
 
 
i. Cell analysis: all bloods will be analyzed for cellular content by antibody 
staining and FACS analysis to determine any effect of prednisolone +/- 1-
!-dihydroxyvitamin D3 on relevant cell populations (i.e. T -, B-, NK-cells, 
monocytes, dendritic cells, eosinophils and neutrophils) and subsets [e.g. 
T naïve, memory, effector, central memory and regulatory cells]  - 5mls 
blood required 
ii. Serum will be prepared for analysis of vitamin D levels (P Timms, 
Homerton Hospital) and concentrations of cytokines of interest (including 
IL-17, Th1, Th2, IL-10), measured using a highly sensitive (1-5pg 
sensitivity) multiplex system (MSD) at indicated sampling points– 5ml 
blood required. 
iii. Ex vivo cytokine analysis: we will collect cell pellets and prepare cDNA 
for direct ex vivo analysis of cytokine gene expression in total blood and 
purified CD3+CD4+ T cell preparations using qRT-PCR27. This will 
identify the overall biological response to the drugs versus the T cell 
contribution to any observed changes. Cytokines of interest include the 
anti-inflammatory mediators IL-10 and TGF", as well as the effector 
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cytokines IL-17 and Th1 and Th2-associated cytokines. Gene expression 
will be compared relative to 18S, using our established methodology27.– 
15mls blood required. 
iv. Does drug administration correlate with the induction of biomarkers 
associated with IL-10 secreting T regulatory cells? We will analyse 
directly ex vivo by qRT-PCR and where feasible flow cytometry, changes 
in the expression of markers associated with naturally occurring 
CD3+CD4+25Treg (e.g. Foxp3), IL-10-Treg (e.g. TLR9, IL-10, CD38), 
Th1 (e.g. T-bet) and Th2 (e.g. GATA-3) lineages at the 5 time points to 
be sampled. Both whole blood and CD3+CD4+ T cells will be studied 
directly ex vivo or following a 4 hour activation protocol with PMA and 
ionomycin. In addition effects on GR! and GR" will be monitored27 – 
20ml blood required. 
v.  Gene array profiling analyses (e.g. Affymetrix): whole blood will be 
stimulated with control stimuli or allergen for 20 hours and then prepared 
for gene array analysis – 15mls blood required. 
vi. Analysis of changes in steroid sensitivity: We will compare changes in 
response to steroid (10-7 to 10-10M) +/- 1-!-25-dihydroxyvitamin D3 (10-
7M) on cytokine gene induction and repression in cultures of total PBMC 
and purified CD+4 T cells stimulated with anti-CD3, using our published 
methodology27, at all time points sampled. Cytokines of interest, as listed 
above, will be assessed using ELISA/MSD, qRT-PCR and FACS as 
appropriate – 40ml blood required. 
 
 
2.2.2 Flowchart 
 
 Screen 
Visit 1 
Screen 
Visit 2 
Treatment 
Visit 1 
Treatment 
Visit 2 
Final 
Visit 
Patient information 
and informed 
consent 
x     
Lung function 
- Spirometry 
- NO 
 
x 
x 
 
x 
x 
  
x 
x 
 
x 
x 
Blood test x x x x x 
ACQ Questionnaire    x x 
Treatment 
- Calcitriol 
- Prednisolone 
 
 
x 
  
x 
 
x 
x 
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2.3 Trial Statistics 
2.3.1 Sample Size calculation 
Although we cannot anticipate the actual magnitude of enhancement of the FEV1 
response to prednisolone produced by concurrent vitamin D therapy in this study, we 
can readily estimate our power to detect theoretical enhancements based on our 
resent study in which 23 moderate to severe asthmatics underwent a similar 
prednisolone trial31 . Mean (SD) percent improvement in FEV1 was 15.0 (32.5%). 
With >/= 40 subjects the proposed study will have 90% power at !=0.05 to detect a 
20% enhancement of the FEV1 response to prednisolone with concomitant vitamin D 
therapy. The powering is therefore conservative to detect even a relatively small 
improvement in the FEV1 response.  
2.3.2 Randomisation 
A statistician/clinician not involved in the trial will generate a randomised list with the 
help of a computerised randomisation plan generator, which will be kept in Guy’s 
pharmacy and treatment allocated accordingly. Allocation concealment will be 
maintained, so that investigators and patients will be blinded to the nature of 
treatment. Eligible participants will be randomised in a 1:1 ratio to receive either 
placebo or calcitriol.  
 
Guy’s and St Thomas’ NHS Foundation Trust and a statistician/clinician not involved 
in the trial will keep a copy of the randomisation code. The investigator or treating 
physician may unblind a participant’s treatment assignment only in the case of an 
emergency, when knowledge of the study treatment is essential for the appropriate 
clinical management or welfare of the subject. 
2.3.3 Statistical Methodology 
Our dual aims are to provide information for a larger study and seek evidence of a 
clinically important effect on lung function. Our analyses will centre on descriptive 
statistics such as means or medians and appropriate confidence intervals, which 
provide measures of between group comparisons that will be useful in estimating 
likely effect sizes and sample size requirements in a larger study. Means, medians 
and confidence intervals can be calculated in the statistical software package, Stata. 
Where statistical analyses are undertaken these will be paired for within patient 
comparisons and unpaired for between patient comparisons. Given the small sample 
sizes we will use non-parametric tests (Mann-Whitney U test for unpaired and 
Wilcoxon matched pairs for paired data). 
3 Trial Medication 
3.1 Investigational Medicinal Product and Placebo 
 
The investigational medicinal product in this study is Calcitriol produced by Roche 
Products Limited, Marketing Authorisation Number PL/0031/0122, 0.25mcg: soft 
capsules. The soft capsule will be encapsulated into a hard capsule to have the 
same appearance as the placebo. 
Subjects randomised to receive the investigational medicinal product will receive 
0.25mcg twice a day orally for 28 days. 
 
The placebo used is matching hard capsules with the same appearance and texture 
as the Investigational Medicinal Product. Subjects randomised to receive placebo will 
receive 1 capsule of matching placebo twice a day orally for 28 days. 
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Subjects will also receive prednisolone 40mg/1.73m2/day (where m2 = Body Surface 
Area, BSA) for 14 days, to be taken at home. The dose will be calculated as 
(patient's BSA (m2)/1.73)x 40mg and rounded down to the nearest 5 mg. 
Prednisolone is produced by Wockhardt UK Ltd, Marketing Authorisation Number PL 
29831/0178: flat faced tablets for 14 days. 
 
4 Selection and Withdrawal of Subjects 
4.1 Inclusion Criteria 
1. Male or Female adults aged between 18 to 75 years. 
2. Documented history and typical symptoms of asthma for ! 6 months prior to 
screening. 
3. Pre-bronchodilator FEV1 < 80% predicted and documented variability in 
airways obstruction of 12% or greater within the previous 5 years or diurnal 
Peak Flow variability of > 20%. 
4. Corticosteroid refractory asthma, as defined by a < 10% improvement in FEV1 
following a 14 day course of prednisolone 40mg/1.73m2/day29-31. 
5. Written informed consent received. 
 
4.2 Exclusion Criteria 
1. Past or present disease, which, as judged by the investigator, may affect the 
study outcome (other than asthma, rhinitis or eczema). 
2. Serum corrected calcium >2.66mmol/L 
3. Clinically significant deviation from normal (physical examination or laboratory 
parameters) as judged by the investigator at the screening visit. 
4. Current smoker or an ex-smoker of less than 5 years with a greater than 5 
pack year history. 
5. Pregnant or lactating females or those at risk of pregnancy (women of 
childbearing age may be offered a pregnancy test prior to recruitment). 
6. History of a respiratory tract infection and/or exacerbation of asthma within 4 
weeks of the screening visit requiring oral corticosteroid tablets. 
7. Participation in a study involving an investigational medicinal product in the 
previous 3 months or blood donation within the last year. 
8. Current or previous allergen immunotherapy. 
9. Concomitant treatment with lithium carbonate or calcium supplements. 
Thiazide diuretics are a contraindication if the participant is taking calcium 
supplements at the same time. 
10. Inability to understand or comply with the research protocol 
 
4.3 Withdrawal of Subjects 
Subjects will be withdrawn from investigational product treatment if they develop  
hypercalcaemia (corrected serum calcium >2.65 mmol/l confirmed on two samples)  
during the course of the trial. This will be monitored at each follow-up timepoint. 
All outcome data at all subsequent follow-ups will continue to be collected for 
subjects. 
Subjects will be replaced to achieve a recruitment number of at least 40 participants. 
4.4 Concomitant Medication 
Medication not permitted before and during trial include Benzothiadiazine derivatives 
and Calcium supplements as per exclusion criteria.  
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Patients requiring rescue medication for exacerbation of asthma in form of 
corticosteroids immediately before and during the trial will be excluded or withdrawn 
from the trial (this includes the four week wash out period).  
Throughout the study the participants are allowed to continue their usual asthma 
medication as prescribed by their doctor (for example short and long acting beta 
agonists (inhaled and oral form) including slow release, anticholinergica, inhaled 
corticosteroids, leukotriene receptor antagonists, theophyllines or antihistamines). 
Changes to background treatment are allowed as prescribed by the participant’s 
doctor. 
5 Assessment of Efficacy 
Hypothesis 
Administration of calcitriol for 4 weeks to moderate/severe asthmatics, who have 
previously demonstrated clinical refractoriness to systemic steroids: 
 
(a) Significantly increases their clinical response to oral prednisolone therapy 
administered, during the final 2 weeks of calcitriol treatment, and 
(b) The degree of clinical response correlates with prednisolone/calcitriol-induced 
T cell IL-10 production ex vivo. 
 
5.1 Efficacy Parameters 
 
5.1.1 Primary Outcome Measure/End Point: 
The primary outcome measure is the change in FEV1 at baseline compared to the 
end of the treatment period. 
 
5.1.2 Secondary Outcome Measure/End Point: 
The secondary outcome measures are  
1. level of the ex-vivo production of IL-10 and other surrogate biomarkers of 
outcome or drug effects/process by T-cells. 
2. Serological markers of inflammation  
3. Fraction of nitric oxide in exhaled air 
4. ACQ score 
6 Assessment of Safety 
6.1 Specification, Timing and Recording of Safety Parameters  
 
Full blood counts and serum biochemistry profiles will be taken on every visit of the 
study. Results outside the normal ranges of the analysing laboratories will be 
reported as adverse events only if considered to be clinically significant by the trial 
investigator. Participants who experience adverse events will be followed up by their 
usual clinical team or the trial investigators for a clinically appropriate duration, as 
determined by the trial investigator, although measurements outside the following 
ranges will be reported as adverse events regardless of their perceived significance: 
 
Sodium <115 or >160 mmol/L 
Potassium<2.5 or >6.0 mmol/L 
Urea >15 mmol/L 
Creatinine >175 umol/L 
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WBC <2.0 or >20.0 x109/L 
RBC <2.0 or >8.0 x1012/L 
HB <9 or >19 g/dL 
PCV <0.2 or >0.7 L/L 
MCV <60 or >120 fL 
MCH <20 or >50 pg 
RDW <5 or >30 
PLT <40 or >600 x109/L 
Neutrophils <0.75 or >20 x109/L 
Lymphocytes <0.5 or >10 x109/L 
Monocytes <0.05 or >5.0 x109/L 
Eosinophils > 5.0 x109/L 
Basophils >5.0 x109/L 
 
In view of the effects of Calcitriol on serum calcium a further safety parameter is:  
1. Specification of the serum corrected calcium:  
Subjects found to have a serum corrected calcium > 2.65mmol/l, which is 
confirmed by a second blood test, will be withdrawn from the study. 
2. The methods and timing for assessing, recording and analysing safety 
parameters: 
Corrected calcium will be determined at 0,2 and 4 weeks post initiation of 
calcitriol by staff in the Department of Clinical Biochemistry at Guy’s Hospital 
or at Barts and The London Hospitals using standard analyser. At each 
follow-up time point the serum corrected calcium result for that day will be 
awaited before any further dose of calcitriol is administrated. If corrected 
serum calcium exceeds 2.65mmol/l at any follow-up time point, the test will be 
repeated. If the second test confirms hypercalcaemia, calcitriol will be 
withheld for the rest of the study. 
3. In addition to the above, patients who develop symptoms of hypercalcaemia 
(nausea, vomiting, malaise, polydipsia or polyuria) in between follow-up visits 
will be advised to contact the research study doctor without delay. The study 
doctor will then arrange for an urgent clinical assessment including 
determination of corrected serum calcium. 
Participants who experience adverse events will be followed up by their usual 
clinical team for a clinically appropriate duration, as determined by their 
consultant. Where an adverse event is attributed to vitamin D, this 
management may be guided by serial determinations of serum calcium levels. 
These patients will be followed up again within 28 days after completing the 
study as part of their usual care. As the elimination half-life of serum calcitriol 
is 5-8 hours in normal subjects only, it is anticipated that any adverse events 
attributable to administration of vitamin D will have resolved within a few days.  
 
6.2 Procedures for Recording and Reporting Adverse Events 
 
The Medicines for Human Use (Clinical Trials) Regulations 2004 and Amended 
Regulations 2006 gives the following definitions: 
Adverse Event (AE): Any untoward medical occurrence in a subject to whom a 
medicinal product has been administered including occurrences which are not 
necessarily caused by or related to that product. 
Adverse Reaction (AR): Any untoward and unintended response in a subject to an 
investigational medicinal product which is related to any dose administered to that 
subject. 
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Unexpected Adverse Reaction (UAR): An adverse reaction the nature and severity 
of which is not consistent with the information about the medicinal product in 
question set out in: 
The summary of product characteristics  (SmPC) for that product (for products with a 
marketing authorisation) 
The Investigator's Brochure (IB) relating to the trial in question (for any other 
investigational product) 
Serious adverse Event (SAE), Serious Adverse Reaction (SAR) or Unexpected    
Serious Adverse Reaction (USAR): Any adverse event, adverse  reaction or 
unexpected adverse reaction, respectively, that 
- Results in death; 
- Is life-threatening; 
- Required hospitalisation or prolongation of  existing hospitalisation; 
- Results in persistent or significant disability or incapacity; 
- Consists of a congenital anomaly or birth defect. 
 
Reporting Responsibilities 
Guy’s and St Thomas’ NHS Foundation Trust and King’s College London have 
delegated the Sponsor responsibilities of Pharmacovigilance (as defined in 
Regulation 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004 to 
the Joint Clinical Trials Office (JCTO).  
All SAEs, SARs and SUSARs (excepting those specified in this protocol as not 
requiring reporting) will be reported immediately by the Chief Investigator to the 
(JCTO) in accordance with the current Pharmacovigilance Policy. 
Death as a result of disease progression and other events that are primary or 
secondary outcome measures are not considered to be SAEs and should be 
reported in the normal way, on the appropriate CRF. 
The JCTO will report SUSARs (Suspected Unexpected Serious Adverse Reactions) 
and other SARs to the regulatory authorities (MHRA, competent authorities of other 
EEA (European Economic Area) states in which the trial is taking place. 
The Chief Investigator will report to the relevant ethics committees. Reporting 
timelines are as follows: 
# SUSARs which are fatal or life-threatening must be reported not later than 7 days 
after the sponsor is first aware of the reaction. Any additional relevant information 
must be reported within a further 8 days. 
# SUSARs that are not fatal or life-threatening must be reported within 15 days of 
the sponsor first becoming aware of the reaction.   
The Chief Investigator will provide an annual report of all SARs (expected and 
unexpected), and SAEs which will be distributed to the Sponsor (JCTO), MHRA 
and the REC. 
6.3 Treatment Stopping Rules 
 
At each follow- up timepoint the serum corrected calcium result for that day will be 
awaited before any further dose of trial medication is administered. If corrected 
serum calcium exceeds 2.65 mmol/l at any follow-up timepoint, the test will be 
repeated. If the second test confirms hypercalcaemia, study medication will be 
withheld for the rest of the study. 
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7 Direct Access to Source Data and Documents 
The sponsor will notify the MHRA of any fatal or life-threatening SUSAR arising  
during the study within 7 days of learning of the event; non-fatal and non-life-
threatening SUSAR will be reported within 15 days of learning of the event. The 
sponsor may also  report other safety issues to MHRA where they might alter the 
current risk-benefit assessment of vitamin D as an adjunct to standard asthma 
therapy, or alter the overall conduct of the trial. They will ensure that quality 
standards are met and that personnel are trained for the purpose of data submission, 
validation, entry and review.  
 
8 Ethics & Regulatory Approvals 
 
The trial will be conducted in compliance with the principles of the Declaration of 
Helsinki and the principles of GCP. 
The study has been submitted to Guy’s Research Ethics Committee and has 
received a favourable opinion. 
Any subsequent protocol amendments will be submitted to the REC and Regulatory 
Authorities for approval. We will comply with regulations, particularly specifying, 
Pharmacovigilance reporting and providing the REC & MHRA with progress reports, 
and a copy of the Final Study Report. 
 
8.1 Ethical Considerations  
 
Rationale for research  
Ethical research must be informed by existing research, and investigate an important 
question. We have addressed this issue by thorough review of the existing literature, 
and by conducting extensive background studies in vitro and in vivo ourselves.  
  
Design of research   
Ethical research must employ the most appropriate design in order to answer the 
research question. When investigating efficacy of a clinical intervention, a double 
blind, randomised, placebo-controlled trial is the gold standard methodology.  
  
Minimization of inconvenience, discomfort and risk for participants   
Ethical research must seek to minimize potential inconvenience, discomfort and risk 
that participants may experience during the course of a study. The principle 
inconveniences of the study arise from the time spent returning for follow-up visits; 
we have sought to minimize these by providing financial compensation for travel 
costs and loss of earnings.  
 
The principle discomfort involved arises from giving blood samples; we have sought 
to minimize this by assuring that venepuncture is performed by either the study 
doctor or a research nurse trained in phlebotomy. Patients with anaemia or at risk of 
blood loss or those who gave blood (1 unit) within the past year are excluded from 
the study.  
The principle risk arises from vitamin D-induced hypercalcaemia; we have sought to 
minimize this by excluding patients known to be at potentially increased risk of 
developing hypercalcaemia after vitamin D supplementation; by giving a dose of 
calcitriol, which is in accordance to the British National Formulary; and by frequent 
monitoring of serum calcium levels. 
 
Confidentiality   
Ethical research projects should ensure that participants' personal data remain 
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confidential. Our procedures for handling, processing, storage and destruction of 
data are compliant with the Data Protection Act 1998.  
  
8.2  Ownership, Storage and Fate of Donated Samples  
  
Donated samples will be treated as a gift from the participant to King’s College 
London University of London. 
King’s College London will have control over what happens to them and will retain 
commercial rights to any profitable invention arising from the research.  
  
Donated samples will be analysed in the laboratory at King’s College University of 
London. Whole blood for DNA extraction will be stored in a freezer until recruitment is 
complete. On completion of recruitment, DNA will be extracted from whole blood and 
analysed cytokine gene expression in total blood and purified CD3+CD4+ Tcell 
preparations using qRT-PCR27. On completion of the study, serum and DNA samples 
will be transported to and stored for up to 15 years in accordance with the Human 
Tissue Act 2004 and Human Tissue Authority Codes of Practice. Any further 
investigation, which made use of these samples, will only be conducted with the 
approval of the ethics committee before the end of this trial. Only laboratory staff will 
have access to frozen samples. Samples will be labeled with participants’ study 
number, and not with their name. Donated samples, which are not stored will be 
destroyed according to standard procedures. 
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PATIENT INFORMATION SHEET 
 
 
 
 
Study Title: Does active vitamin D3 improve the clinical response to 
steroids of steroid-resistant asthma patients? 
 
 
Date  15 Jun 2010   
 
Version   04 
 
 
 
 
You are being invited to take part in a research study.  Before you decide to 
take part it is important for you to understand why the research is being done 
and what it will involve.  Please take time to read the following information 
carefully and discuss it with your friends, relatives and your GP if you wish.  
Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
 
 
Thank you for reading this. 
 
 
 
Chris Corrigan 
Professor of Asthma, Allergy & Respiratory 
Science and Consultant Physician 
Department of Asthma, Allergy and Respiratory Science 
Guy’s Hospital, London SE1 9RT 
Telephone: 0207 188 0610 
Email:  chris.corrigan@kcl.ac.uk 
 
Chris Griffiths 
Professor of Primary care 
Centre for Health Sciences 
Barts and The London School of Medicine 
2 Newark Street 
London E1 2AT 
Telephone: 020 7882 7955 
Email:  c.j.griffiths@qmul.ac.uk 
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Why is this study being carried out? 
 
Steroids are the cornerstones of asthma therapy. However, some patients with 
severe asthma do not improve on steroids at all (steroid resistant), whilst others are 
unhappy taking high doses of steroids for prolonged periods to control their asthma.  
We believe that adding Vitamin D, a safe standard vitamin supplement to steroid 
tablets, will improve the clinical response to steroids in patients who are considered 
to be steroid resistant. We believe this is because vitamin D increases the production 
of an anti-inflammatory protein from your white blood cells called interleukin-10 (IL-
10). It has been shown that patients with severe asthma, who do not respond to 
steroids have lower levels of IL-10. 
 
 
Why have I been chosen? 
 
You have been chosen to participate because you have asthma and we are trying to 
improve asthma treatment. Altogether, we will recruit 40 patients like you for this 
study. 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, we will give you 
this information sheet to keep and ask you to sign a consent form. You are still free 
to withdraw from the study at any time without giving a reason.  If you decide not to 
take part, or to withdraw, it will not affect your normal standard of care, either 
presently or at any time in the future. 
 
Will I get paid to take part? 
 
We will reimburse your travel costs and any inconvenience caused with £40 per visit 
(£200 in total). 
 
 
What will happen during the study? 
 
If you agree to take part in this study you will be asked to attend on 5 occasions as 
described below: 
 
 
First visit: screening visit 1 
This is called the screening visit 1 and will take about 1 hour. 
If the breathing test shows you do not have moderate to severe asthma then you 
cannot be included in this study and will go no further. 
We will ask you a few questions relating to your asthma and your smoking history. 
We will perform lung function tests, where you will be blowing into a tube. You will be 
asked to blow again after a dose of salbutamol (Ventolin®) reliever to see how much 
your asthma improves. You will probably have had this sort of lung function test in 
the past when you visited the asthma clinic. We will ask you not to use your normal 
inhalers for 8 hours before the test unless absolutely necessary. 
Based on the lung function tests we will see whether you have moderate to severe 
asthma and we can tell you whether you are suitable for this study.  
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We will also ask you to record your Peak Flow results during the next coming weeks. 
We will give you a Peak Flow meter to take home and show you how to use it and 
record your results. We ask you to do this twice a day (morning and evening). 
 
If your breathing test shows that you have moderate to severe asthma we would like 
to include you in the study and will perform a blood test (120ml, about half a small 
teacup full) from your arm. We will use this sample to measure your vitamin D levels, 
calcium levels, cortisol levels, eosinophil levels (= white blood cells often elevated in 
asthmatics), and levels of IL-10, the anti-inflammatory marker known to have 
important anti-asthma effects. You will then have a further breathing test called Nitric 
Oxide in exhaled air. Nitric oxide is a marker we can measure when you breathe out 
and is a test to diagnose asthma. Patients with asthma have increased levels of nitric 
oxide. 
 
We will then give you a steroid tablet called Prednisolone at a dose of 30-60mg 
(depending on your body weight) once in the morning for 2 weeks.  
You might have been prescribed this tablet in the past to treat your asthma. You will 
continue using your normal inhalers. 
 
Second visit: screening visit 2 
This is called the screening visit 2. After 2 weeks of taking Prednisolone we will 
repeat your breathing test to see whether any blockage or constriction in your 
airways has improved. If the blockage improves by less than 10% you will qualify for 
this study. This is what we call steroid resistant (no improvement following steroid 
treatment). You will then have a further breathing test called Nitric Oxide in exhaled 
air.  
You will also be asked for another blood sample (120ml).  
This will take about 1 hour. 
 
Third visit: treatment visit 1 
You will attend the clinic again after 4 weeks (during this time you will use your own 
inhalers as usual) and you will be given either vitamin D (calcitriol) at a standard 
dose of 25mcg twice a day or a tablet that looks and tastes the same but contains no 
vitamin D (this is called a placebo). Neither you nor we will know which tablet you 
have taken (although we can find out if necessary). You will have an equal chance of 
getting vitamin D or the placebo tablet. You will take the tablet for 4 weeks. 
You will have a further blood test (100ml) that day. This will take about 30 minutes. 
 
Fourth visit: treatment visit 2 
During this visit we will ask you to answer questions regarding your asthma and how 
it affects your daily life and what symptoms you get (= asthma quality of life 
questionnaire). 
After 2 weeks you will receive a course of Prednisolone tablets at the same dosage 
as at the beginning of the study, which you take together with the vitamin/placebo 
tablet.  
We will repeat a blood test (120ml) and measure your lung function.  
You will have a further breathing test called Nitric Oxide in exhaled air. This visit will 
take about 1 hour. 
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Fifth visit: final visit 
We will go through the same questionnaire as during your last visit, inquiring about 
your asthma-symptoms. 
At the end of the study, having taken vitamin D or placebo and Prednisolone we will 
see you once more for a final blood test (120ml). We will repeat the same breathing 
tests as during your fourth visit: simple lung function tests (spirometry) and 
measurement of nitric oxide when you breathe out. 
This will take about 1 hour. 
 
 
Follow up 
We will contact you via telephone call or on your next routine visit to the asthma clinic 
(if this happens to be around 2 months after your first treatment visit) to check 
whether you remain well and have not suffered any side effects. 
 
 
What is vitamin D? 
 
This is the vitamin that is made in your skin when you sunbathe; you can also get it 
from taking cod liver oil. It is important for healthy bones and a strong immune 
system. The vitamin D that we use has been manufactured and safely prescribed by 
doctors before.  
You should not participate in the study if you are pregnant, have kidney stones, an 
overactive parathyroid gland, a condition called sarcoidosis, or if you have been 
diagnosed with liver problems, kidney problems or cancer. 
 
Why do I only have a 1 in 2 chance of getting vitamin D? 
 
The best way to find out if a treatment works is compare a group of patients who get 
the treatment with a group who do not. In order to make sure the groups are the 
same to start with, we will use a computer program to allocate you to one group or 
the other at random (as if tossing a coin). 
 
 
What are the possible disadvantages and risks of taking part? 
 
High levels of vitamin D have been known to harm the unborn child; you should not 
take part in this study if you are pregnant or breastfeeding. You mustn’t become 
pregnant during the study and we will advise you on double barrier contraception. 
If you do become pregnant during the study you must tell your study doctor 
immediately.   
Potential side effects of the steroid tablet Prednisolone are almost uniquely 
secondary to prolonged use (> 3months) and include: fluid retention, weight gain, 
high blood pressure, potassium loss, headache, muscle weakness, puffiness of and 
hair growth on the face, thinning and easy bruising of the skin, vision problems, 
heartburn, worsening of diabetes, irregular menses, convulsions, and psychic 
disturbances. 
Calcitriol may cause constipation, thirst, dry mouth, muscle pain, bone pain, 
weakness, increased urination, rashes, high levels of calcium in your blood, 
sleepiness, loss of appetite, headaches, vertigo, nausea.  
Venepuncture can cause bruising. 
 
What are the possible benefits of taking part? 
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If you take part in this research we will test your vitamin D level: if we find that this is 
low, we will inform your doctor at the end of the study and advise you how to prevent 
deficiency in the future. 
 
Your participation in this trial may also give us information that could improve 
treatments for other people who suffer from asthma. 
 
 
What happens when the study stops? 
 
When the study stops, the research doctor will let you know whether you have been 
taking vitamin D tablets or the placebo tablet. We will also tell you the result of your 
vitamin D level taken at the beginning of the study. 
 
If your vitamin D level was low at the beginning of the study, and you were given the 
placebo tablet during the study, we will inform your doctor. All patients who had low 
levels of vitamin D at the start of the study will get advice about how to prevent 
deficiency arising in the future. 
 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
doctor in charge of the study. If you remain unhappy and wish to complain formally 
this should be addressed in writing to:  
Professor Chris Corrigan, King’s College London School of Medicine (at Guy’s, 
King’s and St Thomas’ Hospitals), Department of Asthma, Allergy and Respiratory 
Science, 5th Floor, Thomas Guy House, Guy’s Hospital, London, SE1 9RT . 
 
Or: Please contact Patient Advisory Liaison Service (PALS) if you have any concerns 
regarding the care you have received, or as an initial point of contact if you have a 
complaint.   
If you are based at Guy’s and Thomas’ NHS Foundation Trust: Please phone 020 
7188 8801, or email pals@gsst.nhs.uk or visit PALS by asking at any hospital 
reception 
If you are based at The Barts and The London NHS Trust: Please telephone 020 
7377 6335, minicom 020 7943 1350, or email pals@bartsandthelondon.nhs.uk, you 
can also visit PALS by asking at any hospital reception. 
 
 
Will my taking part in the study be kept confidential? 
 
Maintaining confidentiality is important to us. 
Your personal information (for example, your gender, age, the details of your medical 
conditions) and other information (the data collected by King’s College London 
School of Medicine as part of the study) will be identified by a number (i.e., coded).  
Your name will not appear in any publications or reports produced from this study. 
You have the right to ask the study doctor about the data being collected on you for 
the study and about the purpose of this data.  You have the right to ask the study 
doctor to allow you to see your personal information and to have any necessary 
corrections made. 
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We will inform your GP that you have agreed to participate in this study. Should your 
Vitamin D levels be low we will inform you and your GP about it unless you do not 
wish so. 
Your blood samples are identified by means of a unique number and will not be 
traceable directly to you.   
Results obtained from the samples are treated with the strictest confidence and will 
not be used for any other diagnostic purpose.  All of the samples will be stored 
securely within our department. 
 
In the event of surplus samples following completion of this study, it will be stored 
anonymously within the department of Asthma, Allergy & Respiratory Science.  Your 
informed consent to this study allows such surplus material to be used as a gift for 
future, related departmental studies. The samples would only be used in studies 
which receive approval of the ethics committee before the end of this study. 
This situation will only arise following consent of the doctor in charge of this study. 
We will not be using any of the blood for analysis of your genetic code; neither will 
pharmaceutical companies use any of your tissue for commercial gain. 
 
If you join the study, some parts of your medical records and the data collected for 
the study will be looked at by authorised persons from the Institutions sponsoring and 
organising the research. They may also be looked at by authorised people to check 
that the study is being carried out correctly. All will have a duty of confidentiality to 
you as a research participant and we will do our best to meet this duty. 
 
What will happen to the results of the research study? 
 
The data collected from you and other study subjects will be used to prepare a 
detailed research report.  The results may be published in the form of a scientific 
paper. If this is the case, you will not be identified in any results of this study.  If you 
would like to see any published results then please ask your study doctor.  These 
results may not be available for some time, as the study data have to be analysed.   
 
Who is organising and funding the research? 
 
The study is being funded by research grants held by the Department of Asthma 
Allergy and Respiratory Science at Guy’s Hospital and the MRC Asthma UK Centre 
in Allergic Mechanisms, Centre for Health Sciences at Barts and The London 
Hospital NHS Trust. 
 
Who has reviewed the study? 
 
Guy’s Research Ethics Committee has reviewed this study and has given a 
favourable opinion for the research to go ahead. The Committee is recognised by the 
United Kingdom Ethics Committee Authority under the Medicine for Human Use 
(Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of 
clinical trials of investigational medicinal products. 
 
Thank you for taking the time to read this information sheet.  If you have any queries 
concerning this study please contact us on the above number and address. You may 
contact an impartial third party with any questions you have about the research and 
your rights as a research subject. 
 
 
Dr. A. Nanzer, Clinical Research Fellow 
 
 
 
 
 
    
CONSENT FORM 
 
Study title: Does active vitamin D3 improve the clinical response to steroids of 
steroid-resistant asthma patients? 
 
Date 15-Jun-10, Version 5 
 
LREC Reference number: 08/H0804/84 
  
1. I confirm that I have read and understand the information sheet (PIS 
Version 4, dated 15-Jun-10) for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
Sponsor, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records  
 
4. I agree that my blood may be stored for use in this study.  
 
 
5. I agree that my blood may be stored anonymously. I agree that my 
blood may be stored for use in future studies which have been 
approved by the Head of Department and received appropriate ethical 
approval.. 
 
 
6. I agree to take part in the above study 
 
 
 
 
 
 
 
Name of Patient    Date    Signature 
 
 
Name of Person taking consent  Date    Signature 
 
 
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
Chief investigators: Prof. C. Corrigan 
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                                   SITE: _______ 
CASE REPORT FORM 
      (version 03) 
 
 
  Clinical Trial: 
 
Does active vitamin D3 enhance corticosteroid activity 
in severe asthma? 
 
 
__ __ / __ __ /  __ __ __ __ 
(Date of visit)  
Patient Number:                       Visit No: 
 
DEMOGRAPHIC DATA 
 
 
Patient’s initials:                                          
 
Date of Birth:      ______/______/______ 
                                                     (DD  -   MM  - YYYY) 
  
Date subject signed: ______/______/______ 
   written consent form                     (DD  -   MM  - YYYY) 
 
Origin: 1 White / Caucasian 
 2 Black or African 
 3 Oriental 
 4 Other, specify: ________________________________________ 
Sex:  1 Male 
 2 Female 
Smoker:  1 Yes 
 2 No 
Atopic:  1 Yes 
 2 No 
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SCREENING VISIT 1  DATE:  _ _/_ _/_ _ _ _ 
 
PRIOR MEDICAL HISTORY 
 
Condition/illness/surgical procedure Start date 
(DD/MM/YY) 
Stop date/ongoing 
Mark box if ongoing 
(DD/MM/YY) 
 ____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
 
____/____/____ 
ongoing  
____/____/____ 
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CONCOMMITANT MEDICATIONS 
 
 
Medication 
 
 
 
Start Date 
 
(DD/MM/YYYY) 
 
Stop Date 
 
(DD/MM/YYYY) 
 
 
Ongoing 
 
1.    
2. 
   
3. 
   
4. 
   
5. 
   
6. 
   
7. 
   
8. 
   
9. 
   
10. 
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WEIGHT / HEIGHT  
 
Weight:  ___ ___ ___  ___ kg                               Height:  ___ ___ ___  cm 
 
SPIROMETRY  
 
 
 
Predicted 
value 
 
Baseline 
value 
% predicted Value post B2-
agonist 
% change 
post B2 
agonist 
FEV 1 
 
     
FVC (l/min) 
 
     
PEFR (l/min) 
 
     
FEV1 /FVC  
 
     
 
 
Subjects MUST meet the following criteria to be included in the study: 
 
Yes No 
1. MODERATE – SEVERE ASTHMA   
2. REVERSIBILITY   
 
 
 
EXHALED NO:  
 
_________ 
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LABORATORY TESTS 
 
 
 Yes No 
Full Blood Count   
Renal   
Bone Profile   
Vitamin D   
Blood for Experiments   
 
 
 
 
DRUG TREATMENT 
 
 
PREDNISOLONE  
 
Dose:   ______mg / day 
 
 
Start date of ingestion:  _ _/_ _/_ _ _ _        Time of 1st Dose:   _______ 
 
 
 
 
Investigator’s Signature 
 
X________________________________ 
 
Date of 
Signature __ __ / __  __ / __ __ 
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SCREENING VISIT 2  DATE:  _ _/_ _/_ _ _ _ 
 
UPDATE MEDICAL HISTORY AND MEDICATION!       
 
 
ADVERSE EVENTS: 
 
Event 
No 
Event Name 
Start date 
(DD/MM/YY) 
Stop date 
Mark box if 
ongoing 
(DD/MM/YY) 
Serious? Outcome Relation to Study Drug 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
 
 
 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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SPIROMETRY  
 
 
 
Predicted value 
 
Baseline  
(pre-bronchodilator 
value) 
% predicted 
FEV 1 
 
   
FVC (l/min) 
 
   
PEFR (l/min) 
 
   
FEV1 /FVC  
 
   
 
 
Subjects MUST meet the following criteria to be included in the study: 
 
Yes No 
1. STEROID RESISTANT   
 
EXHALED NO:  
 
_________ 
 
LABORATORY TESTS 
 
 Yes        No 
Full Blood Count   
Renal   
Bone Profile   
Vitamin D   
Blood for Experiments   
 
 
 
Investigator’s Signature 
 
X________________________________ 
 
Date of 
Signature       _ _ / _ _ / _ _ _ _  
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TREATMENT VISIT 1  DATE:  _ _/_ _/_ _ _ _ 
 
UPDATE MEDICAL HISTORY AND MEDICATION!       
 
ADVERSE EVENTS 
 
 
Event 
No 
Event Name 
Start date 
(DD/MM/YY) 
Stop date 
Mark box if 
ongoing 
(DD/MM/YY) 
Serious? Outcome Relation to Study Drug 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
 
 
 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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LABORATORY TESTS 
 
 
 Yes No 
Full Blood Count   
Renal   
Bone Profile   
Vitamin D   
Blood for Experiments   
 
FEMALE PATIENT: PREGNANCY TEST ISSUED:      
 
 
DRUG TREATMENT 
 
 
 CALCITRIOL / PLACEBO 
 
 Dose:   0.25 mcg / bd 
 
 
 Start date of ingestion:  _ _/_ _/_ _ _ _        Time of 1st Dose:  _______ 
 
 
Investigator’s Signature 
 
X______________________________ 
 
Date of 
Signature __ __ / __  __ / __ __ __ __ 
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TREATMENT VISIT 2  DATE:  _ _/_ _/_ _ _ _ 
 
UPDATE MEDICAL HISTORY AND MEDICATION!       
 
 
ADVERSE EVENTS 
 
Event 
No 
Event Name 
Start date 
(DD/MM/YY) 
Stop date 
Mark box if 
ongoing 
(DD/MM/YY) 
Serious? Outcome Relation to Study Drug 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
 
 
 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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SPIROMETRY  
 
 
 
Predicted value 
 
Baseline  
(pre-bronchodilator 
value) 
% predicted 
FEV 1 
 
   
FVC (l/min) 
 
   
PEFR (l/min) 
 
   
FEV1 /FVC  
 
   
 
EXHALED NO:  
 
_________ 
 
LABORATORY TESTS 
 
 
 Yes No 
Full Blood Count   
Renal   
Bone Profile   
Vitamin D   
Blood for Experiments   
 
 
ACQ QUESTIONNAIRE 
 
SCORE___________ 
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DRUG TREATMENT 
 
 
PREDNISOLONE 
 
Dose:   _______mg / day 
 
 
Start date of ingestion:  _ _/_ _/_ _ _ _        Time of 1st Dose:  ______ 
 
 
Investigator’s Signature 
 
X________________________________ 
 
 
Date of 
Signature __ __ / __  __ / __ __ __ __ 
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TREATMENT VISIT 3  DATE:  _ _/_ _/_ _ _ _ 
 
UPDATE MEDICAL HISTORY AND MEDICATION!       
 
 
ADVERSE EVENTS 
 
Event 
No 
Event Name 
Start date 
(DD/MM/YY) 
Stop date 
Mark box if 
ongoing 
(DD/MM/YY) 
Serious? Outcome Relation to Study Drug 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
 
 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
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SPIROMETRY  
 
 
 
Predicted value 
 
Baseline  
(pre-bronchodilator 
value) 
% predicted 
FEV 1 
 
   
FVC (l/min) 
 
   
PEFR (l/min) 
 
   
FEV1 /FVC  
 
   
 
EXHALED NO:  
 
_______________________ 
 
 
 
ACQ QUESTIONNAIRE 
 
 
Score           _______ 
 
 
 
LABORATORY TESTS 
 
 
 Yes No 
Full Blood Count   
Renal   
Bone Profile   
Vitamin D   
Blood for Experiments   
 
Investigator’s Signature 
 
X___________________________________ 
 
Date of Signature __ __ /__  __ /__ __ __ __ 
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FOLLOW UP  DATE:  _ _/_ _/_ _ _ _ 
 
How was the patient contacted?                   1 Phone 
                                                                          2 Routine clinic visit 
 
                                                     2 other________________________ 
 
 
UPDATE MEDICAL HISTORY AND MEDICATION!        
 
  ADVERSE EVENTS                                      
 
Event No 
Event 
Name 
Start date 
(DD/MM/YY) 
Stop date 
Mark box if 
ongoing 
(DD/MM/YY) 
Serious Outcome Relation to Study Drug 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
  
____/____/____ 
ongoing  
____/____/____ 
 No 
 Yes  
 No 
 Yes 
____________________________________________________________________________ 
Investigator’s Signature 
 
X_______________________________________
_ 
 
Date of 
Signature __ __ / __  __ / __ __ __  __ 
 
Chief Investigator’s Signature 
 
X_________________________________ 
 
 
Date of   
Signature __ __ / __  __ / __ __ __ __ 
 



Waleed Al-Herz, MDf
Raif S. Geha, MDb!
Talal A. Chatila MD, MScb!
From athe Division of Pediatric Immunology and Allergy, MeramMedical Faculty, Nec-
mettin Erbakan University, Konya, Turkey; bthe Division of Immunology, Department
of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, Mass;
cthe Division of Pediatric Allergy and Immunology, Marmara University Faculty of
Medicine, Istanbul, Turkey; dthe Division of Pediatric Infectious Diseases, American
University of Beirut, Beirut, Lebanon; eUniversity Montpellier 2 and Institute of
Human Genetics, CNRS UPR 1142, Montpellier, France; and fthe Department of
Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait. E-mail:
sevgi.keles@childrens.harvard.edu. Or: talal.chatila@childrens.harvard.edu.
*These authors contributed equally to this work as first authors.
!These authors contributed equally to this work as senior authors.
The work was supported by the National Institutes of Health (grant no. 5R01AI065617
and grant no. 1R21AI087627 to T.A.C. and grant no. 1R01AI100315 to R.S.G. and by
the Scientific and Technological Research Council of Turkey (grant no.
1059B191300622 to S.K.). This project has been funded in part by federal funds
from the National Institute of Allergy and Infectious Diseases, National Institutes
of Health, Department of Health and Human Services, under contract no:
HHSN272201000020C.
Disclosure of potential conflict of interest: T. A. Chatila and R. S. Geha’s institutions have
received grant funding from the National Institutes of Health. G. Dbaibo’s institution
has received funding from the Dubai-Harvard Foundation for Medical Research. The
rest of the authors declare that they have no relevant conflicts of interest.
REFERENCES
1. ZhangQ,Davis JC, Lamborn IT, FreemanAF, JingH, FavreauAJ, et al. Combined im-
munodeficiency associated withDOCK8mutations. N Engl JMed 2009;361:2046-55.
2. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G,
et al. Large deletions and point mutations involving the dedicator of cytokinesis
8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy
Clin Immunol 2009;124:1289-302.e4.
3. Harada Y, Tanaka Y, Terasawa M, Pieczyk M, Habiro K, Katakai T, et al. DOCK8
is a Cdc42 activator critical for interstitial dendritic cell migration during immune
responses. Blood 2012;119:4451-61.
4. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells:
recent progress and open questions. Annu Rev Immunol 2011;29:163-83.
5. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A, et al.
DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell
activation. Nat Immunol 2012;13:612-20.
6. Ozarmagan G, Didem Yazganoglu K, Agacfidan A. Hyper-IgE syndrome
with widespread premalign oral papillomas treated with interferon alpha2b.
Acta Derm Venereol 2005;85:433-5.
7. Crawford G, Enders A, Gileadi U, Stankovic S, Zhang Q, Lambe T, et al. DOCK8 is
critical for the survival and function of NKT cells. Blood 2013;122:2052-61.
8. RandallKL,ChanSS,MaCS,FungI,MeiY,YabasM,et al.DOCK8deficiency impairs
CD8 T cell survival and function in humans and mice. J Exp Med 2011;208:2305-20.
9. Mizesko MC, Banerjee PP, Monaco-Shawver L, Mace EM, Bernal WE, Sawalle-
Belohradsky J, et al. Defective actin accumulation impairs human natural killer
cell function in patients with dedicator of cytokinesis 8 deficiency. J Allergy
Clin Immunol 2013;131:840-8.
Available online April 24, 2014.
http://dx.doi.org/10.1016/j.jaci.2014.03.032
The effects of calcitriol treatment in
glucocorticoid-resistant asthma
To the Editor:
Asthma is a chronic inflammatory disease characterized
clinically by variable small airways obstruction and hyperres-
ponsiveness and pathologically by airways inflammation and
remodeling. The current cornerstone of asthma therapy is
anti-inflammatory glucocorticoids. Although glucocorticoids
improve clinical features of disease and airways inflammation
in most patients, there is a cohort of well-defined asthma patients
in whom high-dose glucocorticoid treatment is not only clinically
ineffective but also potentially detrimental.1 Improved under-
standing and management of glucocorticoid-resistant asthma is
vitally important because these patients are very difficult to
manage clinically and are at high risk of hospitalization,
morbidity, and mortality. A number of mechanisms have been
proposed to contribute to glucocorticoid-resistant asthma,
including increased expression of nuclear factor kappa B and
activating protein 1 (AP-1), increased expression of histone de-
acetylase, polymorphisms in IL-10, increased expression of the
dominant negative isoform of the glucocorticoid receptor beta
(GRb), and vitamin D insufficiency.2-4
Our earlier data showed that peripheral blood CD41 T cells
from glucocorticoid-resistant as compared with glucocorticoid-
sensitive asthmatic patients failed to synthesize the anti-
inflammatory cytokine IL-10 in response to glucocorticoid
in vitro.5 The active form of vitamin D (calcitriol; 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3]) when used in combination
with glucocorticoid restored this IL-10 response both in vitro and
ex vivo following patient ingestion of calcitriol.6 These data,
together with epidemiologic evidence linking vitamin D insuffi-
ciency/deficiency with a poor clinical response to treatment in
asthma,3,4 provided the rationale for this proof-of-concept clinical
trial. We characterized a group of patients with severe asthma as
glucocorticoid resistant following a standardized, 2-week course
of oral prednisolone (Screening) using our previously established
and generally accepted criteria.6 Following a washout period, pa-
tients were randomly assigned placebo or 0.25 mg calcitriol twice
daily, according to British National Formulary guidelines, for 4
weeks with a repeat course of oral prednisolone during the final
2 weeks. We hypothesized that concomitant calcitriol therapy im-
proves clinical glucocorticoid responsiveness in these patients. It
should be noted that calcitriol, a downstream metabolite of
25-hydroxyvitaminD (25[OH]D), would not be expected to
restore vitamin D sufficiency, as defined by circulating 25(OH)
D: our intention was to address the short-term effects of calcitriol
itself. Details of the patient recruitment and study protocol may be
seen in the Methods section of this article’s Online Repository at
www.jacionline.org. Therewere no differences in patients’ demo-
graphic characteristics including age, body mass index, atopic
status, baseline FEV1, and inhaled glucocorticoid usage between
the 2 randomized groups (see Table E1 in this article’s Online
Repository at www.jacionline.org). There were no serious
adverse events, and all such events were self-limiting (see Table
E2 in this article’s Online Repository at www.jacionline.org). Dif-
ferential blood leukocyte counts showed a similar increase in
circulating neutrophils and reduction of eosinophils in response
to both courses of prednisolone therapy in all patients, confirming
compliance with this treatment (data not shown).
On the basis of the primary outcome of change in lung function
from the initial screening visit to the end of treatment, we saw no
significant difference in % predicted FEV1 between the 2 groups
(P 5 .82; Table I). Nevertheless, a within-group comparison
showing the change in lung function during the initial screening
in response to 2-week oral prednisolone (Screening) versus the
response to an identical course of prednisolone plus either pla-
cebo or calcitriol (Treatment) revealed a modest but significant
improvement in absolute and predicted FEV1 within the calcitriol
(P 5 .03) but not the placebo arm (Fig 1, A). These differences
were not apparent in patients randomized to receive calcitriol
before the second course of prednisolone, suggesting that calci-
triol alone had had no effect on lung function.
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In the placebo cohort, 4 of the 11 patients showed a more than
10% improvement in their lung function post-prednisolone in the
treatment phase than in the screening phase. Retrospective
analysis of serum concentrations of 25(OH)D in these patients
showed that 6 patients exhibited elevation of their baseline serum
25(OH)D concentrations from start to final visit of study (Fig 1,
B). A trend for a positive correlation between baseline serum
25(OH)D concentrations and change in predicted lung function
following prednisolone (r 5 0.56, P 5 .08; Fig 1, C) was
observed. Despite the very low numbers, a greater improvement
in FEV1 following prednisolone in those with relatively high
(>50 nmol/L; n 5 6) as compared with low (<50 nmol/L;
n 5 5) serum concentrations of 25(OH)D was seen (P 5 .03;
Fig 1, D).
This study represents the first demonstration to our knowledge
that the clinical responsiveness of asthmatic patients to gluco-
corticoid therapy is subject to manipulation in the short term. Our
data show that treatment with a short course of 1,25(OH)2D3
A
B C D
FIG 1. Treatment with calcitriol or vitamin D sufficiency improves clinical response to steroids. A, Compar-
ison of change in (i) absolute lung function (FEV1 [L]) and (ii) predicted lung function after a 2-week course of
prednisolone at screening (pretreatment) and treatment (together with placebo OR calcitriol). B, Serum
25(OH)D levels of the placebo group at the beginning as compared with the last visit of the clinical trial.
C, Correlation between serum 25(OH)D and change in lung function (predicted %) after a 2-week course
of prednisolone during the treatment phase of the trial (after placebo treatment). D, Comparison of change
in predicted lung function after a 2-week course of prednisolone at screening (pretreatment) and treatment
(together with placebo treatment) in those defined as high serum 25(OH)D (closed squares; >50 nmol/L) or
low serum 25(OH)D (open circles; <50 nmol/L); data shown as median 6 interquartile range.
TABLE I. Primary and secondary outcomes
Clinical measurement
Screening Treatment
Pre-steroids Post-steroids Pre-steroids post-treatment Post-steroids post-treatment
FEV1 (L/s)
Placebo 1.82 (1.44-2.21) 1.82 (1.79-2.44) 1.83 (1.42-2.23) 2.01 (1.61-2.41)
Calcitriol 1.98 (1.67-2.29) 1.88 (1.52-2.23) 1.96 (1.58-2.34) 2.20 (1.64-2.75)
FEV1 (%)
Placebo 59.9 (48.8-71.0) 59.9 (48.3-71.3) 60.6 (46.7-74.7) 65.9 (55.0-76.8)
Calcitriol 62.5 (55.2-69.8) 59.5 (49.8-69.2) 61.6 (53.3-69.9) 68.1 (55.4-80.7)
Serum 25(OH)D (nmol/L)
Placebo 42.6 (26.5-58.6) 44.6 (30.7-58.6) 53.2 (35.4-71.0) 50.8 (31.2-70.5)
Calcitriol 32.5 (21.5-43.5) 34.3 (21.5-43.5) 37.1 (15.9-58.4) 34.4 (19.6-49.2)
Note: Data shown as mean 6 95% CIs.
J ALLERGY CLIN IMMUNOL
JUNE 2014
1756 LETTERS TO THE EDITOR
(calcitriol) may modestly improve the clinical glucocorticoid
responsiveness in asthma, even in patients classified as clinically
glucocorticoid resistant.
This study was not designed to correct or take account of the
patients’ vitamin D status. Nevertheless, all but 1 of the patients
were vitamin D insufficient (<75 nmol/L) and 16 of our patients
were deficient (<50 nmol/L)7 at the commencement of the study
and, as shown, unexpectedly 6 of the 11 patients randomized to
placebo showed considerable improvement in vitamin D status
(insufficient/deficient to sufficient) by the final visit, for reasons
one can only speculate on, but that are likely to include exposure
to sunlight, dietary intake, and supplementation. Even so, we
observed a trend for 25(OH)D concentrations to correlate posi-
tively with clinical glucocorticoid responsiveness. A similar
observation was made in an independent recent study using
asthma exacerbations as a clinical outcome.8
Our data indicate that 1,25(OH)2D3 (calcitriol) may improve
the clinical response to glucocorticoids in resistant asthma
patients. They raise important questions about the design
of future studies. On the one hand, the decision to study a
well-characterized cohort of glucocorticoid-resistant asthmatic
patients produced significant challenges with recruitment and
retention, but on the other hand may have facilitated our ability
to observe a clinical effect that may be manifest most clearly in
this small but important subset of patients. Future studies must
address wider cohorts of asthmatic patients and consider other
end points. Although our study suggests an impact on glucocorti-
coid responsiveness, 2 independent studies implicate vitamin D in
reducing asthma exacerbation rates.8,9 Despite the low power of
this study, these preliminary clinical data are encouraging
and warrant further investigations in larger, ideally clinically
well-defined cohorts, including in pediatric asthma patients for
whom epidemiologic data are arguably the strongest.
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Immunologic response and safety in birch
pollen sublingual versus oral vestibule immu-
notherapy: A pilot study
To the Editor:
To date the efficacy of sublingual immunotherapy (SLIT) in the
form of allergy immunotherapy tablets is well documented with a
large number of clinical trials and it is accepted as an effective
alternative to subcutaneous immunotherapy in the treatment of
type I–mediated respiratory allergies in Europe, but is currently
not likewise accepted in the United States.1 The attention of many
scientists and clinicians is directed toward how immunologic
mechanisms mediate the effect of SLIT and improvement of
its efficacy, while reducing adverse effects. Although the
immunologicmechanisms of SLITaswell as subcutaneous immu-
notherapy remain to be elucidated in detail, the induction of reg-
ulatory T cells as well as a shift from an allergy-mediating TH2
toward an allergy-preventing TH1 immune response is propagated
along with the induction of allergen-specific IgG.2 Moreover,
antibodies with IgE-blocking activities—quantified as the
IgE-blocking factor—have been described recently within
the allergen-specific IgG fraction, which are hypothesized to
correlate with the clinical response to immunotherapy.3 The com-
mon link between these immune reactions are professional
Discuss this article on the JACI Journal Club blog: www.jaci-
online.blogspot.com.
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METHODS
Study participants
Study participants were recruited at Guy’s and St Thomas’ National Health
Service Foundation Trust and Barts Health National Health Service Trust,
tertiary health care centers in London, United Kingdom. The study was
approved by the London Bridge Research Ethics Committee (REC ref
06/Q0605/83), and written informed consent was obtained from all partici-
pants before enrolment. The study is registered with the UKClinical Research
Network (International Standard Randomized Controlled Trial Number
2937824).
Patients aged 18 to 75 years with a documented history and typical
symptoms of asthma for more than 6 months before screening were assessed
for eligibility to participate. All study subjects had a prebronchodilator FEV1
of less than 80% predicted and variability in airways obstruction (>_12% in
response to bronchodilator or >20% diurnal peak expiratory flow rate vari-
ability) documented within the previous 5 years. Individuals were excluded
if they suffered from past or present disease, which, as judged by the investi-
gator, might affect the study outcome (other than asthma, rhinitis, or eczema);
if serum-corrected calcium was more than 2.65 mol/L; if they were a current
cigarette smoker or ex-smoker of less than 5 years with a more than 5 pack-
year history; if they were pregnant or lactating females or at risk of pregnancy;
if they had a history of a respiratory tract infection and/or exacerbation of
asthmawithin 4weeks of the screening visit requiring oral glucocorticoid ther-
apy; if they had participated in a study involving an investigational medicinal
product in the previous 3 months or had made a blood donation within the last
year; if they were currently receiving, or had received, allergen immuno-
therapy or treatment with lithium carbonate or calcium supplements; or if
they were unable to understand or comply with the research protocol. Patients
were asked, and agreed not to take any vitamin supplements for the duration of
the study. Patients remained on their regular maintenance medication for the
duration of the study, including the 4-week washout period. On the day of
screening, 8 (34.7%) patients showed more than 20% peak flow variability
and 15 (65.3%) showed reversibility to a bronchodilator response. However,
all 8 patients whowere enrolled on the basis of peak flow variability had shown
significant bronchodilator response within 5 years prior to enrolling into the
study. All patients who went through the screening period (ie, 2 weeks of
oral corticosteroids) had confirmed bronchodilator reversibility.
Glucocorticoid-resistant asthmawas defined as less than 10% improvement
in baseline FEV1 following a 14-day course of oral prednisolone (Wockhardt
UK Ltd, Wrexham, United Kingdom; 40 mg/1.73 m2/d) in eligible patients.
Routine spirometry was measured before and after the course of prednisolone
using a PC-based spirometer and software (MIR Medical International
Research, Rome, Italy/WinspiroPRO). In addition, differential full blood
cell counts were performed before and after the course of prednisolone using
a LH750 hematology analyzer (Beckman Coulter, Brea, Calif).
Fifty patients were screened for eligibility between April 2009 and
September 2012. Twenty-five patients were excluded before or during the
screening period: 7 patients did not meet inclusion criteria, 3 declined to
participate, 3 were noncompliant with the protocol, and 12 were steroid
sensitive (>10% improvement in FEV1 compared with baseline). One patient
was lost to follow-up after completion of the screening visits. Twenty-four pa-
tients were randomized: 11 were allocated to placebo, 13 to intervention. One
patient in the treatment group withdrew because of an adverse event, thought
to possibly be related to the study drug (Fig E1; clinical flow diagram), making
it 12 patients to complete the treatment group in that arm. There were no
serious adverse events, and all events were self-limiting (Table E1).
Study protocol
The study outline is summarized in Fig E1. Participants who met the eligi-
bility criteria for glucocorticoid-resistant asthma returned following a 4-week
washout period and were randomly allocated to commence treatment with
either calcitriol 0.25 mg soft capsules (Rocaltrol; Roche Pharmaceuticals,
Welwyn Garden City, United Kingdom) or organoleptically identical lactose
placebo generated in-house (Pharmacy Production Unit, St Thomas’ Hospital
NHS Trust, London, United Kingdom) twice daily. Patients were randomized
in a 1:1 ratio using a computerized random plan generated by a physician not
involved in the trial. Patients and trial investigators were blinded to treatment
allocation. Following 2 weeks of calcitriol or placebo treatment, patients were
given a second course of oral prednisolone identical to the first while calcitriol
or placebowas continued. Spirometry was performed at the beginning and end
of this second course of oral prednisolone as before. Serum concentrations of
calcium, corrected calcium, albumin, total protein, phosphate, sodium, potas-
sium, urea, creatinine, and 25(OH)D were analyzed. Concentrations of
25(OH)D2 and 25(OH)D3 were determined by isotope-dilution liquid chro-
matography–tandem mass spectrometry and summed to give values for total
25(OH)D. Sensitivity for this assay was 10 nmol/L. Full blood cell counts
were performed as described above. Albumin, phosphate, and total serum cal-
cium concentrations were determined using anArchitect ci8200 analyzer (Ab-
bott Diagnostics, Chicago, Ill). Calcium concentration was corrected for
serum albumin concentration using the formula: corrected calcium
(mmol/L) 5 total calcium (mmol/L) 1 0.02 3 (40 – albumin [g/L]).
Power calculations predicted that the study of 40 glucocorticoid-resistant
participants would enable detection of an improvement in change in FEV1
from 0.4% to 10%with 80%power, tested at the 2-sided 5% significance level.
Because of difficulties with patient recruitment, however, the decision was
made to terminate the study after 24 patients completed.
The primary outcome measure was change in FEV1 from screening to the
final visit. Secondary outcomes measured included asthma control question-
naire and serum 25(OH)D measurements. There was no difference observed
in the asthma control questionnaire scores between the calcitriol and placebo
treatment groups. Additional analysis of glucocorticoid response was per-
formed within (screening vs treatment phases) and between groups (calcitriol
vs placebo), expressed as absolute values and percentage change. Study sub-
jects were asked to report any adverse events from the day of commencement
of the first course of oral prednisolone until 4 weeks after the second course by
telephone or e-mail or at study visits.
Statistical methods
The differences in % predicted FEV1 at 28 days postrandomization be-
tween treatment groups was assessed using a linear regression model adjusted
for screening values of % predicted FEV1 value and vitamin D status. The
analysis was performed on the complete case population, and statistical signif-
icance was assessed at the 5% level.
For subsequent subanalyses, data were assessed for Gaussian distribution
and equality of variance. Then, for normally distributed data, assessment was
done by either an unpaired or a paired (where appropriate) Student t test and
for non-normally distributed data,Wilcoxonmatched-pairs signed test (paired
data) and Mann-Whitney U test (unpaired). Correlations were nonnormally
distributed and were assessed by Spearman rank correlation test. Normally
distributed data were presented as the mean 6 95% CIs, and nonnormally
distributed data were shown as median 6 interquartile range.
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FIG E1. Schematic of clinical trial design.
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TABLE E1. Patients’ characteristics
Characteristic Placebo Calcitriol
Age (y) 53.5 (47.8-59.1) 50.3 (39.1-61.6)
Ethnic origin
Caucasian 9 8
African 2 3
Asian 0 1
Sex
Male 7 7
Female 4 6
Atopic 10 9
BMI 29.1 (25.0-33.2) 27.4 (25.5-29.2)
Inhaled corticosteroid dose 1236 (830-1643) 1267 (849-1684)
FENO 19.9 (15.7-24.1) 38.4 (20.7-56.0)
n 5 11 n 5 12
Note: Data are presented as the mean and 95% CI. Atopy was defined by skin prick
testing. The dose of inhaled corticosteroids was calculated according to the British
Thoracic Society - Scottish Intercollegiate Guidelines Network (BTS-SIGN)
Guideline on the management of asthma (Table 8b: Equivalent doses of inhaled
steroids relative to BDP and current licensed age indications). Patients were on
beclomethasone 1600 mg/d, budenoside 1600 mg/d, or fluticasone 800 mg/d.
BDP, Beclomethasone dipropionate; BMI, body mass index; FENO, fractional exhaled
nitric oxide; 25(OH)D, 25-hydroxyvitamin D.
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TABLE E2. Side effects documented throughout the trial
Adverse event Study phase Study drug
Related to
study drug
Mild indigestion Screening Prednisolone Yes
Nausea Screening Prednisolone Possible
Increased hunger Screening Prednisolone Yes
Coryzal symptoms Treatment Placebo No
Diarrhea Treatment Placebo No
Coryzal symptoms Treatment Calcitriol No
Coryzal symptoms Treatment Calcitriol No
Coryzal symptoms Treatment Calcitriol No
Constipation, back pain Treatment Calcitriol Possible
Bang to head Treatment Calcitriol No
Note: All effects were nonsevere and resolved spontaneously.
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Asthma and lower airway disease
Enhanced production of IL-17A in patients with severe
asthma is inhibited by 1a,25-dihydroxyvitamin D3 in a
glucocorticoid-independent fashion
Alexandra M. Nanzer, MRCP,a,b* Emma S. Chambers, MSc,a* Kimuli Ryanna, MRCP,a David F. Richards, MSc,a
Cheryl Black, PhD,a Peter M. Timms, FRCPath,c Adrian R. Martineau, PhD,b Christopher J. Griffiths, FRCGP,b
Christopher J. Corrigan, PhD,a and Catherine M. Hawrylowicz, PhDa London, United Kingdom
Background: TH17 cells are proposed to play a role in the
pathology of asthma, including steroid-resistant (SR) disease. We
previously identified a steroid-enhancing function of vitamin D in
patients with SR asthma in restoring the impaired response to
steroids for production of the anti-inflammatory cytokine IL-10.
Objective: We sought to investigate the production of the
TH17-associated cytokines IL-17A and IL-22 in culture in
patients with moderate-to-severe asthma defined on the basis of
their clinical response to steroids and the susceptibility of this
response to inhibition by steroids and the active form of vitamin
D, 1a,25-dihydroxyvitamin D3 (1,25[OH]2D3).
Methods: PBMCs were stimulated in culture with or without
dexamethasone and 1,25(OH)2D3. A cytometric bead array,
ELISA, and intracellular cytokine staining were used to assess
cytokine production. The role of CD39 in inhibition of the TH17
response was studied by using quantitative real-time PCR, flow
cytometry, and addition of the antagonist POM-1 to culture.
Results: Asthmatic patients synthesized much higher levels of
IL-17A and IL-22 than nonasthmatic control subjects, with
patients with SR asthma expressing the highest levels of IL-17A.
Glucocorticoids did not inhibit IL-17A cytokine expression in
patients and enhanced production in cultures from control
subjects. Treatment with 1,25(OH)2D3 with or without
dexamethasone significantly reduced both IL-17A and IL-22
levels. An antagonist of the ectonucleotidase CD39 reversed
1,25(OH)2D3-mediated inhibition of the IL-17A response.
Conclusion: Patients with severe asthma exhibit increased levels
of TH17 cytokines, which are not inhibited by steroids.
1,25(OH)2D3 inhibits TH17 cytokine production in all patients
studied, irrespective of their clinical responsiveness to steroids,
identifying novel steroid-enhancing properties of vitamin D in
asthmatic patients. (J Allergy Clin Immunol 2013;132:297-304.)
Key words: Asthma, vitamin D, IL-17A, steroid resistant, steroid
sensitive, TH17, glucocorticoids
Asthma is broadly defined as bronchial hyperresponsiveness
with reversible expiratory airflow limitation. Historically, asthma
has been described as having an underlying TH2-mediated inflam-
matory profile; however, there is increasing evidence for heteroge-
neity in asthma phenotypes, with a significant proportion of
asthmatic patients demonstrating a low or non–TH2-mediated phe-
notype that appears less sensitive to control by glucocorticoids.1,2
Although glucocorticoids are currently themost effective treatment
for asthma, steroid-resistant (SR) asthma is a significant clinical
problem.These patients generally require prolonged systemic treat-
ment, their asthma is less stable and more difficult to control, and
they are subject to higher morbidity and mortality.3-6 The precise
cause or causes of SR asthmaare unknown, but severalmechanisms
have been proposed to account for it,7-10 including genetic suscep-
tibility, defects in glucocorticoid receptor (GR) binding, increased
expression of the functionally inactive GR-b, activation of tran-
scription factors (eg, activator protein 1), or decreased synthesis
of immunoregulatory cytokines, such as IL-10. Although it is diffi-
cult to investigate SR asthma in patients with milder disease be-
cause its definition is based on improvement in originally
abnormal lung function, it is reasonable to suppose that SR asthma
is likely tobe associatedwith severe anddifficult-to-control disease.
TH17 cells are critical for defense against bacterial and fungal
infections.11 Mouse models demonstrate that animals deficient in
IL-17A or IL-17RA are highly susceptible to infection with mu-
cosal pathogens, such as Klebsiella pneumoniae and Candida al-
bicans.12,13 IL-17A–mediated activation of the innate immune
system and neutrophil influx can be protective against infection
but can also lead to damage of the surrounding tissues associated
with immune pathology.14,15
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Abbreviations used
Foxp3: Forkhead box protein 3
GR: Glucocorticoid receptor
1,25(OH)2D3: 1a,25-Dihydroxyvitamin D3
SR: Steroid resistant
SS: Steroid sensitive
Treg: Regulatory T
A body of circumstantial evidence consistent with the hypoth-
esis that IL-17A exacerbates asthma, reduces patients’ responsive-
ness to therapy, or both already exists. Thus IL-17A expression in
sputumor bronchialmucosal biopsy specimens has been correlated
with bronchial hyperresponsiveness,16 granulocyte infiltration,17
and production of fibrogenic mediators by bronchial fibroblasts.18
Furthermore, increased serum IL-17A appears to be both a
marker19 and an independent risk factor for severe
asthma.16-18,20,21 Involvement of TH17 cells in patients with severe
SR asthma is proposed frommurine and human studies.22,23 In ad-
dition to IL-17A, IL-22 is commonly produced by TH17 cells. In
various animalmodels of disease, IL-22 can elicit damagingor pro-
tective responses, possibly dependent on the location, cellular
source, cytokine milieu, and timing of its expression.24-26
There is great interest in the therapeutic potential of vitamin D
to regulate the severity of asthma and to reduce the amount of
anti-inflammatory medication required for disease control. Sev-
eral studies have pointed out striking links in populations between
vitamin D deficiency and asthma severity or requirements for
anti-inflammatory medication.27-30 In previous studies investigat-
ing the immunologic basis of this relationship, we have shown
that 1a,25-dihydroxyvitamin D3 (1,25[OH]2D3) exerts immuno-
modulatory effects on T cells from patients with SR asthma, en-
hancing the impaired steroid-induced IL-10 response in these
subjects,31 whereas others have highlighted the capacity of this
molecule to inhibit TH17 responses.
32-35
Building on these studies, we hypothesized that 1,25(OH)2D3
inhibits increased IL-17A production by blood TH17 cells from
patients with severe asthma independently of glucocorticoids
in vitro and independently of their clinical responsiveness to glu-
cocorticoid therapy in vivo. To address this hypothesis, we studied
the effects of 1,25(OH)2D3 and the glucocorticoid dexametha-
sone on the production of IL-17A and its common coproduct,
IL-22, by peripheral blood CD41 T cells from a cohort of patients
with severe asthma who were carefully characterized for their
clinical glucocorticoid responsiveness and nonasthmatic control
subjects. Finally, in an attempt to elucidate possible mechanisms
of the effect of 1,25(OH)2D3 in altering IL-17A production, we
measured its effects on the expression of the ectonucleotidase
CD39, increased expression of which has previously been re-
ported to be associated with inhibition of IL-17A production in
patients with autoimmune disease.36 We hypothesized that dexa-
methasone, but not 1,25(OH)2D3, reduces CD39 expression on
blood T cells and that inhibition of its ectonucleotidase activity
abolishes any effects of 1,25(OH)2D3 on IL-17A expression.
METHODS
Subjects
Healthy adults (study approved by the local research ethics committee, 09/
H0804/77) and asthmatic patients (08/H0804/84) were recruited. All healthy
control subjects and patients provided written informed consent. Asthmatic
patients had moderate-to-severe asthma for at least 6 months on therapy step 3
or 4 of the British Thoracic Society guidelines on the management of asthma
diagnosed by a specialist physician. The average inhaled corticosteroid dose in
beclomethasone diproprionate equivalents was 1177 mg for patients with SR
asthma and 1180 mg for patients with steroid-sensitive (SS) asthma. All
patients had a prebronchodilator FEV1 of less than 80%of predicted value, had
documented airway variability of greater than 12% after 400 mg of short-
acting bronchodilator, and had undergone detailed assessment to exclude a di-
agnosis other than asthma and comorbidities affecting asthma control. Patients
were not taking oral corticosteroids for 4 weeks before the study. Steroid sen-
sitivity was defined by an increase in FEV1 of greater than 10% from baseline
after a 2-week course of prednisolone at 40mg/1.73m2 body surface area. Ste-
roid resistance was defined by a less than 10% increase in FEV1 from baseline
after a 2-week course of prednisolone at 40 mg/1.73 m2 body surface area.
Compliance with prednisolone during the study was assessed with cortisol se-
rum levels before and after steroids. Patients undergoing immunotherapy,
smokers, or patients who had a respiratory tract infection or asthma exacerba-
tion during or 4 weeks before enrollment into the study were excluded.
Eighteen patients with SR asthma and 10 patients with SS asthma were
assessedwith amean age of 54 (SR) and 50 (SS) years.Mean prebronchodilator
FEV1 before and after a course of oral corticosteroids was 1.99 L (64.56%) and
1.96 L (64.05%) in the patients with SR asthma and 1.72 L (57.1%) and 2.19
L (73.2%) in the patients with SS asthma (poststeroid FEV1, patients with SR
vs patients with SS asthma: P < .001, analysis of covariance). Ten healthy
control subjects were assessed for comparison (mean age, 41 years).
Cell isolation and culture
Human PBMCs were isolated, as previously described.31 Briefly, CD8-de-
pleted PBMCs were obtained by means of negative selection with CD81 Dy-
nalbeads (Invitrogen, Paisley, United Kingdom). CD41 T cells were purified
bymeans of positive selectionwithDynalbeads. Cells (13 106 cells/mL)were
cultured in RPMI (containing 10% FCS, 2 mmol/L L-glutamine, and 50 mg/
mL gentamicin) and stimulated with plate-bound anti-CD3 (1 mg/mL,
OKT-3) plus 50 U/mL recombinant human IL-2 (Eurocetus, Harefield, United
Kingdom) in the presence or absence of dexamethasone (Sigma-Aldrich,
Gillingham, United Kingdom) and 1,25(OH)2D3 (BIOMOL Research Labs,
Exeter, United Kingdom) at the indicated concentrations in a 24-well plate
for 7 days. There was no significant difference between viability between
the different conditions (data not shown). Where indicated, cells were recul-
tured at the same density of 1 3 106/mL after 7 days with plate-bound anti-
CD3 and IL-2 alone in a 48-well plate, and supernatants were harvested at
48 hours for cytokine analysis.
Flow cytometry
The following antibodies were used for cell-surface phenotyping: CD3
(SK7; BD Biosciences, Oxford, United Kingdom) and CD39 (ebioA1;
eBioscience, Hatfield, United Kingdom). For ex vivo staining, red blood cells
were lysed with FACS Lysing Solution (working dilution, 1:10; BD Biosci-
ences) and then further stained for intranuclear forkhead box protein 3
(Foxp3; PCH101, eBioscience) by using the Foxp3 staining kit per the manu-
facturer’s instructions (eBioscience).
For intracellular cytokine staining on day 7, cells were restimulated for 4
hours with 5 ng/mL phorbol 12-myristate 13-acetate and 500 ng/mL
ionomycin, with 2 mmol/L monensin (Sigma-Aldrich) added for the final 2
hours. Cellswerewashed, fixed, and permeabilizedwith theCytofix/Cytoperm
kit (BD Biosciences) and stained with the fluorescently labeled mAbs to
IL-22 and IL-17A (22URTI and eBio64CAP17, eBioscience). Dead cells
(7-aminoactinomycin D positive, Sigma-Aldrich) were gated out. Analysis
was performed with a FACSCalibur flow cytometer (BD Biosciences).
Quantitative real-time PCR
RNA was extracted from cell pellets with the RNeasy Mini kit (Qiagen,
Crawley, United Kingdom), according to the manufacturer’s instructions. The
RNA was quantified with a Nanodrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, Del), and 250 ng of RNAwas reverse transcribed into
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cDNA. Quantitative real-time PCR was performed in triplicate by using an
Applied Biosystems 7900 HT system and FAM-labeled Assay-on-Demand
reagent sets forCD39 (Hs00969559_m1).Quantitative real-timePCR reactions
were multiplexed with VIC-labeled 18S primers and probes (Hs99999901_s1)
as an endogenous control and analyzedwithSDSsoftware, version2.1 (Applied
Biosystems, Foster City, Calif), according to the 22DDCt method.
Cytokine analysis
IL-22 levels were measured by using ELISA and matched antibody pairs
(BD Biosciences). The lower limit of detection for IL-22 was 100 pg/mL.
IL-17A, IL-10, IFN-g, and IL-5 levels were measured with the Cytometric
Bead Array (BD Biosciences), according to the manufacturer’s protocol; the
lower limit of detection was 1.5 pg/mL.
Statistics
Data are presented as means6 SEMs unless indicated. Data were assessed
for equivalence to a Gaussian distribution and equality variance, after
which the appropriate parametric or nonparametric test was performed
(see individual figure legends). Differences were considered significant at
the 95% confidence level.
RESULTS
Comparison of IL-17A and IL-22 production by
PBMCs in culture from patients with SS and
patients with SR asthma
Details of the 2 cohorts of patients with moderate-to-severe
asthma, defined as SS or SR asthma on the basis of changes in lung
function after a 2-week course of oral prednisolone, and of healthy
nonasthmatic control subjects are provided in the Methods
section. Notably, these 2 patient groups exhibited comparable
disease severity based on impairment of lung function and were
taking comparable doses of inhaled corticosteroids (total dosages
based on beclomethasone dipropionate equivalence).
PBMCs from the asthmatic patients were evaluated for their
capacity to synthesize the TH17-associated cytokines IL-17A and
A
B
C
FIG 1. Patients with severe asthma express higher IL-17A and IL-22 levels. Control and asthmatic cultures
were assessed for IL-17A and IL-22 production by using intracellular flow cytometry and an antibody
capture assay. A, Representative dot plots. B and C, Cumulative data of cytokine-positive cells (healthy sub-
jects, n 5 8; patients with SS asthma, n 5 8; and patients with SR asthma, n 5 14; Fig 1, B) and secreted
cytokines (healthy subjects, n 5 10; patients with SS asthma, n 5 10; and patients with SR asthma,
n5 14; Fig 1, C). *P < .05 and **P < .001, Student t test.Open circles, Patients with SS asthma; solid squares,
patients with SR asthma; and solid triangles, healthy control subjects.
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IL-22 in culture, and comparisons were made with control sub-
jects. PBMCs depleted of CD81 T cells were stimulated in vitro
with anti-CD3 and IL-2 for 7 days and then stained for intracellu-
lar cytokine expression. Significantly greater percentages of
IL-17A1 and IL-221 expressing cells were observed in cultures
from asthmatic patients compared with healthy control subjects
(Fig 1, A and B). When patients were subdivided based on clinical
responsiveness to glucocorticoids, only patients with SR asthma
showed a significant difference in IL-17A immunoreactivity
(SR asthma, P5 .003; SS asthma, P5 .142) and IL-22 immuno-
reactivity (SR asthma, P5 .037; SS asthma, P5 .701) compared
with control subjects (Fig 1, B). Cells coexpressing IL-17A and
IL-22 are proposed to represent the most pathogenic population,
and their numbers were significantly increased in all asthmatic pa-
tients and patients with SR asthma compared with healthy control
subjects (all asthma, P 5 .029; SR asthma, P 5 .009). At day 7,
cells were also harvested and recultured at equal cell densities
for 48 hours with anti-CD3 and IL-2 alone. Culture supernatants
from asthmatic patients contained significantly higher quantities
of secreted IL-17A and IL-22 compared with those from healthy
control subjects (Fig 1, C). Production of IL-17A and IL-22 was
significantly increased in patients with SR asthma compared with
that seen in control subjects (IL-17A, P5 .009; IL-22, P5 .036).
Supernatants from patients with SR asthma had significantly
more IL-17A compared with those from patients with SS asthma
(P 5 .016), whereas culture supernatants from patients with SS
and patients with SR asthma contained comparable levels of IL-
22 (see Fig E1, A, in this article’s Online Repository at www.
jacionline.org).
Glucocorticoids do not inhibit IL-17A and IL-22
synthesis in culture
The capacity of glucocorticoids to alter production of IL-17A
and IL-22 was next examined. Addition of 1027 mol/L dexameth-
asone to cultures from healthy control subjects significantly in-
creased the mean percentage of cells expressing IL-17A but
did not alter the low percentage of cells expressing IL-22
(Fig 2, A). IL-17A and IL-22 secretion was increased in a
concentration-dependent manner by dexamethasone in cultures
from healthy donors (Fig 2, B and C). IL-2 is present in the stim-
ulation cultures, and addition of IL-2 plus IL-4 has previously
been described to promote steroid insensitivity in culture.37
Therefore the effects of dexamethasonewere assessed in the pres-
ence or absence of anti-CD3, IL-2, or both on IL-17A and a range
of additional cytokines (see Fig E2 in this article’s Online Repos-
itory at www.jacionline.org). Notably, IL-17A (and IL-10)
enhancement by dexamethasone only occurred when the combi-
nation of anti-CD3 and IL-2 was present. Dexamethasone in-
hibited the production of IFN-g, IL-13, and IL-5, although the
inhibition of IFN-g in particular was less marked when anti-
CD3 plus IL-2 compared with anti-CD3 or IL-2 alonewas present
in these cultures.
The effects of dexamethasone in asthmatic patient cultures
were less marked, where notably there was a greater than 7-fold
higher basal level of IL-17A synthesis compared with that seen in
nonasthmatic cultures (Fig 2, B). A trend toward increased
IL-17A secretion (P 5 .102; Fig 2, B) and a significant increase
in the frequency of IL-17A1 cells in patient cultures containing
1027 mol/L dexamethasone was observed (Fig 3, A). An effect
observed in both the SS asthma and SR asthma subgroups was
partial inhibition by dexamethasone of IL-22 secretion
(Fig 2, C, and see Fig E1).
1a,25-dihydroxyvitamin D3 inhibits IL-17A and IL-22
expression
The capacity of 1,25(OH)2D3 to inhibit IL-17A production
alone and in combination with dexamethasone was next investi-
gated in cultures from asthmatic patients. 1,25(OH)2D3 signifi-
cantly decreased the mean percentages of cells that were
immunoreactive for IL-17A or IL-22 in culture (Fig 3). Although
dexamethasone did not reduce IL-22 or IL-17A immunoreactivity
compared with control cultures, the combination of dexametha-
sone and 1,25(OH)2D3 led to a marked reduction in the frequency
of cytokine-positive cells that was not significantly different from
cultures with 1,25(OH)2D3 alone (Fig 3). Protein expression in
culture supernatants after 1,25(OH)2D3 treatment alone or in
combination with dexamethasone demonstrated a comparable
trend, with no significant difference in the mean concentration
of IL-17A or IL-22 between cultures containing 1,25(OH)2D3
or 1,25(OH)2D3 plus dexamethasone (Fig 3). The effects
of 1,25(OH)2D3 on IL-17A and IL-22 synthesis were comparable
in the patients with SS asthma and those with SR asthma (see Fig
E1, B). The reduction in IL-17A production by 1,25(OH)2D3 is
unlikely to be explained by inhibition of proliferation (see Fig
E3 in this article’s Online Repository at www.jacionline.org) or
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decreased viability (data not shown) because 1,25(OH)2D3 at the
concentration used did not inhibit either, as recently reported.38
These data highlight the capacity of 1,25(OH)2D3 to counteract
any detrimental effect or lack of effect of dexamethasone on
TH17-associated cytokine synthesis in cell cultures from
asthmatic patients. 1,25(OH)2D3 effectively inhibited IL-17A
production in cultures from healthy control subjects (data not
shown), as previously reported by others.33-35
1,25(OH)2D3 enhances expression of CD39
1 T cells,
a potential mechanism for IL-17A inhibition
Expression of the ectonucleotidase CD39 by Foxp31 regula-
tory T (Treg) cells has previously been reported to be associated
with inhibition of IL-17A production.36,39,40 Analysis of ex vivo
expression ofCD39demonstrated a significantly higher frequency
of CD31CD391 T cells in the peripheral blood of healthy donors
compared with that of patients with severe asthma (P 5 .003).
CD39 can be expressed on both CD41 memory and Foxp31 T
cells,36,39 and therefore we further analyzed expression on
Foxp31 and Foxp32 populations. A significantly higher fre-
quency of CD39-expressing cells was detected in both
CD31Foxp32 and CD31Foxp31 T cells in the nonasthmatic do-
nors compared with the patients with severe asthma (Fig 4, A) in
contrast to the higher IL-17A synthesis observed in the patients.
Next, the effect of 1,25(OH)2D3 and dexamethasone on CD39
expression was investigated. CD41 T cells cultured in the pres-
ence of 1,25(OH)2D3 demonstrated a significantly increased
gene expression of CD39 (Fig 4, B). When surface expression
of CD39 was assessed by using flow cytometry, there was a mod-
est but significant increase in the expression level of CD39, as
determined based on mean fluorescence intensity, but there
were no differences in the overall frequency of CD391 T cells.
In comparison, addition of dexamethasone reduced the percent-
age of CD391 T cells and mean fluorescence intensity (Fig 4, C
and D). To investigate the role of CD39 in 1,25(OH)2D3 inhibi-
tion of IL-17A production, we used POM-1, a known inhibitor
of CD39 ectonucleotidase activity. POM-1 partially abrogated
the inhibition of IL-17A synthesis effected by 1,25(OH)2D3 in
cultured T cells. This effect was specific for IL-17A because
the production of IL-10 and other TH1 and TH2 cytokines was
not affected (Fig 4, E).
DISCUSSION
Our data demonstrate that the production of IL-17A and IL-22
by human peripheral blood CD41 T cells is increased in patients
with severe asthma. Notably, IL-17A levels, but not IL-22 levels,
were approximately 5-fold greater in patients with SR asthma
compared with those seen in patients with SS asthma. Strikingly,
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the glucocorticoid dexamethasone significantly enhanced the fre-
quency of IL-17A1 cells in culture in both nonasthmatic control
subjects and asthmatic patients, although IL-17A secretion was
only significantly increased by dexamethasone in control cul-
tures. In contrast, the active form of vitamin D reduced levels
of both cytokines directly and also when dexamethasone was pre-
sent in culture. Importantly, this in vitro effect was equivalent in
clinically glucocorticoid-resistant and glucocorticoid-sensitive
asthmatic patients, with greater than 80% inhibition of the
TH17 response in both patient cohorts. The data support a poten-
tial role for the ectonucleotidase CD39 in 1,25(OH)2D3-mediated
inhibition of the IL-17A response. Together, our data are consis-
tent with the hypothesis that 1,25(OH)2D3, through inhibition of
IL-17A, improves disease control in asthmatic patients indepen-
dently of their glucocorticoid responsiveness.
The present study extends earlier observations showing an
association between increased IL-17A production and severe
asthma by investigating 2 asthmatic patient cohorts with
clearly defined clinical responsiveness or nonresponsiveness
to steroids at the time of study but comparable disease
severity. Although blood T cells from all asthmatic patients
demonstrated increased IL-17A and IL-22 synthesis, the most
striking differences from the control group were observed
in the patients with SR asthma. Analysis of cytokine produc-
tion from patients with SS asthma alone demonstrated a
nonsignificant trend for enhanced IL-17A and IL-22 produc-
tion in comparison with that seen in healthy control subjects.
In comparisons between patients with SS asthma versus
patients with SR asthma, the most notable differences were
in the frequency of the levels of secreted IL-17A and
IL-17A1IL-221 double-positive cells. Double-positive con-
ventional T cells are proposed to represent the more patho-
genic population, with studies showing that IL-22 enhances
the proinflammatory properties of IL-17A.32,41
Independent studies have suggested that TH17 cytokine pro-
duction plays a mechanistic role in increasing asthma severity
and reducing corticosteroid sensitivity.22,42 Nevertheless, we can-
not completely exclude from the present data the possibility that
increased IL-17A production is associated with inhaled cortico-
steroid administration. Although dexamethasone increased the
frequency of IL-17A1 cells in both nonasthmatic and asthmatic
cultures, the levels secreted were only significant in nonasthmatic
cultures, although a trend for an increasewas observed (P5.102).
A major difference between these 2 subject groups was the base-
line level of IL-17A synthesis, which was more than 7-fold lower
in the nonasthmatic cultures comparedwith the asthmatic cultures
and might contribute to the capacity to visualize the enhancement
by dexamethasone. Furthermore, in a retrospective analysis of our
data, we observed an association between inhaled corticosteroid
dosages (beclomethasone equivalent before the trial of oral
A
B
C
D
E
FIG 4. 1,25(OH)2D3 increases CD39 expression by CD4
1 T cells. A, The frequency of CD391 and CD31 T cells
(i) and CD391 and Foxp31 and Foxp32 T cells (ii) in the peripheral blood of healthy donors (n 5 8) and
patients with severe asthma (n 5 19). B-D, Effects of treatment with dexamethasone or 1,25(OH)2D3 in
culture on healthy nonasthmatic donors. Fig 4, B, Relative CD39 mRNA (n5 5). Fig 4, C, Representative his-
tograms. Fig 4, D, Cumulative data on CD39 expression (n 5 6). E, Cumulative data (n 5 8) on effects of
POM-1 (10 mmol/L, CD39 antagonist) on 1,25(OH)2D3-modulation of IL-17A, IFN-g, IL-10, and IL-5 expressed
as fold change from the no-drug condition. *P < .05, **P < .01, and ***P < .001; Fig 4, B and D, 1-way ANOVA
with the Tukey post test, and Fig 4, E, Wilcox matched pairs signed-rank test.
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prednisolone therapy) and the amounts of blood PBMC IL-17A
released in vitro (Pearson correlation r 5 0.459, P 5 .014), sup-
porting the possibility that at least some of the IL-17A produced
by PBMCs in asthmatic patients results from corticosteroid
exposure.
Our data are also broadly complementary of studies in an
animal model, demonstrating that IL-17A production by
PBMCs was not inhibited by dexamethasone in culture and
that airways inflammation induced in mice by adoptive transfer
of TH17 cells was not inhibited by dexamethasone, which is in
contrast to that mediated by the adoptive transfer of TH2 cells.
22
IL-17A might contribute to asthma pathogenesis through a num-
ber of different mechanisms, such as induction of neutrophilia
and stimulation of lung innate and structural cells, to secrete
proinflammatory cytokines.15,43,44 Also worthy of note is the
association of IL-17A with subepithelial fibrosis, a feature of
airway remodeling shown in some studies to correlate with
asthma severity.45
IL-17A has been proposed to affect global corticosteroid
responsiveness through effects on the GR. GR-a is ubiquitously
expressed and responsible for the induction and repression of
target genes, whereas GR-b is expressed at much lower levels and
is a dominant negative inhibitor of GR-a. Increased expression of
GR-b has been linked to severe asthma in some studies,42,46 and a
recent study suggested that IL-17A and IL-17F increase the ex-
pression of GR-b, an effect that was more prominent in asthmatic
patients than in healthy control subjects.23 These data imply a
complex and potentially detrimental relationship between IL-
17A, steroid treatment, and responsiveness in patients with severe
asthma, on which vitamin D might have a positive effect.
We investigated a possible mechanism for the inhibition of T-
cell IL-17A synthesis by 1,25(OH)2D3. The ectonucleotidase
CD39, which is expressed by memory T cells, as well as Foxp31
Treg cells, has previously been reported to inhibit IL-17A synthe-
sis.36,39,40 In the present study treatment with 1,25(OH)2D3 in-
creased the mean intensity of CD39 expression by human
CD41 T cells, whereas the CD39 antagonist POM-1 partially ab-
rogated 1,25(OH)2D3-mediated inhibition of the IL-17A produc-
tion, supporting a mechanistic role for this pathway but not
excluding others. In contrast, dexamethasone tended to reduce
CD39 expression.
Manipulation of vitamin D status for therapeutic benefit in
asthmatic patients and patients with other respiratory conditions
is currently highly topical. This arises in part from studies
demonstrating that patients with poorly controlled asthma, poor
responsiveness to corticosteroids, or both have significantly
reduced vitamin D levels, at least as assessed by the circulating
precursor 25-hydroxyvitamin D3.27-30,47 We and others have pre-
viously demonstrated an association with 25(OH)2D3 status and
airways smooth muscle mass.27,28,48 Bronchial smooth muscle
hypertrophy and hyperplasia are prominent features of airway re-
modeling, as is subepithelial fibrosis, and IL-17A is a key medi-
ator implicated in lung structural changes with profibrotic
activity within the bronchial epithelium.45 Understanding the var-
ious mechanisms through which vitamin D controls respiratory
health and steroid responsiveness is central in targeting this
pathway therapeutically, and our results provide support for
an additional beneficial effect. We believe that evidence of
1,25(OH)2D3 downregulating proinflammatory cytokines, such
as IL-17A and IL-22, and its capacity to enhance antimicrobial
pathways, Treg cells, and other homeostatic mechanisms, such
as CD200,49 are all likely to contribute to promoting homeostasis
in the airway and lung health.
Key messages
d PBMC cultures from steroid refractory asthma patients
synthesize significantly higher levels of IL-17A than ste-
roid sensitive patients and nonasthmatic control cultures.
d Glucocorticoids do not inhibit IL-17A synthesis in patient
cultures and enhance synthesis in nonasthmatic cultures.
d 1,25(OH)2D3 inhibits the IL-17A response in a glucocorti-
coid-independent manner, suggesting additional benefits
of vitamin D to control severe asthma.
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FIG E1. 1,25(OH)2D3 inhibits TH17-associated cytokines in patients with SS severe asthma and patients with
SR severe asthma. A, Cumulative data showing higher IL-17A expression in patients with SR asthma and
comparable IL-22 levels in cultures from patients with SS asthma and patients with SR asthma (SS asthma,
n 5 10; asthma, n 5 18). B, Secreted IL-17A and IL-22 from cultures of patients with SS asthma (left) and
patients with SR asthma (right) containing dexamethasone and 1,25(OH)2D3 (SS asthma, n 5 10; SR
asthma, n5 18). *P < .05, **P < .01, and ***P < .0001; Fig E1, A, unpaired t test, and Fig E1, B, 1-way ANOVA
with the Tukey post test. D-x and V-x, Dexamethasone and 1,25(OH)2D3, respectively, at 10
27 mol/L.
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FIG E2. Effect of IL-2 in culture on dexamethasonemodulation of IL-10, IFN-
g, and IL-5. Levels of secreted IFN-g, IL-10, IL-13, IL-5, and IL-17A under
different stimulation conditions in healthy control subjects are shown
(n 5 6). Dx, Dexamethasone at 1027 mol/L.
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FIG E3. Dexamethasone, but not 1,25(OH)2D3, inhibits PBMC proliferation. A, Representative dot plots.
B, Cumulative data showing proliferation of PBMCs in the presence or absence of dexamethasone and
1,25(OH)2D3 in healthy control subjects (n 5 4). C, Cumulative data cytokine secretion data of IFN-g,
IL-10, and IL-5 secretion in healthy donors (n 5 8). *P < .05, **P < .01, and ***P < .001; Fig E3, B and C,
1-way ANOVA with the Tukey post test. Dx and Vx, Dexamethasone and 1,25(OH)2D3, respectively, at
102x mol/L.
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Distinct endotypes of steroid-resistant asthma
characterized by IL-17Ahigh and IFN-ghigh
immunophenotypes: Potential benefits of calcitriol
Emma S. Chambers, PhD,a* Alexandra M. Nanzer, MRCP,a,b Paul E. Pfeffer, MRCP,a David F. Richards, MSc,a
Peter M. Timms, FRCPath,c Adrian R. Martineau, PhD,b Christopher J. Griffiths, FRCGP,a,b Christopher J. Corrigan, PhD,a
and Catherine M. Hawrylowicz, PhDa London, United Kingdom
Background: A small population of patients with severe asthma
does not respond to glucocorticoids (steroid resistant [SR]).
They have high morbidity, highlighting an urgent need for
strategies to enhance glucocorticoid responsiveness.
Objective: We investigated the immunologic differences
between steroid-sensitive (SS) and SR asthmatic patients and
the effect on immunophenotype of oral calcitriol treatment
because it has been previously shown to beneficially modulate
the clinical response to glucocorticoids in patients with SR
asthma.
Methods: CD8-depleted PBMCs were isolated from 12 patients
with SS and 23 patients with SR asthma and cultured for 7 days
with anti-CD3 and IL-2 with or without dexamethasone.
Cytokine production was assessed in supernatants by using the
Cytometric Bead Array. Patients with SR asthma were
subsequently randomized to oral calcitriol or placebo therapy,
and identical studies were repeated.
Results: Patients with SR asthma produced significantly
increased IL-17A and IFN-g levels compared with those in
patients with SS asthma, although it was evident that cells from
individual patients might overproduce one or the other of these
cytokines. Production of IL-17Awas inversely and production of
IL-13 was positively associated with the clinical response to
prednisolone. Oral calcitriol, compared with placebo, therapy of
the patients with SR asthma significantly improved
dexamethasone-induced IL-10 production in vitro while
suppressing dexamethasone-induced IL-17A production. This
effect mirrored the previously demonstrated improvement in
clinical response to oral glucocorticoids in calcitriol-treated
patients with SR asthma.
Conclusions: IL-17Ahigh and IFN-ghigh immunophenotypes exist
in patients with SR asthma. These data identify immunologic
pathways that likely underpin the beneficial clinical effects of
calcitriol in patients with SR asthma by directing the SR
cytokine profile toward a more SS immune phenotype,
suggesting strategies for identifying vitamin D
responder immunophenotypes. (J Allergy Clin Immunol
2015;nnn:nnn-nnn.)
Key words: Asthma, steroid resistant, steroid sensitive, glucocorti-
coids, IL-17A, vitamin D
Asthma is an inflammatory lung disease characterized by
airways hyperresponsiveness and remodeling and is one of
the most common long-term medical conditions. The majority
of asthmatic patients achieve control of their disease with
b2-adrenergic agonists and glucocorticoids (steroids) and
therefore have steroid-sensitive (SS) asthma.1 However, there is
a proportion of patients who do not show improvement in symp-
toms and lung function after compliant treatment with inhaled
steroids, oral steroids, or both; these patients with steroid-
resistant (SR) asthma experience considerable ill health and
impart a considerable financial burden on the health care system.
Asthma is a heterogeneous disease, and phenotype-specific
therapies have been suggested to enhance the likelihood of
therapeutic success in patients relatively refractory to conventional
therapy.2 Recently, significant effort has been directed at defining
severe asthma and, in particular, its endotypes or phenotypes.3
A number of newer biological agents are currently being tested
in clinical trials, and although therapeutic benefit has been
observed with some of them, they appear to target small subsets
of patients.4-9 Furthermore, they are expensive to manufacture
and administer. On the other hand, steroid-sparing or enhancing
strategies for refractory patients remain relatively unexplored.
Asthma historically was characterized as being a CD41
TH2-mediated disease with increased production of IL-4, IL-13,
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Abbreviations used
BAL: Bronchoalveolar lavage
GR-b: Glucocorticoid receptor b
25[OH]D: 25-Hydroxyvitamin D
1,25(OH)2D3: 1,a25-Dihydroxyvitamin D
ROC: Receiver operating characteristic
SR: Steroid resistant
SS: Steroid sensitive
and IL-5. More recently, these studies have been refined to
identify clinical and immunologic subtypes (phenotypes and
endotypes, including immunophenotypes). For example, there is
established evidence of an IL-17Ahigh phenotype in patients with
severe asthma. Subgroups of patients with severe asthma have
been demonstrated to have increased concentrations of the
proinflammatory cytokine IL-17A in sputum and bronchoalveolar
lavage (BAL) fluid.10-13 Additionally, IL-17A production has
been correlated with airways hyperresponsiveness.14 Although
TH17 cells have been shown to be important for defense against
fungal and bacterial lung infections, a critical balance between
this and an association with various immune pathologies,
including autoimmune disease, appears to exist. Studies in
mice suggest an association between steroid resistance and
TH17-mediated disease: adoptive transfer of TH17 cells resulted
in increased concentrations of chemokines and granulocyte
colony-stimulating factor in the BAL fluid of mice with severe
combined immunodeficiency, and treatment with dexamethasone
resulted in increased neutrophil infiltration but no improvement in
airways hyperresponsiveness.15 More recently, we showed that
blood T-cell IL-17A expression was increased 7-fold in patients
with SR asthma compared with that seen in patients with SS
asthma.16 Additionally, we found that although the synthetic
glucocorticoid dexamethasone did not inhibit IL-17A production,
calcitriol (1,a25-dihydroxyvitamin D [1,25(OH)2D3]), the active
form of vitamin D, significantly inhibited IL-17A production in a
glucocorticoid-independent manner.16 Additionally SR asthma
has been associated with increased expression of the
transcriptionally inactive glucocorticoid receptor b (GR-b),17
whereas increasedGR-b expression has been reported in response
to exogenous IL-17A and IL-23 in vitro, an effect that was more
prominent in asthmatic patients than in healthy control
subjects.18,19 Together, these studies constitute a firm platform
for implicating IL-17A in the pathogenesis of SR asthma.
There is a large body of epidemiologic data suggesting
that vitamin D insufficiency, as defined by the serum
25-hydroxyvitamin D (25[OH]D) concentration, is strongly
associated with impaired respiratory health,20 risk of asthma,21,22
asthma severity, and refractoriness to current therapy.23-27 We
have previously shown that patients with SR asthma have a
defective T-cell IL-10 response to dexamethasone in vitro28 and
that this could be restored by 1,25(OH)2D3.
29 These data, along
with the epidemiologic evidence, prompted us to design a
proof-of-concept, placebo-controlled clinical trial assessing
whether treatment with calcitriol could restore clinical
responsiveness to a standard 2-week trial of oral prednisolone
in patients with SR asthma. Indeed, in this trial we showed that
treatment with calcitriol resulted in significant improvement in
steroid responsiveness in these patients.30
The aim of the present study was to use PBMC samples from
the patients in this trial to further assess the immunophenotypes of
SS and SR asthma at baseline and after calcitriol therapy in the
patients with SR asthma to identify potential immunophenotypes
of steroid refractoriness and also the likely effect of treatment
with calcitriol.
METHODS
Subjects
Asthmatic patients receiving step 3 or 4 therapy according to the British
Thoracic Society guidelines and receiving optimized care by tertiary care
respiratory physicians were recruited and provided written informed consent
(ethics 08/H0804/84). All patients had a prebronchodilator FEV1 of less than
80%of predicted value and documented airway variability of greater than 12%
after 400 mg of short-acting bronchodilator and had undergone detailed
assessment to exclude a diagnosis other than asthma and comorbidities
affecting asthma control. Patients had not received oral glucocorticoids
(steroids) for at least 4 weeks before the study. Patients receiving
immunotherapy, smokers, or patients with a respiratory tract infection or
asthma exacerbation during the 4 weeks before enrollment were excluded.
Steroid resistance was defined as less than 10% improvement in
baseline prebronchodilator FEV1 after a 14-day course of oral prednisolone
(40 mg/1.73 m2/d; Wockhardt UK, Wrexham, United Kingdom) in eligible
patients. Routine spirometry was measured before and after the course of
prednisolone by using a PC-based spirometer and software (WinspiroPRO
Medical International Research, Rome, Italy).
Participants who were identified as having SR asthma were randomized to
receive either 0.25-mg calcitriol soft capsules (Rocaltrol; Roche, Mannheim,
Germany) or organoleptically identical lactose placebo generated in house
(Pharmacy Production Unit, St Thomas’ Hospital NHS Trust, London,
United Kingdom) twice daily for 4 weeks after a 4-week washout period
(full details of the clinical trial study outline and patient details can be found in
the article by Nanzer et al30; see Fig E1 in this article’s Online Repository at
www.jacionline.org for a study schematic). After 2 weeks of calcitriol or
placebo treatment, patients were given a second course of oral prednisolone
identical to the first while calcitriol or placebo was continued. Spirometry
was performed at the beginning and end of this second course of oral
prednisolone, as before.
Flow cytometry
The following antibodies were used for ex vivo phenotyping of peripheral
blood obtained from asthmatic donors: CD3, CD4, CD8, and CD19 (SK7,
RPA-T4, RPA-T8, and HIB19, respectively; BD Biosciences, Oxford, United
Kingdom). Red blood cells were lysed after staining with BD FACS lysing
solution; the samples were subsequently assessed on a FACSCalibur
(BD Biosciences). Absolute and differential blood leukocyte counts were
performed routinely with an LH750 hematology analyzer (Beckman Coulter,
Brea, Calif) and analyzed in conjunctionwith flow cytometric data to calculate
cell numbers.
Cell isolation and culture
Human PBMCs were isolated, as previously described.29 Briefly,
CD8-depleted PBMCs were obtained by means of negative selection with
CD81 Dynabeads (Invitrogen, Paisley, United Kingdom). Cells (1 3 106
cells/mL) were cultured in RPMI (containing 10% FCS, 2 mmol/L
L-glutamine and 50 mg/mL gentamicin) and stimulated with plate-bound
anti-CD3 (1 mg/mL, OKT-3) plus 50 U/mL recombinant hIL-2 (Eurocetus,
Harefield, United Kingdom) in the presence or absence of dexamethasone at
indicated concentrations (Sigma-Aldrich, Gillingham, United Kingdom)
and/or 10 ng/mL hIL-4 in a 24-well plate for 7 days. There was no significant
difference in cellular viability under all culture conditions (data not shown).
Where indicated, after this initial 7-day period, cells were harvested and
readjusted to the same density of 1 3 106/mL viable cells and then cultured
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for a further 48 hours with plate-bound anti-CD3 and IL-2 alone in 48-well
plates, after which supernatants were harvested for cytokine analysis.
Cytokine analysis
IL-17A, IL-10, IFN-g, and IL-13 concentrations in culture supernatants
were measured by using the Cytometric Bead Array (BD Biosciences),
according to themanufacturer’s protocol. The lower limit of detection for each
analyte was 1.5 pg/mL.
Statistics
Data were assessed for equivalence to a Gaussian distribution and equality
of variance, after which the appropriate parametric or nonparametric test was
performed (see individual figure legends) with GraphPad Prism 6 software
(GraphPad Software, La Jolla, Calif). Differences were considered significant
at the 95% confidence level. Data are presented as means, with error bars
representing 95% CIs.
RESULTS
To investigate the immunologic phenotypes of SS and SR
asthma, we recruited patients with moderate-to-severe asthma
whowere defined as having either SS or SR asthma based on their
changes in lung function after 2 weeks of therapy with oral
prednisolone at pharmacodynamically uniform dosages (for a
clinical trial schematic, see Fig E1).30 The patients with SS and
SR asthma were similar in terms of demographics, mean body
mass index, mean equivalent inhaled glucocorticoid dosages,
and mean FEV1 at baseline. The only clinical difference between
patients in the 2 groups was their changes in lung function after
oral prednisolone (mean DFEV1 percent predicted); the patients
with SS asthma showed a significant improvement (from 56.0%
[95% CI, 47.4% to 64.6%] to 70.8% [95% CI, 62.6% to
79.0%], P < .0001), whereas the patients with SR asthma did
not (from 61.3% [95% CI, 55.3% to 67.3%] to 59.7% [95% CI,
52.8% to 66.5%], P5 .18; Table I).30,31 There was no significant
difference in mean peripheral blood eosinophil counts in the pa-
tients with SS asthma compared with those in the patients with
SR asthma. Oral prednisolone therapy was associated in both
groups with a significant increase in mean blood neutrophil
counts and a reduction in mean blood eosinophil counts (see
Fig E2 in this article’s Online Repository at www.jacionline.org).
Increased expression of IL-17A and IFN-g in patients
with SR asthma compared with patients with SS
asthma
Because asthma is believed to be a CD41 T cell–mediated
disease, we used CD8-depleted PBMC cultures with T-cell
stimulation, as performed in our previous studies,16,29 to compare
T-cell immunophenotypes in both patients with SS and those with
SR asthma. Blood samples for these studies were taken at
screening visit 1 (see Fig E1). CD8-depleted PBMCs from both
groups were cultured for 7 days with anti-CD3 and IL-2 in the
presence or absence of IL-4. After 7 days, cells were washed,
recounted, and replated at 1 3 106/mL to allow for any
differential changes in the numbers of cells between the groups
and stimulated for a further 48 hours. Cytokine protein expression
in culture supernatants was then assessed by using the Cytometric
Bead Array for IL-17A, a TH17 cytokine; IL-13, a TH2 cytokine;
and IFN-g, a TH1 cytokine, as well as the anti-inflammatory
cytokine IL-10. There were no significant differences in ex vivo
mean numbers of blood T cells (including CD41 and CD81 cells)
and B cells in the asthmatic patients classified as having SS or SR
asthma (see Fig E2, B).
Under these conditions, CD8-depleted PBMCs from the
patients with SR asthma produced significantly increased mean
concentrations of both IL-17A and IFN-g compared with the
those seen in the patients with SS asthma, although the mean
production of IL-10 and IL-13 did not significantly differ. This
difference in IFN-g production between the 2 groups was no
longer observed when exogenous IL-4 was included in the culture
conditions (Table II). Attempts were made to detect IL-17A in the
cultures containing exogenous IL-4, but concentrations were low
or undetectable (data not shown). This is in line with earlier
studies showing that IL-4 inhibited IL-17A production, whereas
anti–IL-4 enhanced IL-17A production from CD41 T cells.32
Conversely, IL-4 signaling through the IL-4 receptor is known
to enhance IL-10 responses.33
Differential response to the glucocorticoid
dexamethasone in patients with SR asthma
compared with that in patients with SS asthma
We next examined whether there were differences in
responsiveness to the synthetic steroid dexamethasone in vitro
between patients with SS asthma and patients with SR asthma
that might reflect the differences seen clinically. Cells from the
patients with SR asthma compared with those from the patients
with SS asthma continued to show increased mean production
of IL-17A and IFN-g across a range of dexamethasone
concentrations. Indeed, high concentrations of dexamethasone
further significantly increased IL-17A production by cells from
the patients with SR asthma, a phenomenon not observed in cells
TABLE I. Patients’ characteristics
Patients with
SS asthma
(n 5 12)
Patients with
SR asthma
(n 5 23)
P
value
Age (y) 49.0 (40.7-57.3) 51.8 (45.9-57.8)
Ethnic origin
White 9 (75.0) 17 (73.9)
African 3 (25.0) 5 (21.7)
Asian 0 1 (4.4)
Sex
Male/female 4 (33.3)/8 (66.6) 14 (60.8)/9 (39.2)
Atopic* 10 (83.3) 19 (82.6)
BMI (kg/m2) 31.8 (28.0-35.6) 28.2 (26.2-30.2) .06
Inhaled corticosteroid
dose (BDP)
1113 (798-1469) 1225 (985-1520) .60
FEV1 (L)
Before steroids 1.7 (1.4-1.9) 1.9 (1.7-2.1) .13
After steroids 2.1 (1.8-2.4) 1.8 (1.6-2.1)
FEV1 (%)
Before steroids 56.0 (47.4-64.6) 61.3 (55.3-67.3) .97
After steroids 70.8 (62.6-79.0) 59.7 (52.8-66.5)
Serum 25(OH)D
(nmol/L)
38.8 (27.6-50.1) 36.9 (27.6-46.2) .51
Where applicable, data are means with 95% CIs or frequencies (percentages). P values
are shown for noncategorical clinical parameters assessed by using an unpaired t test.
BDP, Daily beclomethasone dipropionate equivalent dosage according to the British
Thoracic Society/SIGN guidelines on the management of asthma31; BMI, body mass
index.
*Atopy was defined based on skin prick test responses.
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from the patients with SS asthma. Although increased production
of IFN-g by cells from the patients with SR asthma was retained
in the presence of dexamethasone, high concentrations of
dexamethasone nevertheless inhibited IFN-g production in both
the patients with SS and those with SR asthma. Dexamethasone
significantly inhibited IL-13 production by cells cultured in the
presence of IL-4 from patients in both groups. Conversely,
dexamethasone increased IL-10 production only in cells from
the patients with SS asthma and strikingly so in the presence of
exogenous IL-4 (P 5 .008), which is in line with our earlier
observations (Fig 1, B).28
IL-13 and IL-17A production associate positively and
negatively with clinical responsiveness to
glucocorticoid therapy
We next investigated whether these observed differences
correlated with clinical measurements. Cytokine production
was analyzed according to absolute lung function in both the
patients with SS and those with SR asthma, and there was no
significant association with production of any cytokine (see Fig
E3 in this article’s Online Repository at www.jacionline.org).
However, when the patients with severe asthma were segregated
into quartiles according to their change in lung function after 2
weeks of oral prednisolone therapy (DFEV1 [in liters]), it was
apparent that cells from those asthmatic patients in the lowest
quartile whose lung function actually decreased with steroid
therapy produced a significantly increased mean quantity of
IL-17A at baseline compared with those who showed an
improvement. There was a similar trend with IFN-g production,
although this was not statistically significant. Conversely, cells
from those asthmatic patients who were in the upper quartile of
lung function improvement produced a significantly increased
mean quantity of IL-13 at baseline. No such association
was observed with IL-10 production (Fig 2, A), although
those patients whose cells produced the highest mean ratios of
IL-10/IL-17A, as well as IL-13/IL-17A, were more likely to fall
in the upper quartile of the degree in lung function improvement
after taking oral prednisolone (Fig 2, B).
Production of IL-17A and IFN-g predict clinical
glucocorticoid responsiveness
Because increasedproductionof both IL-17Aand IFN-g byCD8-
depleted PBMCs was associated with clinical unresponsiveness
to glucocorticoid therapy, we compared production of these
cytokines in the entire population of asthmatic patients (both SS
and SR asthma). Contrary to our expectations, there was no
correlation between overproduction of IL-17A and IFN-g (Fig 3,
A), suggesting that both immunophenotypes contribute to
corticosteroid responsiveness. Indeed, combined production of
both cytokines correlated inversely with change in absolute FEV1
TABLE II. Cytokine production in cultures from both patients with SS and those with SR asthma at baseline
Cytokine
CD3/IL-2
P value
CD3/IL-2 1 IL-4
P valuePatients with SS asthma Patients with SR asthma Patients with SS asthma Patients with SR asthma
IFN-g 11.0 (8.3-13.7) 19.7 (14.2-25.2) .02 8.5 (4.9-12.1) 11.6 (9.0-14.2) .15
IL-10 1.3 (0.2-2.4) 0.8 (0.5-1.2) .51 1.2 (0.5-2.0) 1.6 (0.6-2.6) .61
IL-13 3.6 (0.7-6.6) 2.6 (0.8-4.4) .89 5.1 (1.7-8.6) 4.3 (2.7-5.8) .59
IL-17A 11.3 (1.5-21.0) 47.0 (27.8-66.2) .007 ND ND
Cytokine production (in nanograms per milliliter) by cells either stimulated with CD3 plus IL-2 or additionally in the presence of IL-4 in culture is shown. Data are means and 95%
CIs.
ND, Not detected/measured.
FIG 1. Differential cytokine production by both patients with SS and those with SR asthma in response to
dexamethasone in vitro. Cytokine production by CD8-depleted PBMCs (y-axis) in the presence of
dexamethasone (102x mol/L) in vitro (x-axis) stimulated with CD3 plus IL-2 (A) and additional IL-4 (B) is
shown. Open squares, Patients with SR asthma; solid circles, patients with SS asthma. Data are means
and 95% CIs and assessed by using 2-way ANOVA with Dunnett multiple comparisons tests of cytokine
production in the presence of different concentrations of dexamethasone compared with no
dexamethasone. *P <_ .05, **P < .01, and ***P < .001.
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FIG 2. IL-17A is negatively and IL-13 is positively associated with clinical response to 2 weeks of
prednisolone. Cytokine production (A) and ratio of IL-13/IL-17A and IL-10/IL-17A cytokine production
(B) separated based on change in absolute lung function in response to 2 weeks of prednisolone (DFEV1)
are shown. Data are means and 95% CIs and assessed by using Kruskal-Wallis 1-way ANOVA with the
Dunn multiple comparison post hoc statistical test. *P <_ .05 and **P < .01.
FIG 3. IL-17A and IFN-g production predict glucocorticoid responsiveness. A, Comparison of IL-17A and
IFN-g production in patients with SS asthma (solid circles) and patients with SR asthma (open squares).
B, Combined production of IL-17A and IFN-g correlated with change in absolute lung function (DFEV1) in
response to 2 weeks of prednisolone, as assessed by using the Spearman rank correlation statistical test.
C, ROC curves for prediction of steroid resistance based on production of IFN-g, IL-17A, and their
combination.
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after glucocorticoid therapy (Fig 3, B). Additionally, we
performed analysis of the data in Fig 3, B, in the absence of the po-
tential outlier (withDFEV15 1.34), and interestingly, in the absence
of this point, the correlation was statistically stronger, with a new r
value of20.41 and a P value of .018.
Consequently, we analyzed the sensitivity and specificity of
IL-17A and IFN-g production, both separately and in
combination, to predict the clinical effect of oral prednisolone
therapy in changing FEV1. In the case of IL-17A, receiver oper-
ating characteristic (ROC) analysis was highly significant (P 5
.002): an IL-17A production threshold of greater than 28.1 ng/
mL produced a sensitivity of 63.6% and a specificity of 91.7%
for detecting glucocorticoid resistance. In the case of IFN-g,
ROC analysis provided less robust outcomes (P 5 .06): an IFN-
g production threshold of greater than 20.7 ng/mL produced a
sensitivity of 34.8% and a specificity of 91.7%. The combination
of IL-17A and IFN-g production proved to be a better test: ROC
analysis was highly significant (P 5 .0002), showing that a pro-
duction threshold of greater than 38.5 ng/mL for the sum of
both cytokines predicted clinical glucocorticoid resistance with
a sensitivity of 81.8% and specificity of 91.7% (Fig 3,C). This de-
gree of sensitivity and specificity is at least comparable with that
of noninvasive markers, which have been claimed to predict
glucocorticoid-resistant asthma.34
IL-13 production positively correlates with serum
25(OH)D concentrations
Vitamin D has been reported to inhibit lymphocyte production
of IL-17A and IFN-g in vitro16,29,35 while enhancing TH2
cytokine production.36 To examine such possible effects in vivo,
we next compared cytokine production in all of the study
participants with their vitamin D status based on serum 25(OH)
D concentrations before calcitriol or placebo therapy. Serum
25(OH)D concentrations did not correlate with production of
IL-10, IL-17A, or IFN-g, but we did observe a significant
positive correlation with IL-13 production that was further
strengthened in the presence of exogenous IL-4 (Fig 4). After
removal of a potential outlier (67 nmol/L; 16 ng/mL), IL-13 still
significantly correlated (r5 0.35; P5 .047) with serum 25(OH)D
levels in the cultures without exogenous IL-4.
Calcitriol therapy of patients with SR asthma
reverses induction of IL-17A and augments IL-10
production in response to dexamethasone
In our recent clinical report of the same patients used in the
present study, we showed that treatment of our patients with SR
asthma with calcitriol compared with placebo improved their
clinical responsiveness to glucocorticoid therapy.30 We used
samples collected from these patients, and notably, no difference
was observed between patients with SR asthma subsequently
allocated to either placebo or calcitriol treatment at baseline
before any treatments with regard to their lymphocyte
populations at screening visit 1 (see Fig E2, C). We studied these
patients to establish the possible effect of oral calcitriol therapy on
the immunologic phenotype of peripheral blood cells. We found
that after 4 weeks of therapy with calcitriol/placebo and an
additional identical 2-week course of oral prednisolone for the
final 2 of these 4 weeks (treatment visit 3, see Fig E1), there
was significant induction by dexamethasone of IL-17A
production in the placebo-treated group, as seen at baseline
(screening visit 1). Strikingly, this effect was no longer evident
in the calcitriol-treated group (Fig 5, A). Furthermore, as
FIG 4. Serum 25(OH)D concentration correlates with IL-13 expression in vitro. Cytokine production in
cell-culture supernatants was assessed by using the Cytometric Bead Array and correlated with baseline
vitamin D status (defined as the serum 25[OH]D concentration). A, Cells stimulated with CD3 plus IL-2.
B, Cells stimulated with addition of IL-4 in culture. Open circles, Patients with SR asthma; solid squares,
patients with SS asthma. Data were assessed by using Spearman rank correlation.
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predicted from our earlier work,28,29 cells from the calcitriol-
treated patients with SR asthma now showed a significant
increase in IL-10 production in response to dexamethasone, an
effect that was most marked in the presence of IL-4 in
culture (Fig 5, B). Although IL-13 production correlated with
serum 25(OH)D concentrations at baseline, as shown above, there
was no apparent effect of 4 weeks of calcitriol treatment on
production of IL-13 or its inhibition by dexamethasone. Similarly,
dexamethasone modestly but significantly inhibited IFN-g
production as before and equivalently in the calcitriol- and
placebo-treated patients. Although the numbers are small,
further analysis of the calcitriol-treated patients with SR asthma
showed that the patients whose improvement in lung function
was in the upper quartile in response to the second course of
oral prednisolone were those whose cells produced the
highest mean quantities of IL-13 and the lowest mean quantities
of IL-17A (see Fig E4 in this article’s Online Repository at
www.jacionline.org).
DISCUSSION
The data presented in this article demonstrate that there is a
significantly higher production of IL-17A and IFN-g in PBMC
cultures from patients with SR asthma compared with those from
patients with SS asthma. Notably, these appear to reflect 2
distinct immunophenotypes of SR asthma, an IL-17Ahigh and an
IFN-ghigh profile, which are largely nonoverlapping. We have pre-
viously reported,30 and develop here, evidence that glucocorticoids
can aggravate the excessive production of proinflammatory TH17
by blood lymphocytes in patients with SR asthma, which
characterizes a subgroup of these patients. We demonstrate that
the levels of IL-17A synthesis in the PBMC cultures negatively
and IL-13 synthesis positively correlate with the absolute change
in lung function (FEV1) after 2 weeks of oral prednisolone treat-
ment in our adult asthma cohort. Our data further support earlier
findings that TH2
high asthma, as characterized by increased IL-13
production, is more likely to be associated with glucocorticoid
responsiveness.37
The second major finding of this study relates to the capacity of
calcitriol to reverse the SR immune phenotype to one more
closely aligned to that of patients with SS asthma. Thus the
IL-17Ahigh profile is abrogated by calcitriol therapy in a
glucocorticoid-independent manner. Conversely, calcitriol
therapy also restores the impaired, corticosteroid-induced
anti-inflammatory IL-10 response that characterizes patients
with SR asthma, extending our earlier findings in this area.29 In
addition to effects on IL-10 synthesis, calcitriol might reduce
the induction of IL-17A through enhancement of a number of
FIG 5. Calcitriol treatment decreases expression of IL-17A in cultures from patients with SR asthma.
Cytokine production by CD8-depleted PBMCs from patients with SR asthma in the presence of
dexamethasone (102x mol/L) in vitro after 4 weeks of calcitriol or placebo therapy and 2 weeks of oral
prednisolone therapy and cells stimulated with CD3 plus IL-2 (A) and additional IL-4 (B) is shown.
Open triangles, Calcitriol; solid triangles, placebo. Data are means and 95% CIs. Data were assessed by
using 2-way ANOVA with Dunnett multiple comparisons tests. *P <_ .05, **P < .01, and ***P < .001.
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regulatory mechanisms, including the inhibitory CD39/adenosine
pathway and regulatory T cells.16,35,38-40
Several mechanisms have been proposed to contribute to
clinical glucocorticoid refractoriness in asthmatic patients at the
cellular level, particularly in T cells, including overexpression of
proinflammatory transcriptional regulators, such as nuclear factor
kB and activator protein 1; increased expression of histone
deacetylases, polymorphisms of the IL10 gene; increased
expression of the dominant negative isoform of the GR-b;
overexpression of TH2 cytokines; and vitamin D insuffi-
ciency.17,24,25,41-44 More recent evidence also suggests that
IL-17A overexpression can be both a marker and a risk factor
for severe and SR asthma.11-14,16 In this studywe confirm the latter
association and show an independent association with
overexpression of the TH1 cytokine IFN-g. Previous mechanistic
studies in autoimmunemodels of disease have suggested that path-
ologic IL-17A production is by IL-17A1IFN-g1 coexpressing
cells,45-47 but our datawere not consistent with this, rather suggest-
ing separate ‘‘immunophenotypes’’ of SR asthma. It is notable
from our study that the IL-17Ahigh phenotype might be enhanced
by glucocorticoids in some subjects and that patients with this
phenotypewere more likely to show deterioration in lung function
after oral prednisolone, raising the possibility that oral glucocorti-
coid therapy is not only unhelpful but also detrimental in some of
these patients. Although lymphocyte cultures might not be prac-
tical as routine clinical biomarkers, further research might be
anticipated to reveal more practical novel biomarkers of IFN-ghigh
and IL-17Ahigh SR asthma similarly to the development of perios-
tin as a biomarker of TH2
high asthma.48
The mechanisms behind glucocorticoid enhancement of
IL-17A production by CD4 cells are not fully understood and
represent an area of active research. A recent article described a
detailed transcriptional time course during TH17 differentiation,
suggesting a number of potential candidates for further study.49
Previous data from our laboratory suggest that glucocorticoids
do not inhibit proliferation of IL-17A–expressing cells; the
mechanisms behind these differential effects on proliferation
are unknown and currently under investigation. The differences
observed in this study are not due to differences in the ex vivo
baseline populations of the major lymphocyte groups because
no differences were observed; however, we cannot rule out there
being an enrichment of certain subsets of memory cells. The only
difference we have observed previously was in the frequency of
FoxP3–positive regulatory T cells,39 where we showed that there
was a higher frequency of FoxP3–positive T cells in the peripheral
blood of patients with SS asthma compared with that seen in pa-
tients with SR asthma. However, it seems unlikely that this small
population of cells can account for the large differences observed
in this study.
It is important to note that a somewhat contradictory scientific
literature exists on the capacity of vitamin D to inhibit and/or
enhance TH2 responses experimentally and in animal models
(reviewed by Lange et al50). Our data indicate that serum
concentrations of 25(OH)D positively correlate with IL-13 syn-
thesis in culture. Importantly, however, administration of oral cal-
citriol did not lead to enhancement of IL-13 production in culture.
Although IL-13 is implicated in asthma pathogenesis, its produc-
tion is strongly inhibited by glucocorticoids16,51; indeed, the
TH2
high asthma phenotype is now widely regarded as a marker
of glucocorticoid responsiveness.37 Therefore our data support
the concept that vitamin D improves responsiveness to
glucocorticoids at least partly by altering the immunophenotype
away from a glucocorticoid-resistant TH17 phenotype toward a
more responsive TH2 immunophenotype. Thus although calcitriol
does not improve lung function in asthma directly, it does improve
responsiveness to glucocorticoid therapy.30
A limitation to this study was that the data observed were
collected from peripheral blood, although we were able to show
significant correlations between cytokine production in culture
and changes in lung function. Future studies need to be directed at
the target organ to gain full insight into changes in cytokine
expression in these patients. It would be informative to have
studied BAL samples, as well as peripheral blood, providingmore
information about the tissue of interest. However, bronchoscopy
with BAL carries risks and side effects, especially in patients with
severe asthma, and therefore was not part of the current study
design. One approach we took to counteract this limitation was to
perform our peripheral blood cultures in the presence or absence
of IL-4 in an attempt to simulate the TH2-like environment of the
asthmatic bronchial mucosa.52 In our previous work we showed
that the vitamin D–induced effects on IL-10 were most profound
when IL-4 was present in culture.28,40,53
Data from several clinical trials investigating the clinical
efficacy of vitamin D in asthma are emerging.30,54-56 The biggest
published trial to date (408 patients randomized) was the VIDA
trial. In this placebo-controlled trial patients were supplemented
with an initial bolus of 100,000 IU oral vitamin D3 and then
subsequently supplemented with 4,000 IU daily. The primary
outcome was time to first asthma treatment failure, and no
significant improvement in this outcome after vitamin D
supplementation was observed. However, the trial also assessed
changes in the clinical response to inhaled glucocorticoids, and
vitamin D3 supplementation modestly decreased the overall
dose of steroid used.54 Additionally, a striking reduction in the
cumulative number of exacerbations was observed in patients
within the treatment arm. Two recent smaller studies showed a
more positive role for vitamin D supplementation in asthmatic
patients in which vitamin D therapy improved lung function
and reduced asthma exacerbations in the treatment arms
compared with the placebo arm.56,57 Another interesting earlier
trial investigated the effect of vitamin D3 supplementation
(1,200 IU/d) on seasonal influenza A infection and, despite low
numbers, in a secondary outcome measure a significant reduction
in the number of asthma attacks in the group that was receiving
vitamin D3 was reported.55
The studies reported to date have used different forms of
vitamin D at different concentrations and dosing regimens over
varying periods of time. In several studies many patients were not
or were borderline vitamin D deficient, which will affect the
efficacy of vitamin D treatment. Clearly, further investigation is
required to fully understand the effect of vitamin D treatment on
asthma control and prevention. What is unique about our study
was the use of the active form of vitamin D, calcitriol, which we
have previously shown to improve the SR asthmatic response to
2-week prednisolone therapy. Calcitriol is an attractive short-term
adjunct to oral glucocorticoid therapy for severe exacerbations of
disease in patients with SR asthma, particularly those
already taking maintenance oral glucocorticoids. Although
there are concerns about long-term prescription of this form of
vitamin D, short-term therapy might be a viable strategy,
particularly because expression of Cyp27B1, the catalytic
enzyme that converts circulating 25(OH)D into active calcitriol
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(1,25[OH]2D3), is inhibited by glucocorticoids
58; treatment of
patients with SR asthma with oral calcitriol would bypass this
effect.
In summary, comparison of immunophenotypes in both
patients with SS and those with SR asthma highlights both
IL-17Ahigh and IFN-ghigh immunophenotypes as independent
indicators of glucocorticoid refractoriness and suggests that
calcitriol ameliorates the glucocorticoid responsiveness of
IL-17Ahigh patients. We believe the data from this study, although
from a small cohort, justify further investigation of calcitriol
therapy, and comparison with 25(OH)D supplementation in
patients with SR asthma identified with biomarkers indicative
of nonresponsiveness to glucocorticoids.
Key messages
d IL-17Ahigh and IFN-ghigh immunophenotypes are indica-
tive of SR asthma.
d Calcitriol potentially improves the clinical response to
glucocorticoids through reduction in IL-17A production
and enhancement of steroid-induced IL-10.
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FIG E1. Clinical trial schematic. Patients with severe asthma were recruited
and given prednisolone at screening visit 1 and returned 2 weeks later at
screening visit 2 when patients with SS asthmawere excluded from the trial
and patients with SR asthma were retained. After a 4-week washout period,
the patients with SR asthma were randomly assigned to receive calcitriol or
placebo for 1 month (treatment visit 1). After 2 weeks (treatment visit 2), the
patients were started on additional oral prednisolone and then returned 2
weeks later for the final visit (treatment visit 3). Lung function was assessed
at all clinical trial visits except treatment visit 1. CD8-depleted PBMCs were
assessed from peripheral blood collected at screening visit 1 and treatment
visit 3.
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FIG E2. Peripheral leukocyte counts. A, Peripheral blood total and
differential leukocyte counts in the patients with SS asthma (solid symbols)
and patients with SR asthma (open symbols) before and after 2 weeks of
prednisolone. B and C, Total B cells (CD191), T cells (CD31), and CD41
and CD81 T cells were assessed by using ex vivo flow cytometric analysis
of peripheral blood from screening visit 1 of both patients with SS and
those with SR asthma (Fig E2, B), as well as in the same patients with SR
asthma separated based on their assignment to calcitriol or placebo
treatment (Fig E2, C). Data were assessed by using the Wilcoxon
matched-pairs statistical test (Fig E2, A) or the Mann-Whitney U statistical
test (Fig E2, B and C). *P <_ .05, **P < .01, and ***P < .001.
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FIG E3. Cytokine production does not associate with lung function. Cytokine production from all patients
with severe asthma separated according to their absolute lung function at baseline (FEV1) is shown.
Data were assessed by using Kruskal-Wallis 1-way ANOVA with the Dunn multiple comparison post hoc
statistical test.
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FIG E4. Effects of calcitriol on lung function and IL-13 and IL-17A levels.
Cytokine production was separated based on individual changes in
absolute lung function (DFEV1) in response to 2 weeks of prednisolone
before (baseline; black bars) and after (after 4 weeks of calcitriol and 2
weeks of prednisolone; white bars) treatment. Numbers of patients with
SR asthma are indicated in parentheses above.
J ALLERGY CLIN IMMUNOL
nnn 2015
10.e4 CHAMBERS ET AL
